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Patients with asthma often have symptoms at night (Floyer, 1698;
Turner-Warwick, 1984), with maximal bronchoconstriction in the early
hours of the morning (Turner-Warwick, 1977). There is also evidence
for an excess of nocturnal deaths due to asthma (Cochrane and Clark,
1975; Lancet, 1983). However, the causes and physiological
consequences of nocturnal bronchoconstriction in asthma are poorly
understood (Turner-Warwick, 1977; Barnes, 1984; Douglas, 1985).
Recent studies have emphasised that sleep itself can cause changes in
respiration. Perhaps the best known example of this is the sleep
apnoea syndrome (Guilleminault et al, 1976, 1978), in which
intermittent cessation of breathing during sleep causes loud snoring
at night and hypersomnolence during the day, symptoms that often lead
to marriage problems and difficulties with employment and driving.
In infants, sleep apnoea may have even more tragic consequences, for
it has been implicated in some cases of the sudden infant death
syndrome (Steinschneider, 1972; Guilleminault et al, 1986). In
chronic bronchitis and emphysema, marked falls in arterial oxygen
saturation occur during sleep in the absence of apnoea (Flick and
Block, 1977; Douglas et al, 1979b; Catterall et al, 1983). These
nocturnal hypoxaemic episodes in chronic bronchitis and emphysema
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also may be important clinically, for there is evidence that they
contribute to the development of pulmonary hypertension (Douglas et
al, 1979a; Boysen et al, 1979; Fletcher and Levin, 1984; Catterall et
al, 1985), cor pulmonale (Moore-Gillon and Cameron, 1985) and
secondary polycythaemia (Moore-Gillon and Cameron, 1985).
In 1978, I began research into the mechanism of transient nocturnal
hypoxaemia in chronic bronchitis and emphysema. This work, which
was initiated by Professor D C Flenley and Dr N J Douglas in the
Department of Medicine, University of Edinburgh is reported in detail
elsewhere (Catterall et al, 1983a,b and 1985; Brezinova et al, 1982;
Calverley et al, 1982). In the course of these investigations,
however, I became aware that there had been no similar studies in
asthmatic patients, despite the fact that they have more nocturnal
symptoms than patients with chronic bronchitis and emphysema. I
wondered whether asthmatic patients might become hypoxaemic during
sleep and also whether sleep itself might be a cause of nocturnal
bronchoconstriction in asthmatic patients.
I therefore began to investigate the relationships between sleep and
breathing in patients with asthma. These investigations are the
subject of my thesis.
Part I of the thesis contains a brief review of the clinical
importance of nocturnal asthma, and an account of the methods used to
study breathing during sleep.
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The original work of the thesis is divided into three further parts:
In Part II are described studies of breathing and oxygenation during
sleep in normal subjects. These studies were performed to establish
a normal range of apnoea, hypopnoea and oxygenation during sleep and
to determine the effects of age and sex on these variables.
Part III contains the results of similar studies in patients with
asthma. Breathing patterns and oxygenation during sleep in
asthmatic patients were compared with those of normal subjects and
those of patients with chronic bronchitis and emphysema.
The studies described in Part IV were designed to explore the
relationship between sleep and bronchoconstriction. I wished to
establish whether sleep was essential for nocturnal
bronchoconstriction and to determine whether bronchoconstriction was
associated with one particular stage of sleep.
The results are summarised at the end of each section, and the





THE CLINICAL IMPORTANCE OF NOCTURNAL ASTHMA
The term asthma is derived from the greek word meaning "laboured
breathing" (Onions, 1966). In the early history of the disease, the
word "asthma" referred to a symptom, and confusion with other causes
of breathlessness occurred (Major, 1953). Nocturnal "asthma"
appeared very early in the literature, but in view of the frequently
loose use of the word, it is difficult to be certain when the
nocturnal occurrence of bronchial asthma was first reported (Hetzel,
1980).
1. Tfre recognition of nocturnal asthma
One of the earliest convincing descriptions of nocturnal asthma was
by Aurelianus Caelius in the 4th or 5th century AD (De morbis acutis
and chronicis,•1709). The first physician to associate asthma with
bronchoconstriction, however, was Willis (1649) some 1300 years
later. Both of these physicians were familiar with the tendency for
asthmatic attacks to occur at night, but perhaps the most vivid and
complete descriptions of nocturnal asthma were made by Doctor (later
Sir) John Floyer (1698), himself an asthmatic. Cullen (1784), Bree
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(1797), Reisseissen (1822), Laennec (1827) and Trousseau (1868) also
described nocturnal asthma. Salter (1868), who introduced the
concept of bronchial hyperreactivity, commented that nocturnal
attacks were the most constant feature of the disease. He also
observed that airways obstruction could be present during sleep,
reporting a case whose wheezing did not immediately waken the
patient, but could, nevertheless, be heard in the next room.
Thorowgood (1878) considered nocturnal asthmatic attacks to be more
frequent "towards early morning" and he discussed treatments for
nocturnal asthma which included the anticholinergic agents,
strammonium and belladonna.
2. The measurement Of nocturnal btpnchoconstriction
Although these physicians were aware of nocturnal asthma, they were
not able to measure the extent to which airflow limitation increases
at night. In 1960, Lewinsohn and colleagues measured forced
expiratory volume in 1 second (FEV-^) at intervals during the day in 5
healthy subjects and 12 patients with "generalised airway
obstruction", including some with asthma. FEV-^ fell in the early
morning in both groups, but this fall was much greater in the
patients with airway disease than in the healthy subjects. Further
studies (McDermott, 1966; Guberan et al, 1969; Reindl et al, 1970;
Reinberg et al, 1970; Kerr, 1973) confirmed that there is a normal
circadian variation in airways resistance, the highest resistances
and the lowest peak expiratory flow rates occurring during the night,
and that this is greatly magnified in patients with asthma (Reinberg
et al, 1970; Reindl et al, 1970; Turner Warwick, 1977; Connolly,
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1977; Hetzel and Clark, 1980) but not in patients with chronic
bronchitis and emphysema (Zedda and Sartorelli, 1971; Connolly, 1979;
Dawkins and Muers, 1981). Turner-Warwick (1977) coined the term
"morning dips" for these early morning falls in peak expiratory flow
rate (PEFR) in asthma.
In a study of 16 asthmatic patients with morning dips in PEFR, Hetzel
and colleagues (1977b) showed that the percentage rise in PEFR
between 6 am and 2 pm was similar to the percentage changes in FEV^
and specific conductance, and that these changes were accompanied by
hyperinflation and gas trapping. Thus, their results confirmed that
there are large circadian variations in airflow limitation in asthma
and that PEFR is a reliable index of the severity of nocturnal and
early morning asthma.
In the same study, Hetzel and colleagues (1977b) attempted to
determine the probable site of airways obstruction in early morning
asthma. Specific airways conductance increased more than twofold
between 6 am and 2 pm, suggesting that there was a considerable
increase in obstruction of the large airways during the night (Cotes,
1975). To determine the relative importance of large airway
narrowing and small airway narrowing, they also studied diurnal
changes in the response of the maximal expiratory flow rate to a
helium-oxygen mixture. Two patients showed a response to helium
(Despas et al, 1972) at all times, seven were consistent non-
responders, and seven had a variable response. These results were
unhelpful in determining the relative contributions of large and
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small airways to circadian changes in airflow limitation, possibly
because the low flow rates generated by some of their patients may
have rendered the test invalid (Hetzel, 1984). Mak and colleagues
(1982) reconsidered this question, studying eight asthmatic children
with less severe airflow limitation than in the adult study.
Response to oxy-helium mixture was similar at both of the times
studied (8 am - 9 am and 5 pm - 6 pm), and this was interpreted by
the authors as evidence that both large and small airways are
involved in the circadian variation of pulmonary function in asthma.
However, these children had relatively mild asthma and the mean
circadian variation in PEFR recorded during the study, although
statistically significant, was only 5%.
In conclusion, there is evidence that large airway narrowing occurs
in nocturnal asthma but the importance of small airway narrowing is
unclear. The severity of nocturnal and early morning asthma can be
assessed by measurements of PEFR.
3. The prevalence of nocturnal bronchoconstriction in asthma
Hetzel and Clark (1980) used cosinor analysis to compare normal and
asthmatic circadian rhythms in peak expiratory flow rate (PEFR).
They made PEFR measurements four times daily in 221 normal
individuals of whom 145 (66%) showed a significant circadian rhythm
in peak expiratory flow rate, and 56 asthmatic patients, of whom all
showed significant circadian variation of PEFR on cosinor analysis.
The amplitude of the PEFR rhythm in the asthmatic patients (mean 51%
of each individual's average daily PEFR) was significantly greater
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than that in the 145 normal subjects with PEFR rhythms (mean 8.3%),
but the mean phases of the normal and asthmatic rhythms were not
significantly different, the highest daily PEFR occurring between 2
pm and 10 pm in the great majority of subjects in each group. The
authors concluded that nocturnal bronchoconstriction in asthma
probably represents an exaggeration of a normal circadian rhythm and
they suggested that a diurnal PEFR rhythm amplitude exceeding 20% of
the mean daily PEFR might be a useful screening test for asthma.
However, not all patients with asthma have "morning dips" (Turner
Warwick, 1977). Connolly (1979) recorded peak flow rates five times
daily for at least four days in 115 asthmatics, and found that about
one-third regularly bronchoconstricted overnight, a further third
bronchoconstricted before sleep and remained bronchoconstricted
overnight, whilst another third showed no circadian pattern.
Furthermore, the observations in both these studies (Hetzel and
Clark, 1980; Connolly, 1979) were based on asthmatic patients in
hospital or immediately after discharge, and less marked circadian
fluctuations in PEFR may be seen in asthmatic out-patients or
patients in remission. Johnstone and colleagues (1984), for
example, using cosinor analysis on measurements made three times
daily, found that the mean circadian variation in PEFR in 63
asthmatic schoolchildren was 12% of the average daily peak flow, and
Ryan and colleagues (1982) observed a mean circadian PEFR variation
(based on two measurements daily and expressed as a percentage of the
maximum daily value) of only 7.5% in 27 adult asthmatic out-patients.
At present, therefore, although nocturnal bronchoconstriction is
common in asthma, it is not possible to define a threshold for
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circadian variation in PEFR by which asthma can be diagnosed.
Nevertheless, interval measurements of peak expiratory flow over the
24 hour period are of great value in the clinical assessment of
asthmatic patients (Turner-Warwick, 1977; Hetzel et al, 1977a, b;
Bateman and Clark, 1979). They have also facilitated the study of
nocturnal asthma, including the investigation of its causes (see Part
IV) and the assessment of its clinical significance.
4. The clinical consequences of nocturnal asthma
Morbidity: Nocturnal symptoms are common in asthma. In a study of
patients attending asthma clinics at two centres in the UK, some two-
thirds of patients stated that they had nocturnal attacks of asthma
and/or chest tightness on waking in the morning (Turner-Warwick,
1984).
Mortality: Fortunately, mortality from asthma is much less common
than morbidity. Nevertheless, in England, Scotland and Wales some
1500 deaths per year are attributed to asthma, and approximately one-
tenth of these are in patients aged 5-34 years (Office of
Population, Censuses and Surveys, England and Wales, 1974-1984;
Annual Report of the Registrar General for Scotland, 1974-1984).
Although asthma in the old and very young may be confused with other
conditions that cause wheeze and dyspnoea (Speizer et al, 1968a), the
asthma fatality figures compiled for other age groups, especially the
5-34 year group (Speizer et al, 1968a; Jackson et al, 1982), are
accurate. Furthermore, there have been well documented epidemics of
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asthma mortality in recent years - one in the 1960's affecting
Britain, New Zealand, Australia and Ireland (Fraser and Doll, 1971)
and another current epidemic affecting the population of New Zealand
(Jackson et al, 1982). Recent figures indicate that the death rate
from asthma is also increasing again in England and Wales (McBurney,
1986). These figures emphasise the potentially serious nature of
asthma.
The relationship between asthma deaths and nocturnal
bronchoconstriction has been studied by a number of authors. Hetzel
and colleagues (1977a) analysed 10 sudden deaths and ventilatory
arrests in 1169 consecutive hospital admissions for asthma. The
risk of sudden death or ventilatory arrest could not be related to
the severity of the attack of asthma but it did correlate with the
presence of marked diurnal variation in the peak expiratory flow
rate. Two deaths after a sudden attack of asthma in young people
were reported by Bateman and Clarke (1979) from a clinic set up to
identify and manage such "at risk" patients. Both these patients
had been shown to have marked diurnal variation in PEFR. These
authors concluded that a wide diurnal variation in PEFR may be a
better guide to recognition of the susceptible patient than "other
factors such as length of history, age of onset, allergic factors,
etc."
Although these observations demonstrate that a wide circadian
variation in PEFR is associated with an increased risk of dying from
asthma at any time of day, they do not prove that the nocturnal
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asthmatic attacks are the immediate cause of death. Cochrane and
Clark (1975) analysed asthma deaths occurring in 1971 in the Greater
London hospitals in the 35-64 year old age group. They observed
that 13 of the 19 deaths attributable to asthma occurred between
midnight and 8 am. This initial study was followed by two studies
from Cardiff in which asthma deaths in all age groups, both in and
out of hospital, were analysed. In the first (Macdonald et al,
1976a), 90 deaths due to asthma were reported and death was noted to
be more common in patients who had recently been discharged from
hospital after a previous attack. The time of death was known in 79
of the 90 patients and showed no significant trend, but actual
details of the times were not given nor was the method of analysis
stated. The second paper (Macdonald et al, 1976b) reported 53
deaths over the same period of time (1963-74) that occurred in
hospital. The hour of death was known in 44 of the 53 subjects and
again showed no significant trend. Twelve patients were given
assisted ventilation and therefore the time of nocturnal death may
have been obscured as no data was given of the time that assisted
ventilation was initiated. Hetzel et al (1977a), however, in their
analysis of sudden deaths and ventilatory arrests due to asthma,
observed that 8 of 10 ventilatory arrests occurred between midnight
and 8 am.
Data on time of death from the four largest reported studies on
asthma mortality (Cochrane and Clark, 1975; Macdonald et al, 1976a
and b; British Thoracic Association, 1982), including previously
unpublished data, was recently combined, and analysed together
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(Lancet, 1983). Of the 219 deaths for which time of death was
known, 93 had occurred between midnight and 8 am, indicating a
significant (p < 0.01 on chi square) excess of nocturnal deaths.
The increase in death rate between midnight and 8 am in these
asthmatics was 28%, much higher than the average 5% increase in death
rate at night in the general population (Smolensky et al, 1972).
At best, therefore, nocturnal asthma is a nuisance, a minor symptom
to which the patient can become accustomed (Hetzel et al, 1977b).
At worst, it can threaten life and even occasionally kill.
Despite the clinical importance of nocturnal bronchoconstriction in
asthma, its causes and physiological consequences are poorly
understood. The purpose of the studies in Part III of this thesis
was to investigate the effects of asthma on electroencephalographic
sleep patterns, and to study nocturnal oxygenation and breathing
patterns in asthmatic patients. Before this could be done, however,
it was necessary to establish a normal reference range for irregular
breathing and oxygenation during sleep; this was the main purpose of
the studies in part II of the thesis. The studies in Part IV were




METHODS AND EVALUATION OF EQUIPMENT
Ideally, the methods used to study the physiology and pathophysiology
of sleep should satisfy at least four criteria:
(i) They should permit the investigator to define when the patient
is asleep.
(ii) The methods used should interfere with sleep as little as
possible.
(iii) They should be suitable for continuous recording, since sleep
is now known to comprise a number of different stages
(Aserinsky and Kleitman, 1953).
(iv) They should also be performed at night since that is when sleep
is most likely to be normal (Dahlgreen, 1981).
In addition, if studies are to be used clinically, it is important
that the methods and equipment be acceptable to patients.
The first study of breathing and oxygenation during sleep to satisfy
all of these criteria was described by Aserinsky in 1965. This
study combined three techniques which previously had been described
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separately: the definition of sleep and different sleep stages by
electroencephalography, electromyography and electrooculography; the
non-invasive measurement of arterial oxygen saturation by ear
oximetry; and the monitoring of breathing patterns by methods which
do not involve physical connection to the airway.
These were the methods used in the studies described in parts II and
III of the thesis. In part IV I studied the relationship between
sleep and airway calibre. This chapter contains a review of the
development and principles of these methods.
1. Definition of sleep and different sleep stages
In early studies of the relationship between sleep and respiration
(Smith, 1860; Mosso, 1878; Loewy, 1890; Magnus-Levy, 1894; Gujer,
1928; Ostergaard, 1944; Doust and Schneider, 1952; Robin et al,
1958), sleep was defined by behavioural criteria - either by
observation alone or by the failure of the subject to respond to
external stimuli. However, these criteria are highly subjective and
there must be some doubt as to whether the subjects were always
asleep when measurements were made. In most of the studies,
moreover, sleep was assumed to be a homogeneous state.
The modern era of research into the physiology of sleep began in
1953, when Aserinsky and Kleitman first described rapid eye movement
sleep (REM sleep), and its association with a characteristic
electroencephalographic pattern, dreaming, and changes in autonomic
nervous system activity including respiration. This important
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discovery demonstrated conclusively that the traditional view of
sleep as a homogeneous state was incorrect, and indicated that pre¬
existing observations or theories regarding sleep had to be re¬
examined or re-interpreted taking the stage of sleep into
consideration.
In this thesis, sleep is staged using the criteria of Rechtschaffen
and Kales (1968) who divide sleep into rapid eye movement (REM) and
subdivisions of non-rapid eye movement (NREM) sleep, according to
electroencephalographic (EEG), electromyographic (EMG) and
electrooculographic (EOG) features which are outlined briefly in
table 1.
These criteria are now widely accepted and allow reasonable
comparisons between studies. Sleep is a cyclical process, which
always starts in normal subjects with NREM sleep. Periods of REM
sleep are interpersed throughout NREM sleep and occur approximately
every 90 minutes throughout the night, lasting approximately 15
minutes in the first REM period, the subsequent REM periods tending
to be progressively longer (Williams et al 1974). It is thus
possible to predict roughly when a REM period is going to occur.
This was an important consideration in designing the experiment
described in Chapter 11.
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TABLE 1
CRITERIA FOR SLEEP STAGIMG
(after Rechtstaffen and Kales, 1968)













loss of alpha reduced
sleep spindles reduced
K complexes
> 20% delta waves reduced










EEG, electroencephalogram; EMG, electromyogram; EOG,
electrooculogram. Alpha activity consists of waves at a frequency
of 7-16 cycles per second. Sleep spindles are bursts of waves with
a frequency of 12-14 cycles/sec. K complexes consist of a well
defined sharp negative deflection in the EEG followed by a sharp
positive deflection, the amplitude exceeding background EEG activity.
Delta waves are high voltage slow waves (< 2 cycles/sec) and thus
stages 3 and 4 are sometimes termed "slow wave sleep".
2. Measurement of arterial oxygen saturation using non-invasive
techniques
Numerous authors have sampled blood intermittently during sleep from
indwelling arterial catheters (Birchfield et al, 1958; Pierce et al,
1966; Atlan et al, 1968; Bristow et al, 1969; Interiano et al, 1972;
Koo et al, 1975; Leitch et al, 1976; Flick and Block, 1977; Schroeder
et al, 1978; Coccagna and Lugaresi, 1978; Guilleminault et al, 1980;
Skatrud et al, 1981; Fletcher et al, 1983; Catterall et al, 1985).
While this method allows accurate measurement of the tensions of both
oxygen and carbon dioxide at separate time points, it is invasive,
and it is a poor method of detecting transient changes.
Non-invasive measurement of arterial oxygen saturation by ear
oximetry was first described in 1935 (Kramer, 1935; Matthes, 1935)
and an oximeter designed by Millikan (1942) was used to study
oxygenation during sleep in healthy individuals as early as 1952
(Doust and Schneider, 1952). However, these early models were
relatively insensitive, they were difficult to calibrate, and they
were cumbersome. It was not until the 1970's that accurate and
reliable ear oximeters, suitable for clinical use, became available.
In all of the studies described in this thesis, the Hewlett Packard
47201A ear oximeter was used. This instrument measures the
absorbance of light of eight different wavelengths transmitted
through the ear, and then calculates the subjects' arterial oxygen
saturation (SaC^) by relating these measurements to the absorbance
characteristics of each wavelength at known values of SaC^. A
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number of authors have shown this device to be accurate (Saunders et
al, 1976; Chaudhary and Burki, 1978; Douglas et al, 1979b; Ries et
al, 1984) irrespective of normal variations in skin pigment (Saunders
et al, 1976), and to have a rapid time response (Douglas et al,
1979b; Rebuck et al, 1983). In the largest of these studies,
Douglas and colleagues (1979b) in this laboratory compared the
arterial oxygen saturation measured by this instrument with
measurements in simultaneously sampled arterial blood, from both
normal subjects and patients with chronic bronchitis and emphysema,
on 465 occasions. They found that, provided the SaC>2 was greater
than 65 percent, and the carboxyhaemoglobin concentration less than 3
percent, the ear oximeter measured SaC>2 within 95 percent confidence
limits of
_ 4 percent. Changes in Sa02 in an individual are
probably measured more accurately than this (Ries et al, 1984).
Although the ear oximeter measures arterial oxygen saturation
accurately and continuously during the night, there is no general
agreement on the most appropriate way of expressing this data, for it
is unclear which parameters of nocturnal oxygenation are the most
important in pathophysiological terms. The measurements that have
been used by different authors include: the lowest SaC^ and maximal
fall in SaC>2 during sleep (Flick and Block, 1977; Douglas et al,
1979a; Stradling and Lane, 1983), the mean fall in SaC>2 during sleep
(Stradling and Lane, 1983), the number of 10 percent falls in SaC^
(Douglas et al, 1979a), the number of 4 percent falls in SaC>2 (Block
et al, 1979), the mean baseline SaC^ during sleep (Douglas et al,
1979a), and the percentage of time a patient's SaC^ is below a given
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value (Weil et al, 1978; Wynne et al, 1979). However, none of these
parameters alone adequately expresses all aspects of the oxygenation
profile (Slutsky and Strohl, 1980). In this thesis, therefore, as
in most previous papers, more than one measurement was made from the
oxygenation trace of each patient. The measurements chosen were the
SaC>2 when awake and supine, the number of 4 percent falls in SaC>2,
and the lowest SaC^ during sleep (see chapter 4).
3. The study of breathing patterns during sleep
In many studies of breathing during sleep, measurements of tidal
volume have been made using either a mouthpiece and noseclip, or a
facemask (reviewed by Douglas, 1982d). Although theoretically these
methods provide the most accurate means of assessing ventilation,
they suffer from a number of inherent errors including some which are
particularly relevant to sleep. First, both systems may modify the
depth and pattern of ventilation (Gilbert et al, 1972; Askanazi et
al, 1980). Second, leaks may occur, especially during sleep as
facial muscle tone decreases and patients move during sleep. Third,
these systems may be cumbersome and uncomfortable and are therefore
likely to interfere with sleep itself (Krieger and Kurtz, 1983).
Douglas and colleagues (1982a-d) have recently developed a tight-
fitting facemask with built-in leak detectors that is suitable for
detailed studies of the physiology of breathing during sleep (Douglas
et al, 1982a-c; Hudgel et al, 1984a, b; White et al, 1983, 1985), but
this equipment requires constant checks for leaks and is
unnecessarily sophisticated for most clinical studies.
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The study of breathing patterns by methods which do not involve
physical connection to the airway are more acceptable to the subject
being studied, and thus probably interfere less with sleep and
breathing patterns than either facemasks or mouthpieces and
noseclips. Many methods are available and they have been reviewed
by Sackner (1980). In the studies in this thesis, air flow was
detected by thermocouples, and thoracic movement was measured semi-
quantitatively by magnetometry.
3(i) Detection of airflow bv thermocouples: Thermocouples placed in
the path of airflow from the nose and mouth register the temperature
of respired gas. They can distinguish warm expired gas from the
cooler ambient air but they would not be expected to be sensitive
indicators of expired volume. In practice we have found that
respiration can virtually cease before thermocouple output
diminishes. Thus thermocouples can be used- to detect apnoea but are
not useful for detecting smaller changes in ventilation (Catterall et
al, 1983).
The respiratory magnetometer, however, can be used to provide semi¬
quantitative measurements of tidal volume.
3 (i i) Assessment of thoracic movement by magnetometry: The
respiratory magnetometer, developed by Mead and associates (1967),
is a convenient method for studying breathing during sleep both in
adults (Mortola and Anch, 1978; Tusiewicz et al, 1977; Sharp et al,
1980; Lopata and Onal, 1982; Skatrud et al, 1982; Goth et al, 1982;
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Catterall et al, 1983; Skatrud and Dempsey, 1985) and in children
(Bryan, 1979; Hagan et al, 1977). One coil of the magnetometer,
placed on the anterior surface of the thorax, generates a magnetic
field which is detected by another coil placed on the posterior
surface of the thorax. The output voltage is proportional to the
strength of the magnetic field which in turn varies with the cube of
the distance separating the transmitting and sensing coils (Sharp et
al, 1975). Since tidal volume is determined by movements of two
compartments - the rib cage and abdomen (Kono and Mead, 1967) - and
since tidal volume changes in these two compartments are linearly
related to changes in their anteroposterior diameters (Kono and Mead,
1967), the chest magnetometer can be used to measure tidal volume
quantitatively, provided that the relative contributions of chest and
abdominal compartments do not change throughout the measurement
period.
In this thesis, breathing was assessed by a magnetometer placed at
the level of the third intercostal space anteriorly. The linearity
of the magnetometer with respect to expired volume was assessed in
two normal subjects, a 29 yr old man and 28 yr old woman (fig 1).
The subjects wore a noseslip and breathed through a mouthpiece
connected by low resistance respiratory tubing to an Ohio 670 Wedge
Spirometer, while wearing magnetometer coils secured with adhesive
tape. The spirometer was calibrated using a 1 litre gas syringe
and both magnetometer and spirometer outputs were recorded on a
Bryans 28000 time-based recorder.
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Fig 1 Comparison of magnetometer signal with spirometer volume for
150 breaths in each of two normal subjects. The regression
(solid) line and 95% confidence limits for the measurements
(dashed lines) are indicated.
Recordings were made of 150 breaths in five series each of 3 0
breaths. The first series was with the subject supine, the second
in the left lateral position, the third supine, the fourth in the
right lateral position, and the fifth supine once more. This
allowed assessment of posture dependence and whether the calibration
returned to its previous level when a given posture was resumed.
Care was taken not to dislodge the magnetometer coils as the changes
in posture were made. The majority of measurements were made in the
supine posture because most subjects spent most of the night in that
position.
In both subjects, there was a highly significant linear correlation
(r = 0.77 and 0.74, both p < 0.001) between the magnetometer signal
and the spirometer measured volume (fig 1). When only data obtained
in the supine posture was used, the correlations were improved (r =
0.91 and 0.79 respectively, both p < 0.001).
Thus the thoracic magnetometer gives a reasonably good index of
expired volume in awake subjects. During sleep, however, the use of
the chest magnetometer to measure tidal volume is complicated by two
probiens:
First, we have observed that posture changes can sometimes cause
major changes in the calibration of the magnetometer and that these
calibration changes can persist after the body movement has ceased.
These sudden changes in calibration produced by alterations of
posture are easily recognised from the magnetometer signal but they
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mean that changes in the amplitude of chest movement during sleep can
only be assessed during periods when there are no major changes in
posture.
Second, the relative contributions of thorax and abdomen to tidal
breathing do change during sleep. Mosso (1878) first reported that
the thoracic contribution increased during sleep, a finding
subsequently confirmed by Shepard (1914) but not by Reed and Kleitman
(1926) or Magnussen (1944). Studies performed with EEC sleep
staging have all shown that the thoracic contribution to tidal volume
is increased in MREM sleep compared to wakefulness (Goldie and Green,
1961; Timmons et al, 1972; O'Flaherty et al, 1973; Tusiewicz et al,
1977; Mortola and Anch, 1978; Stradling et al, 1985), the largest
study in adults (Gothe et al, 1981) showing a signficant increase in
the ratio of rib cage to total measurement from 38 + 4 (SE)% in
wakefulness to 49 1 4% in NREM sleep. During REM sleep, however,
intercostal muscle tone is reduced (Tusiewicz et al, 1977; Tabachnik
et al, 1981a), and the relative contribution of the rib cage falls
again (O'Flaherty et al, 1973; Tusiewicz et al, 1977, Mortola and
Anch, 1978; Tabachnik et al, 1981; Stradling et al, 1985). In all
but the smallest of these studies (Tusiewicz et al, 1977), the
thoracic contribution to tidal volume in REM sleep was similar to
that in wakefulness.
In view of the changing thoracic contribution in different sleep
stages, wide limits had to be set to ensure that differences in
anteroposterior chest movement reflected differences in ventilation.
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In this thesis, therefore, I have defined hypopnoea as a reduction
of 50% or more in the amplitude of chest wall movement from the
previous stable baseline during sleep, lasting for at least 10
seconds, and hyperpnoea as at least a doubling of the amplitude of
chest wall movement for 10 seconds or longer (see Chapter 4).
In recent years, many investigators have used the respiratory
inductive plethysmograph (Milledge and Stott, 1977; Sackner, 1980) to
measure tidal volume during sleep. In theory, this device avoids
the problem of'changing thoracic and abdominal contributions for it
allows measurement of both rib cage and abdominal movements
simultaneously (Sackner, 1980). Inaccuracies due to posture changes
during sleep are not abolished by use of this instrument, however
(Zimmerman et al, 1983; Stradling et al, 1984). The studies
described in this thesis were commenced before the respiratory
inductive plethysmograph became popular and for the sake of
consistency the chest magnetometer was used throughout.
4. Assessment of airway calibre at night
Whereas breathing patterns and arterial oxygen saturation can now
readily be studied during sleep, it remains difficult to measure
airway calibre while patients are asleep. Lopes and colleagues
(1983) recently measured transpulmonary resistance during sleep in
five normal volunteers, using an oesophageal balloon to measure
pressure and the differentiated signal of a respiratory inductive
plethysmograph to obtain flow. However, this study did not
distinguish resistance in the bronchial tree from upper airway
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resistance. Furthermore, the measurement of flow using a
respiratory inductive plethysmograph has been shown to produce a
noisy signal even in awake immobile subjects (Mannix et al, 1984).
During sleep, this inaccuracy is likely to be increased because of
body movement (Zimmerman et al, 1983) and because of changes in the
phase relationship and relative contributions of the different
components of the chest and abdominal wall (Tusiewicz et al, 1977;
Mortola and Anch, 1978; Gothe et al, 1981; Tabachnik et al, 1981a,
b). Hudgel and colleagues measured flow with a pneumotachograph
attached to a tight fitting facemask during sleep. By placing an
additional catheter in the retroepiglottic space, they also
distinguished resistance changes above the larynx from those in the
lower airway. They found no significant changes in lower airv/ay
resistance during sleep, but their measurements were made only in
normal volunteers. Furthermore, sleep was severely disturbed in
these studies, with some of the patients not even entering stage 3 or
4 sleep. Similar studies in asthmatic patients would be very
difficult for they have disturbed sleep even without such
instrumentation (see Section III). Similar studies have recently
been attempted in our laboratory but with little success because of
the subjects' disturbed sleep.
In this thesis, I used measurements of forced expiratory volume in
one second (FEV^) and peak expiratory flow rate (PEFR) to study the
relationship between bronchoconstriction and sleep. In order to
relate these measurements to sleep or individual sleep stages,
patients were woken from electroencephalographically documented sleep
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and the measurements made immediately. The main drawback of this
approach is that sleep - one of the variables under study - has to be
disturbed in order for the measurements to be made. Another
potential problem is that forced expiratory manoeuvres are effort-
dependent, and it could be argued that patients who have just been
woken from sleep may not be as well motivated to produce a maximal
effort as they are during the day. This latter point is unlikely
to be a major source of error, however, since circadian changes in
peak flow can be demonstrated in patients who have not just been
wakened and, furthermore, asthmatic patients often waken from sleep
spontaneously because of wheeze.
Clearly it is not ideal to use FEVj and PEFR measurements to study
the relationship between bronchoconstriction and sleep. However, I
believe that this approach does provide useful information and, to
date, it is the only method of studying nocturnal bronchoconstriction
that has been shown to be practicable in patients with asthma.
5. Factors affecting sleep and breathing during sleep
Strict criteria for sleep stages and breathing patterns, and accurate
measurements of oxygenation and bronchoconstriction, allow
reasonable comparisons to be made between sleep studies. Equally
important, however, are the conditions under which sleep studies are
performed, for many variables can affect the results. These
include:
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5 (i) The "first night" effect
Most investigators (Agnew et al, 1966; Mendels and Dawkins, 1967;
Schmidt and Kaelbling, 1971; Webb and Campbell, 1979), but not all
(Kader and Griffin, 1983), agree that the sleep of normal subjects
(and therefore potentially any sleep-induced changes in breathing and
oxygenation) is disturbed in unfamiliar surroundings, the duration
and quality of sleep returning to normal on the second to fourth
consecutive nights. For this reason all of the studies in this
thesis were performed on two consecutive nights but data was
collected only on the second night.
5(ii) Time of study and shift work
In order to avoid the inconvenience of collecting data at night, some
sleep studies, including one of the most comprehensive studies of
breathing during sleep in normal subjects (Bulow, 1963), have been
performed during daytime in night workers, including some who changed
shifts frequently. Shift workers, however, especially those with
frequent changes of shift (Dahlgreen, 1981), are sleep deprived and
have abnormal patterns of sleep. Furthermore, sleep-deprivation can
interfere with ventilatory responses (Cooper and Phillips, 1982;
Schiffman et al, 1983; White et al, 1983). In this thesis, all of
the studies were performed at night and none of the subjects worked
shifts.
5(iii) Commonly used drugs and drinks
Alcohol, benzodiazepines and coffee can each affect sleep and also
breathing during sleep. It is important that this be taken into
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account in the interpretation of studies of breathing and oxygenation
during sleep.
Alcohol: Several workers have shown that alcohol increases the
frequency and duration of apnoeas in patients with the obstructive
sleep apnoea syndrome (Guilleminault et al, 1980; Issa and Sullivan,
1982; Scrima et al, 1982), although there is debate whether this
occurs in healthy subjects (Taasan et al, 1981; Scrima et al, 1982).
Dolly and Block (1982) also found a small but significant increase in
the frequency and duration of sleep apnoea in patients with chronic
obstructive lung disease who had taken alcohol, although episodes of
hypopnoea and desaturation, which are much more common than apnoea in
chronic obstructive airways disease (Catterall et al, 1983), did not
increase.
Benzodiazepines: Benzodiazepine hypnotics can cause an increase in
apnoea frequency and duration in normal subjects (Dolly and Block,
1982) and an increase in the duration and severity of arterial oxygen
desaturation in patients with chronic obstructive lung disease (Block
et al, 1984). Mendelson and colleagues (1981) described a 38 year
old man with a history of snoring, insomnia and hypersomnolence who,
after taking 30 mg of flurazepam for two nights, had an increasein
the number of sleep apnoeas from 18 per night to 100 per night with
an increase in daytime hypersomnolence.
Coffee: Coffee is a stimulant which decreases sleep and could
therefore affect nocturnal breathing patterns and oxygenation
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indirectly. Whether coffee affects breathing patterns during sleep
by a direct mechanism is unknown, but it can act as a bronchodilator
(Salter, 1859; Rail, 1980) and could almost certainly affect the
interpretation of studies of bronchoconstriction.
In order to avoid the above problems we studied no subjects who were
taking hypnotics and we instructed all the subjects to avoid alcohol
and coffee on study nights.
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Part II




REVIEW OF THE LITERATURE
Most studies of breathing and oxygenation during sleep in healthy
subjects have been concerned with the mechanism and control of
breathing in different sleep stages (REM and NREM). These studies
have been reviewed extensively (Phillipson, 1978; Douglas, 1985;
Krieger, 1985). In contrast, relatively little is known of the
normal variation in breathing and oxygenation during sleep among
different individuals, or of the factors which influence that
variation. It is important to know these variations since they
provide important reference data for clinical studies, and they may
also contribute to our understanding of the physiological factors
which control breathing during sleep. In this chapter I shall
review previous work on the normal inter-individual variation of
breathing and oxygenation during sleep and the factors which account
for that variation.
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1. Htp normal range of irregular breathing and oxygenation
during sleep
According to Guilleminault and colleagues (1978) a sleep apnoea
syndrome is diagnosed if, during seven hours of nocturnal sleep, at
least 30 apnoeic episodes are observed in both REM and NREM sleep,
some of which have to appear repetitively in NREM sleep. This
definition of the sleep apnoea syndrome has proved to be useful in
clinical practice, and it is widely quoted and accepted. However,
there remains uncertainty about the normal range of apnoea and
hypopnoea during sleep.
The study on which the above definition was based included only 20
normal control subjects (Guilleminault et al, 1978). Furthermore,
Guilleminault and colleagues (1978) gave relatively few details of
those normal subjects, stating only that "they were 40 to 60 years of
age and included subjects of both sexes." It is not clear how the
subjects were distributed with regard to age or sex, nor how the
authors defined normality. Also, this study involved no assessment
of the amount of hypopnoea, yet authors from the same centre, in a
different paper, diagnosed a sleep apnoea syndrome if patients had a
total number of apnoeas plus hypopnoeas which exceeded 30. This
confusion has been compounded by the fact that different groups have
defined hypopnoea in different ways (Block et al, 1979; Guilleminault
et al, 1980a, Catterall et al, 1983a).
Most patients with the sleep apnoea syndrome have many more than 30
apnoeas per night, so that diagnosis of this condition does not
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usually present problems. When trying to determine the importance
of sleep-disordered breathing in other diseases, however, (e.g.
asthma or chronic bronchitis ana emphysema) or in patients with ill-
defined symptoms - where differences from normality are likely to be
less marked - it is important to have more detailed reference data.
Block and colleagues (1979) questioned Guilleminault's definition of
the sleep apnoea syndrome. Some of their asymptomatic subjects
(Block et al, 1979) had frequent episodes of apnoea and/or oxygen
desaturation during sleep, and the authors suggested that arbitrary
separation of the sleep apnoea syndrome from normal at 30 apnoeic
episodes per night was unwarranted. However, most of the irregular
breathing and oxygen desaturation in the study by Block and
colleagues occurred in four very obese subjects (see below). The
normal range of apnoea, hypopnoea and oxygenation during sleep thus
remains uncertain.
2. Factors which mav account for the normal variation in breathing
and oxygenation during sleep in healthy subjects
2(i) Familial and genetic factors
There are rare instances in which a sleep apnoea syndrome may run in
families. Some well-known genetic disorders such as myotonic
dystrophy predispose to sleep apnoea (Cummiskey et al, 1978), but
other examples of familial sleep apnoea syndromes are less well
understood (Strohl et al, 1978; Elliott, 1978; Walsh and Montplaisir,
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1982). Guilleminault and colleagues (1986) recently reported five
families, each with a history of "near miss" or actual sudden infant
death syndrome, in which both children and adults had a small
posterior airway at the level of the tongue.
Thus, it seems likely that genetic factors may occasionally increase
susceptibility of patients to sleep apnoea. However, in most
patients with abnormalities of breathing and oxygenation during
sleep, there is no obvious hereditary element.
2(ii) Body weight
Obesity is such a common disease that obese subjects are sometimes
included in series of so-called normal subjects (Block et al, 1979;
Block, 1986). This is inappropriate in studies of respiration
during sleep, however, for obesity can undoubtedly affect sleep-
induced breathing patterns and nocturnal oxygenation.
Many patients with the sleep apnoea syndrome are obese. It has been
estimated that the sleep apnoea syndrome is at least 25 times more
common among morbidly obese patients than among patients of normal
weight (Peiser et al, 1984). Moreover, weight reduction in these
patients, accomplished either by dieting (Guilleminault et al, 1978;
Kerin et al, 1979; Browman et al, 1984) or by gastrointestinal bypass
surgery (Peiser et al, 1984), causes a reduction in the number of
sleep apnoeas per night. In 15 morbidly obese subjects with the
sleep apnoea syndrome, Peiser and colleagues (1984), found a
significant correlation (p < 0.025) between the number of apnoeas per
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hour of sleep and the percent excess weight. After weight
reduction, however, there was no linear relation between the amount
of weight lost and the decrease in apnoeas. Furthermore, most obese
patients do not suffer from the sleep apnoea syndrome (Peiser et al,
1984), and approximately half of the patients with the sleep apnoea
syndrome are within 20 percent of ideal body weight (Guilleminault et
al, 1978; Sullivan and Issa, 1985).
In summary, obese subjects are more likely to have the sleep apnoea
syndrome than non-obese subjects, although there is no clear cut
relationship between body weight and the incidence of sleep apnoea.
2(iii) Sex
Most patients with the sleep apnoea syndrome are men (Guilleminault
et al, 1978; Sullivan and Issa, 1985), and it has been suggested that
there may be a fundamental sex difference in breathing and
oxygenation during sleep (Block et al, 1979). However, there is
insufficient published data to know whether this is correct.
Although numerous studies of respiration during sleep have included
both male and female subjects (Smith, 1860; Ostergaard, 1944; Doust
and Schneider, 1952; Birchfield et al, 1959; Bulow, 1963; Duron,
1972; Snyder et al, 1974; Block et al, 1979; Ancoli-Israel et al,
1981; Carskadon and Dement, 1981; Smallwood et al, 1983), relatively
few publications (Bulow, 1963; Block et al, 1979; Ancoli-Israel et
al, 1981; Carskadon and Dement, 1981; Smallwood et al, 1983) have
contained sufficient data for a formal comparison to be made between
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the sexes, and only three of these (Bulow, 1963; Block et al, 1979;
Guilleminault et al, 1978) have included subjects under the age of 50
years.
Bulow (1963) in his study of respiration during sleep in 31 men and
22 women observed periodic breathing in most of the subjects studied,
but found no sex difference in either the severity or incidence of
periodic breathing. However, the subjects were studied during the
day and therefore probably slept poorly, and detailed observations on
breathing pattern were made only during sleep onset. Furthermore the
measurements were made with a mouthpiece and noseclip, which may be
inaccurate during sleep (see Chapter 2). Bulow observed that
ventilation in REM sleep was highly variable but no data was given
for either sex, and there were no measurements of oxygenation in that
study.
Block and colleagues (1979), using surface measurements to monitor
breathing patterns and ear oximetry to measure oxygenation, studied
breathing during sleep in 49 "normal" adults, of whom 30 were men.
Apnoea occurred in 3 of the 19 women and in 12 of the 30 men.
Desaturation (falls in arterial oxygen saturation of greater than 4
percent from the preceding base line) did not occur in the women, but
251 episodes of desaturation, in 17 subjects, were observed in the
men, most of these hypoxaemic episodes being associated with either
hypopnoea or apnoea. The authors concluded that sleep apnoea,
hypopnoea and oxygen desaturation occur in normal subjects and that
these findings are "almost exclusively male characteristics."
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However, there were important differences between the men and women
studied which could have affected the results. Most of the
irregular breathing and hypoxaemia in that study occurred in four
very obese men. The men were also older than the women, and there is
evidence that irregular breathing during sleep may increase with age
(see below). Furthermore, the men were more hypoxaemic than the
women even when awake and thus were predisposed to greater falls in
arterial oxygen saturation since they started the night on a steeper
part of the oxyhaemoglobin dissociation curve (Catterall et al, 1983;
Stradling and Lane, 1983). It is possible, therefore, that some of
the observed differences between the male and female groups in that
study could have been due to variables other than the subjects' sex.
The study by Guilleminault and colleagues (1978) also included
separate data for the two sexes. They monitored 20 normal control
subjects, between 40 and 60 years of age, over four consecutive
eight-hour nocturnal sleep periods, and found that the mean number of
apnoeic episodes per night was 7 (range 1-25) in the men and 2.1
(range 0-5) in the women. It is unclear whether these differences
were significant, however, for the authors gave no further details of
the results or of the subjects studied.
Neither Ancoli-Israel and colleagues (1981) nor Carskadon and Dement
(1981) found a sex difference in breathing patterns during sleep, but
these studies were performed exclusively on subjects over 62 years of
age. Furthermore, although the latter investigation is usually
quoted as an example of a study of normal individuals, the subjects
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were selected for study only if they had a history suggestive of
sleep apnoea. Smallwood and colleagues (1983) found apnoea and
hypopnoea during sleep to be more prevalent in elderly men than in
elderly women, but only 6 normal female subjects took part in that
study compared with a total of 35 women in the two earlier studies.
In none of these three studies of the elderly was oxygenation
measured.
In summary, there have been no detailed studies of breathing and
oxygenation during sleep in which healthy non-obese men have been
compared with healthy non-obese women over a wide age spectrum. In
previous work suggesting a fundamental sex difference in respiration
during sleep, the men and women were poorly matched for age, body
weight and oxygenation when awake, whereas the studies which shov/ed
no sex difference in respiration during sleep were all performed on
elderly subjects.
2(iv) Age
Breathing during sleep in children differs from that in adults
because the central nervous system, respiratory muscles, and
osteochondral structures are not fully developed. These differences
from adults are particularly marked in the newborn, and have been
reviewed elsewhere (Eenderson-Smart and Read, 1978; Ariagno and
Guilleminault, 1985).
In adults, Bulow (1963) found that the incidence and severity of
periodic breathing during sleep were not related to age. However,
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as noted above, these observations were made only during sleep onset.
Webb (1974), in contrast, using a loose-fitting facemask, observed
periodic breathing with episodes of apnoea in 9 of 11 normal subjects
over the age of 45 years but in none of the subjects under 45 years.
Carskadon and Dement (1981) used surface measurements to study
breathing patterns during sleep. They studied 40 elderly volunteers
aged 62 - 86 years and compared their results with those from 20
younger subjects aged 40 - 60 years who had been studied in the same
laboratory several years earlier (Guilleminault et al, 1978). They
concluded that the elderly subjects had many more "respiratory
events" during sleep than the younger subjects and that 15 of the 40
normal volunteers had a sleep apnoea syndrome. However, the authors
were not justified in drawing this conclusion from the data
presented, for a respiratory event was defined differently in the two
studies: in the elderly subjects the number of respiratory events
was taken as the number of apnoeas plus the number of hypopnoeas,
whereas in the younger subjects Guilleminault and colleagues (1978)
had counted only the number of apnoeas.
In none of the foregoing studies comparing older and younger subjects
was nocturnal oxygenation measured. Block and colleagues (1979)
found that falls in arterial oxygen saturation during sleep became
more frequent with increasing age. However, this initial study did
not include any women over the age of 51 years, and the average age
of the female subjects studied was only 29 years. In a subsequent
study (Block et al, 1980), the same group studied breathing and
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oxygenation during sleep in postmenopausal women and compared the
results with those of their initial study. They found that
postmenopausal women resembled men in having more falls in arterial
oxygen saturation than premenopausal women, i.e. the premenopausal
women appeared to be protected from irregular breathing and
hypoxaemia during sleep. The authors suggested that this might be
due to the higher levels of circulating progesterone in the
premenopausal women. However, the premenopausal women also differed
from the men and the postmenopausal women in a number of other
respects, each of which could have affected the results of those
studies. The premenopausal women were on average 18.5 kg lighter
than the men and they were both less heavy and less tall than the
postmenopausal women. They also slept for a shorter length of time
than the other subjects and they had a higher arterial oxygen
saturation when awake than either the men or the postmenopausal
women. This last difference between the premenopausal women and the
other subjects would have affected not only the nocturnal oxygen
saturation (the premenopausal women being less likely to desaturate
because of their position at the start of the nicht on a flatter
part of the oxyhaemoglobin dissociation curve) but also the authors'
estimate of the amount of irregular breathing, for Block and
colleagues (1979) diagnosed hypopnoea only if the change.in breathing
patern was accompanied by a significant (4 percent or greater) fall
in saturation.
In summary, these studies suggest that older subjects are more likely
to have irregular breathing and oxygen desaturation during sleep than
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younger subjects, but this has not been proved conclusively, partly
because of the methodological problems (including different
definitions of hypopnoea by different groups) and partly because some
studies included grossly obese subjects whose ages were not given.
The results of Block and colleagues (1979) suggest that the effect of
age may be more marked in women than in men but this also remains
unproven.
In order to clarify the effects of age and sex on respiration during
sleep in healthy subjects, and to determine a normal range of
irregular breathing and hypoxaemia during sleep, I performed studies




STUDIES OF BREATHING AND OXYGENATION DURING SLEEP IN
NON-CBESE HEALTHY SUBJECTS
This study was performed in order to establish a normal reference
range for irregular breathing and oxygenation during sleep in our
laboratory, and also to investigate the effects of age and sex on
respiration during sleep in non-obese subjects.
METHCPS
Subjects
Volunteers were sought, and all were studied if they were non-obese.
None of the volunteeers experienced daytime somnolence nor did they
report disturbed nocturnal sleep. Twenty of the subjects (10 M,
10 F) were younger than 45 years and 20 (9 M, 11 F) were older than
45 years (table 2). The 10 women younger than 45 yr were all
premenopausal and the 11 women over 45 yr were all at least 2 years
postmenopausal, 10 after natural menopause and 1 (a 46 yr old woman)
after a hysterectomy and bilateral salpingo-oophorectomy 3 years
previously. None of the subjects had present or previous evidence
of cardiorespiratory disease and, although 5 (3 M, 2 F) were smokers
and 4 (2 M, 2 F) were ex-smokers, all had normal FEV^, FVC, chest
44
Fig 2 Illustration of subject under study, showing
electroencephalograph^, electromyographic and electro-
oculographic leads, ear oximeter, thermocouples on nasal
prongs and magnetometer (white). The black sensor above
the magnetometer is a transcutaneous oxygen electrode which
was used in some studies, but proved to be inaccurate.
radiograph, and ear oxygen saturation when awake. No subject was
receiving hypnotic, sedative or stimulant drugs. Four of the
premenopausal women were taking contraceptive pills, and 3 subjects
older than 55 yr (2 M, 1 F) were receiving hypoglycaemic agents
orally for maturity onset diabetes, but none had evidence of either
peripheral or autonomic neuropathy (Catterall et al, 1984). All the
subjects studied were within 12% of average body weight (Documenta
Geigy, 1970).
As in all studies described in this thesis, each subject gave
informed consentto the study, which had the approval of the South
Lothian Division of Medicine Ethical Advisory Committee.
Procedure
The subjects slept in a quiet darkened room on 2 consecutive nights
(fig 2). The first night was for acclimatisation, and data were
collected only on the second night. Air flow was recorded at the
nostrils and mouth by thermocouples mounted on nasal prongs,
anteroposterior chest wall movement was recorded by magnetometer
coils at the level of the third intercostal space anteriorly, and
arterial oxygen saturation (SaC^) was recorded by the Hewlett-Packard
47201A ear oximeter (Hewlett-Packard, Waltham, MA) (Douglas et al,
1979b). Electroencephalogram (EEG) was recorded by 2 midline
frontoparietal electrodes, electrooculogram (EOG) by 4 electrodes




DEMOGRAPHIC DATA OF NORMAL SUBJECTS STUDIED
Female Subj ects
Premenopausal (n = 10) Postmenopausal (n = 11)
Mean Range Mean Range
Age (yr) 29 22-42 55 45-64
Body weight
(% average) 100 85-105 97 87-112
SaOo awake
(%) 97 95-99 96 9 5-9 8
Male Subj ects
Younger than 45 yr (n = 10) Older than 45 yr (n = 9)
Mean Range Mean Range
Age (yr) 31 23-42 55 45-68
Body weight
(% average) 98 87-104 98 88-105
SaO~ awake
(%) 97 9 5-99 96 94-9 8
Average body weight data derived from Documenta Geigy, 1970.
Fig 2 Illustration of subject under study, showing
electroencephalographic, electromyographic and electro-
oculographic leads, ear oximeter, thermocouples on nasal
prongs and magnetometer (white). The black sensor above
the magnetometer is a transcutaneous oxygen electrode which
was used in some studies, but proved to be inaccurate.
Once this equipment had been attached (approximately 11.15 pm), the
subject lay awake for 15 minutes, during which time data were
collected. Thereafter, the lights were switched off ("lights out")
and the subject was allowed to sleep. Unless assistance was sought
from the doctor and/or nurse present, the subjects were not disturbed
until 6.30 am. After final awakening ("lights on") at least 15
minutes of data were obtained before the monitoring equipment was
removed.
The Sa02, breathing patterns, and EEG traces were recorded on
separate time-based recorders synchronised by a computer-generated
time code every 15 minutes. EEG, EOG and EMG were recorded on an
SLE E8b recorder running at 15 mm/sec. Arterial oxygen saturation,
air flow and chest wall movements were displayed on a Mingograff 81
recorder running at 5 mm/sec. To allow easier identification of
long term shifts in oxygenation, saturation was also r-ecorded on a
Bryans 28000 recorder at 30 mm/hr. I analysed all breathing and
oxygenation traces without knowledge of the age or sex of the subject
under study and the breathing trace was analysed without knowledge of
the oxygenation record and vice versa. Both were analysed without
knowledge of the EEG sleep stage. Breathing patterns and
oxygenation during periods of wakefulness were excluded from the
final analysis as the aim of the study was to examine respiration
during sleep itself and also because subjects tended to be restless
if they woke transiently during the night, making analysis and
interpretation of the traces difficult at those times.
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Analysis of sleep duration and quality
The EEG. EOG and EMG traces were kindly analysed by Dr C M Shapiro
from the Department of Psychiatry, University of Edinburgh. The
traces were analysed by standard criteria (Rechtschaffen and Kales,
1968; table 1) in 20-second epochs, and the following variables
determined:
Time in bed (or total recording time), from "lights out" to "lights
on".
Sleep period time, from sleep onset (the onset of the first epoch of
stage 2 sleep) to final awakening.
Total sleep time, this being the total time spent in EEG sleep stages
1, 2, 3, 4 and REM.
Sleep efficiency index, a calculation of the total sleep time divided
by the time in bed.
Sleep onset latency, this being the time from "lights out" to sleep
onset.
The cumulative duration of each sleep stage, expressed both in
minutes and as a percentage of the total sleep time.
Aral yens of breathing patterns (fig 3)
The breathing pattern traces were analysed for:
Apnoea. defined as cessation of air flow at the mouth and the
nostrils for at least 10 seconds, and classified as obstructive or
central by conventional criteria (Guilleminault et al, 1976; fig 3).
Hypopnoea, in which, despite continued air flow, the amplitude of the













Fig 3 Classification of breathing patterns.
C = chest wall movement; N = airflow at nostril,
x is the amplitude (in arbitrary units) of the chest wall
movement in a subject during stable regular breathing while
asleep. In B, an episode of obstructive apnoea (in which
chest wall movement continues despite cessation of airflow)
is shown following an episode of central apnoea (in which
both airflow and chest movement cease).
immediately preceding regular breathing, for every breath during at
least 10 seconds (fig 3).
Hyperpnoea. in which the amplitude of the magnetometer signal doubled
for at least 10 seconds with continued air flow (fig 3).
Over 95% of episodes of apnoea, hypopnoea or hyperpnoea occurred
repetitively, giving easily recognised periods of irregular
breathing. Such a period was defined as starting with either an
apnoea, a hypopnoea, or a hyperpnoea, and ending at the beginning of
the next 2 minute period in which there was uninterrupted regular
breathing. The total duration of irregular breathing in each
subject was the sum of all these periods.
Analysis of arterial oxygen saturation
The following data were obtained from each oxygen saturation trace:
Awake saturation, this being the average of the pre and post sleep
values, there being no significant difference between these values.
This value thus reflected at least 30 min of EEG' confirmed
wakefulness, normally longer depending on sleep onset latency and the
time of final awakening, during which the subject was supine.
The lowest oxygen saturation during sleep, readings below 65% being
corrected to allow for the fact that the Hewlett-Packard ear oximeter
underestimates SaC^ at these levels (Douglas et al, 1979b).
The number of hypoxaemic episodes A hypoxaemic episode was defined
as a fall in arterial oxygen saturation of more than 4% from the
immediately preceding stable saturation during sleep, such a fall




Fig 4 Definition of a hypoxaemic episode. A hypoxaemic episode
was defined as a fall in arterial oxygen saturation (ear
oximeter) of more than 4% from the immediately preceding
stable saturation during sleep, lasting at least 1 min.
Results are quoted as mean * standard error or as mean and range.
The significance of observed differences between sexes and between
age groups was assessed by the unpaired "t" test (Documenta Geigy,
1970) .
RESULTS
Individual examples of the oxygen saturation traces and EEG sleep
stages obtained in four subjects are shown in fig 5.
The results for all the subjects are summarised in table 3 and in
figures 6 and 7.
The data for the subjects individually are shown in the appendix.
Tables 11 and 12 (appendix) contain the data on sleep duration and
quality, tables 13 and 14 the data on breathing patterns, and tables
15 and 16 the data on oxygenation.
Sleep duration and quality
Time in bed averaged 7 h 6 min with no significant difference between
the men and the women or between the older subjects (aged 45 yr or
more) and the younger subjects (under 45 yr; table 3). Total sleep
time averaged 6 h 17 min of which 81% (range 69 to 98%) was NREM
sleep and 19% REM sleep. There was no sex difference in the total
sleep time or the duration of individual sleep stages (table 3).
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Fig 5 Examples of arterial oxygen saturation (ear oximeter) and
EEG sleep stages throughout the night in 4 non-obese healthy
subjects. Top left, a 23 year old man; top right, a 22
year old woman; bottom right, a 68 year old man; bottom
left, a 63 year old woman.
 
Footnot to table 3
In subject 1, the EEG, EOG and EMG traces were of poor quality and no
sleep data was analysed. For the sleep data only, therefore, n = 20
for female subjects and n = 19 for the subjects under 45 yr. For
data on individual subjects, see appendix (tables 11-16).
those younger than 45 yr, with a shorter total sleep time (p < 0.02)
and less time spent both in stage 3 sleep (p < 0.01) and stage 4
sleep (p < 0.01) than the younger subjects (table 3). The duration
of REM sleep was similar in the older and younger subjects (table 3).
Breathing patterns
Episodes of hyperpnoea were very uncommon, occurring in only 3
subjects 1 to 3 times per night. They were not associated with any
significant EEG or SaC>2 change, and hyperpnoea is therefore not
considered further.
There was no difference between men and women in either the number of
apnoeas per night, the number of episodes of hypopnoea per night or
the sum of these in each subject (fig 6, table 3). Apnoea tended to
occur more frequently in the subjects older than 45 yr than in those
younger than 45 yr but there was a wide-range of values, especially
in the older subjects (appendix, tables 13, 14) and the difference
did not reach statistical significance (table 3). However, the
pumber of hypopnoeas (p < 0.01), the total number of apnoeas and
hypopnoeas (p < 0.01) and the duration of irregular breathing (p <
0.01) were each significantly greater in the subjects over the age of
45 yr than in those under 45 yr (fig 6; table 3). Almost all (168
of 179) of the apnoeic episodes recorded were obstructive. There
was no difference in any of these parameters of irregular breathing
between the men and women in either age group (table 3).
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Fig 6 Number of episodes of apnoea and hypopnoea per night in
relation to each subject's age and sex, showing that the
number of episodes increases with age but that there is no
difference between the sexes.
apnoeas per night. In a further two subjects (a 63 yr old woman and
a 68 yr old man), the total number of apnoeas plus hypopnoeas
exceeded 30 (Guilleminault et al, 1978; Carskadon and Dement, 1981;
fig 6).
Three subjects described themselves as snorers. These were a 51 yr
old man with 45 apnoeas and 40 episodes of hypopnoea, a 52 yr old man
with 2 apnoeas and 8 episodes of hypopnoea and a 63 yr old woman with
1 apnoea and 35 hypopnoeas. These three snorers did not have
significantly more irregular breathing than the other 37 subjects and
the difference in irregular breathing between the older subjects and
younger subjects remained significant if the three smokers were
excluded.
Arterial oxygen saturation
Arterial oxygen saturation when awake averaged 97% (range 94 to 99%),
with no significant difference between the men and the women (table
3). There was also no sex difference in either the number of
hypoxaemic episodes per subject or the lowest Sa02 recorded during
sleep in each subject (fig 7, table 3). In both sexes there was a
tendency for the arterial oxygen saturation to fall with increasing
age, especially during sleep (fig 7). The lowest Sa02 during sleep
averaged 89% (range 71 to 95%) in the men and women older than 45 yr
and 93% (range 90 to 96%) in those younger than 45 yr (p < 0.02; fig
7, table 3). Almost all (26 of 28) of the hypoxaemic episodes
occurred in the 20 older subjects, the majority (19 of 28) in
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Fig 7 Lowest arterial oxygen saturation (SaC^) during sleep in
relation to each subject's age and sex, showing that older
subjects become more hypoxaemic than younger subjects, but
that there is no sex difference at any age.
45 yr were also more hypoxaemic when awake than the younger subjects
(p < 0.05; table 3).
Sleep stage and breathing pattern during hvpoxaemic episodes
Of the 28 hypoxaemic episodes, all but 2 were associated with apnoea
or hypopnoea (appendix, tables 15, 16). Seventeen occurred during
REM sleep, 10 in stage 2 sleep, and 1 in stage 1 sleep (appendix,
tables 15, 16). The distribution of the hypoxaemic episodes through
the different sleep stages was similar in both sexes (appendix,
tables 15, 16).
Patient follow-up
In an attempt to determine the clinical significance of irregular
breathing and hypoxaemia during sleep, I reviewed all the subjects
who had more than 30 episodes of apnoea and/or hypopnoea per night,
and/or or falls in Sa02 below 90%. The mean follow-up period was 71
(range 29 to 81) months after the sleep study was performed. These
7 subjects (4 M, 3 F) were 51 to 68 yr of age when studied. One
later died at the age of 71 of a daytime myocardial infarction,
approximately 3 years after the sleep study. The other 6 subjects
were still alive at the time of writing. One of the women (63 yr
old at the time of the study) had developed mild angina and tinnitus
during the intervening 7 years but all the other patients had
remained asymptomatic. Specifically, none of the 6 patients still
available for review described any daytime somnolence, sleep
disturbance, or cardiac failure.
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DISCUSSION
The above results show that even in non-obese healthy subjects
breathing patterns and oxygenation during sleep show a wide
variability. There was no sex difference in hypoxaemia or irregular
breathing during sleep in this study, but the older subjects became
more hypoxaemic and had more episodes of apnoea and hypopnoea than
did the younger subjects. Some of the older subjects had more than
30 apnoeas per night (and thus satisfied the currently accepted
criteria for a sleep apnoea syndrome) but there was no evidence that
this was associated with increased morbidity or mortality over an
average follow-up period of 6 years.
There was no sex difference in breathing and oxygenation during sleep
in either the younger subjects or the older subjects. Thus these
results are in agreement with previous (Block et al, 1980; Ancoli-
Israel et al, 1981; Carskaddon and Dement, 1981) and concurrent
(Kreiger et al, 1983; Ancoli-lsrael et al, 1985; Bixler et al, 1985)
studies which showed no sex difference in respiration during sleep in
the elderly, but they contrast sharply with the observations of Block
and colleagues (1979), who found a strong male predominance in
irregular breathing and hypoxaemia during sleep. However, in that
study by Block and colleagues the men were more hypoxic than the
women when awake, and they were also both older and heavier than the
women. Since each one of these factors would have tended to
predispose the men to hypoxaemia and/or irregular breathing (see
Chapter 4), they may account for the differences between the sexes
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observed in that study. In the present study, the level of
oxygenation when awake was similar in the two sexes, the men and
women were age-matched, and none of the subjects was obese.
In the study by Block and colleagues (1979), the method of analysis
was slightly different from ours, as their definition of hypopnoea
required concomitant desaturation. This also would have tended to
produce a sex differential in their results, as the men in that study
started the night on a steeper part of the oxyhaemoglobin
dissociation curve than the women. To make the results of the
present study more strictly comparable to those of Block and
colleagues, we analysed the present study using their definition, but
the conclusion that there was no sex difference at any age was not
altered.
Krieger and colleagues (1983b) recently made observations similar to
our own in 40 normal subjects, aged 20 - 76 yr. Although their
definitions of hypopnoea and apnoea differed from the conventional
ones (being based on periods of 8 seconds rather than the
conventional 10 seconds), they also observed no sex difference in
breathing patterns during sleep. Measurements of oxygenation were
not included in that study.
Most patients with the sleep apnoea syndrome are male, and many are
obese (Guilleminault et al, 1978; Sullivan and Issa, 1985). The
present study does not exclude a sex difference in sleeps-disordered
breathing in obese subjects (Harman et al, 1981). Harman and co-
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workers (1981) found that asymptomatic obese men became hypoxaemic
during sleep and that asymptomatic obese women did not. Again,
unfortunately, the men in that study were considerably more hypoxic
than the women when awake, and this could account for most of their
excess sleep-disordered breathing. Further, some of the
asymptomatic obese young women studied by Kopelman and colleagues
(1983) did desaturate during sleep. Thus, it is not clear whether
there is a sex difference in sleep-disordered breathing in obese
subjects.
It has previously been reported that postmenopausal women have more
irregular breathing and hypoxaemia during sleep than premenopausal
women (Block et al, 1980), and this has led to speculation that
progesterone, a ventilatory stimulant, may influence breathing
patterns during sleep in normal subjects (Block et al, 1979,1980).
In the present study we found that the increase in sleep-disordered
breathing with age occurred equally in both sexes. Further, Douglas
and colleagues (1982a) also failed to detect any sex difference in
spontaneous ventilation during sleep in normal young subjects.
I
Thus, physiological levels of circulating progesterone may have
little influence on breathing during sleep, except perhaps in
pregnancy (Brownwell et al, 1986).
Although many previous (Webb, 1974; Lafont et al, 1978; Block et al,
1979 and 1980; Carskaddon and Dement, 1981; Ancoli-Israel et al,
1981) and concurrent (Smallwood et al, 1983; Krieger et al, 1983;
Bixler et al, 1985) studies have shown irregular breathing during
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sleep to be common in the elderly, there is much less published data
on oxygenation during sleep in normal subjects of different ages
(Block et al, 1979 and 1980). The tendency for nocturnal hypoxaemia
to increase with age in the present study was due to a combination of
two factors. The older subjects had more apnoeas and hypopnoeas
than the younger subjects, and also they were predisposed to falls
in arterial oxygen saturation by having lower oxygen saturations when
awake (Catterall et al, 1983; Stradling and Lane, 1983). The
importance of sleep apnoea as a cause of nocturnal hypoxaemia in the
elderly was recently noted by Bixler and colleagues (1985) although
they did not assess the amount of hypopnoea during sleep in their
elderly subjects. In the present study nocturnal hypoxaemia was
associated with hypopnoea as well as apnoea.
During an average follow-up period of 6 years only 1 of our subjects
with sleep-disordered breathing died. Furthermore, he was a 71 yr
old man and died in the afternoon of a myocardial infarction, a
condition extremely common in men of that age in this country.
These results suggest that irregular breathing and hypoxaemia during
sleep are relatively common in subjects ovr 50 yr of age but that the
individuals affected are often asymptomatic and that their sleep-
disordered breathing may be of little clinical significance.
However, these data are based on relatively few subjects. There is
a need for larger scale longitudinal studies of patients with
asymptomatic sleep disordered breathing to determine its clinical
significance.
56
The results of this study illustrate the limitations of the currently
accepted criteria for diagnosis of the sleep apnoea syndrome. Block
and colleagues (1979) were the first to question the usefulness of an
arbitrary cut-off of 30 apnoeas per night (or 4 apnoeas per hour of
sleep), mainly as a result of their observations on asymptomatic
obese men. The present study, and also that of Krieger and
colleagues (1983b), confirm that even non-obese healthy subjects can
have more than 30 apnoeas per night, although this has only been
reported in non-obese healthy subjects over the age of 50 yr. In
fact there is probably no need to have such a low cut-off for
diagnosis of the sleep apnoea syndrome since patients with this
syndrome nearly always have many more apnoeas per night than 30
(Guilleminault et al, 1978).
Should hypopnoeas be included in the criteria for diagnosis of a
sleep "apnoea" syndrome? The present study does not address this
issue. However, it does show that nocturnal hypoxaemia in normal
subjects is more often caused by hypopnoea than apnoea. There is
very little data on the clinical significance of hypopnoea but we
have recently described 5 patients with symptoms strongly suggestive
of a sleep apnoea syndrome who had frequent hypopnoeas during sleep
but relatively few apnoeas (Gould et al, 1986). This suggests that
there may also be a "sleep hypopnoea syndrome ", and that hypopnoeas,
as well as apnoeas, during sleep should be included in the assessment
of patients with a suspected sleep apnoea syndrome.
These results emphasise the importance of age-matched control
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subjects in studies of breathing and oxygenation during sleep, and
they also imply that sleep apnoea may sometimes be an incidental
finding in patients over 50 yr of age. Hence, a sleep apnoea
syndrome should be diagnosed only if the patient's symptoms suggest
the diagnosis. Furthermore, even if a patient over the age of 50 yr
is found to have frequent episodes of sleep apnoea, care must be
taken to exclude other causes for his or her symptoms.
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SUMMARY - PART II
The purpose of the studies in this part of the thesis was to
establish normal reference ranges for apnoea, hypopnoea and
oxygenation during sleep, and to investigate the effects of age and
sex on these variables.
Ear oxygen saturation (SaC^), oronasal airflow, chest movement and
electroencephalographic sleep stage were monitored throughout an
undisturbed night's sleep in 40 non-obese healthy adults (19 men and
21 women), aged 21 - 68 yr.
The results were as follows:
1. There was a wide range of irregular breathing and oxygenation
during sleep in the normal subjects, especially in those over
the age of 50 yr.
2. Older subjects had more irregular breathing and hypoxaemia
during sleep than young subjects.
3. In these non-obese healthy adults, irregular breathing and
hypoxaemia during sleep were equally common in men and women at
all ages.
4. Hypoxaemia during sleep was associated with hypopnoea as well as
apnoea.
59
5. Seven subjects had more than 30 episoldes of apnoea ana/or
hypopnoea per night, an/or SaC>2 falls below 90%, but none of
these individuals developed symptoms of the sleep apnoea
syndrome over an average follow-up period of six years.
The following conclusions were drawn:
1. Studies of breathing and oxygenation during sleep should include
age-matched control subjects.
2. Full assessment of irregular breathing during sleep should
include an assessment of the amount of hypopnoea as well as the
number of apnoeas.
3. There is no fundamental sex difference in irregular breathing
and oxygenation during sleep. Previous reports to the contrary
can probably be explained by poor matching of the men and women
with respect to age and sex.
4. In asymptomatic subjects over the age of 50 yr, irregular
breathing and hypoxaemia during sleep may be of little clinical
significance. However, this conclusion is based on
observations of only a small number of subjects, and long-term
studies involving more subjects will be needed to confirm this.
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5. The current definition of the sleep apnoea syndrome should be
modified. In particular, the syndrome should not be diagnosed
from the number of apnoeas (and hypopnoeas) alone; diagnosis
should also include consideration of the patient's symptoms.
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Part Hi
BREATHING AND OXYGENATION DURING SLEEP IN ASTHMA
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REVIEW OF THE LITERATURE
Despite the clinical importance of nocturnal asthma (see Chapter 1)
there have been relatively few studies of the physiological changes
which occur during sleep in asthmatic patients. However, there is
abundant evidence that sleep can induce changes in respiration in
other conditions.
In this chapter"I shall review (i) evidence that disordered breathing
induced by sleep can be clinically significant, (ii) previous studies
of oxygenation during sleep in patients with respiratory disease, and
(iii) previous studies of EEG sleep stages in patients with asthma.
1. Irregular breathing during sleep
l(i) The sleep apnoea syndrome
In 1965, Gastaut and colleagues observed frequent episodes of apnoea
during sleep in the Pickwickian syndrome (Burwell et al, 1956).
Although this was not the first description of sleep apnoea -
Broadbent having clearly described apnoea during deep sleep in a
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healthy elderly man in 1877 - the patients described by Gastaut and
colleagues were remarkable in that they had very large numbers of
apnoeas and, as a result (Drachman and Gumnit, 1962), frequent
disruptions of sleep. The authors suggested that the episodes of
sleep apnoea might be the underlying cause of the daytime
hypersomnolence which occurs in the Pickwickian syndrome.
The fact that these patients actually had apnoea during sleep was not
judged to be particularly remarkable, however, since patients with
the Pickwickian syndrome hypoventilate even when awake (Burwell et
al, 1956). Furthermore, sleep apnoea was subsequently observed in
other conditions associated with hypoventilation when awake,
including Ondine's curse (primary alveolar hypoventilation; Lugaresi,
1968), bilateral cervical cordotomy and other neurosurgical lesions
(Fielding, 1975; Krieger, 1978; Vella et al, 1984), poliomyelitis
(Hill et al, 1983) and encephalitis (White et al, 1983).
In 1973, Guilleminault and colleagues reported recurrent episodes of
sleep apnoea in two patients who had presented with insomnia.
Importantly, these patients did not have ventilatory failure when
awake. Guilleminault and colleagues suggested that sleep apnoea
might be the primary cause of these patients' symptoms and named the
new syndrome "Insomnia with sleep apnoea" (Guilleminault et al,
1973). They subsequently observed sleep apnoea in many more
patients presenting to a sleep disorders clinic, and noted that
insomnia was less common than a variety of other symptoms, including
daytime hypersomnolence, loud snoring, and morning headaches
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(Guilleminault et al, 1976 and 1978). They coined the term "sleep
apnoea syndrome" (Guilleminault et al, 1976, 1978, 1980, 1984), and
their observations were confirmed by many other workers (Lugaresi et
al, 1978; Remmers et al, 1978; Orr et al, 1979; Sullivan et al, 1981;
Coleman et al, 1982). The episodes of apnoea in most patients were
shown to result from intermittent collapse of the upper airway during
sleep (Remmers et al, 1978; Onal et al, 1982), often in patients who
had anatomical narrowing of the pharynx while awake (Harponi et al,
1983; Rivlin et al, 1984), and recent studies by Sullivan and
colleagues (1981) have shown that the condition can be treated
effectively by preventing upper airway collapse, using continuous
positive airways pressure administered via the nose. The prevalence
of the sleep apnoea syndrome is uncertain (Shapiro et al, 1982;
Ancoli-Israel et al, 1985; McNicholas, 1986) but one recent study of
working men in Israel suggested that the condition may affect some 1%
of the adult male population (Lavie et al, 1983).
The discovery of the sleep apnoea syndrome established the clinical
importance of disordered breathing during sleep, and led to the
widespread application of sleep studies in clinical practice (Kryger,
1985; Martin et al, 1985). Studies of breathing patterns during
sleep are relatively new to clinical medicine, however, and the
extent of their usefulness has still to be defined. Some of the
issues that need to be clarified are discussed below. The sleep
apnoea syndrome itself will not be discussed in detail in this
thesis, as it has been the subject of many recent reviews
(Guilleminault et al, 1976, 1978, 1980, 1984; Cherniak, 1981; White,
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1985; Sullivan and Issa, 1985).
l(ii) Sleep apnoea in other conditions
Sleep apnoea has been implicated in some cases of the sudden infant
death syndrome (SIDS; Kelly, 1983, Guilleminault et al, 1986).
However, an increased risk for SIDS does not apply equally to all
infants with apnoea (Kelly and Shannon, 1982; Southall et al, 1982)
and the majority of SIDS victims have not previously been identified
as having had apnoea (Mandell, 1981). The relationship between SIDS
and sleep apnoea is still unclear, therefore.
In adults, an increased prevalence of sleep apnoea has recently been
noted in patients with essential hypertension (Kales et al, 1984;
Lavie et al, 1984; Fletcher et al, 1985). Since episodes of sleep
apnoea are associated with a rise in systemic blood pressure
(Coccagna et al, 1972; Schroeder et al, 1978) and since 60-80% of
patients with severe sleep apnoea are hypertensive (Guilleminault et
al, 1980b and 1981), it has been suggested (Kales et al, 1984;
Fletcher et al, 1985) that sleep apnoea may be a cause of
hypertension. This intriguing relationship between sleep apnoea and
hypertension clearly warrants further study.
Guilleminault and colleagues (1980a) reported an increased number of
apnoeas during sleep in patients with chronic obstructive airways
disease. However, their patients had presented to a sleep disorders
clinic, and subsequent studies (Catterall et al, 1983) showed no
increase in sleep apnoea in patients with chronic bronchitis and
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emphysema who had presented to a clinic for respiratory diseases.
These results, and also more recent observations by Goldstein and
colleagues (1984), suggest that chronic bronchitis and emphysema is
not usually associated with an increased number of sleep apnoeas, but
that the sleep apnoea syndrome can occasionally coexist with chronic
obstructive airways disease.
l(iii) Sleep hypopnoea
As well as complete apnoea during sleep, hypopnoea can occur, as
discussed in Sections I and II. Episodes of sleep hypopnoea usually
occur during REM sleep, and in patients with pre-existing hypoxaemia
they can cause marked arterial oxygen desaturation (Flick and Block,
1977; Douglas et al, 1979; Catterall et al, 1983a). Recent studies
suggest that there may also be a "sleep hypopnoea syndrome" (Gould et
al, 1986; see Chapter 4).
l(iv) Breathing patterns during sleep in asthma
It is clear from the above examples that irregular breathing during
sleep has been implicated in the pathogenesis of a variety of
conditions. Asthmatic patients have marked worsening of symptoms at
night, but it is not known whether they have an increased number of
apnoeas or hypopnoeas during sleep, nor is it known whether
asthmatics have prolonged expiration during episodes of nocturnal
bronchoconstriction, as frequently observed clinically during acute
exacerbations of asthma (Batten, 1978; Fraser and Parre, 1979). If
a characteristic breathing pattern were associated with nocturnal
bronchoconstriction, it would facilitate the study of nocturnal
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asthma, for there is currently no satisfactory method, of measuring
airway calibre while patients are asleep (see Chapter 2).
2. Oxygenation during sleep in patients with respiratory disease
Non-invasive techniques for studying oxygenation and breathing during
sleep have been used not only to identify patients with the sleep
apnoea syndrome - in whom the major abnormalities usually lie not in
the lungs but in the upper airways or in the central control of
ventilation (Turino and Goldring, 1978) - but also to study patients
with respiratory disease. Most of these studies have been performed
in patients with chronic bronchitis and emphysema.
2(i) Nocturnal hypoxemia in chtonic bronchitis apd emphysema
Marked falls in arterial oxygen saturation during sleep are now known
to be common in patients with chronic airflow limitation. This was
first demonstrated by Trask and Cree (1962), who measured arterial
oxygen saturation continuously during sleep in 7 emphysematous
patients, using a Water's ear oximeter. They found that all 7
patients had worsening of hypoxaemia during sleep, and they also
noted that the lowest saturations during sleep were recorded in those
whose saturations were lowest when awake. They did not confirm
sleep electroencephalographically (see Chapter 2), however, the first
study to do so being that of Pierce and colleagues (196 6). These
investigators, and subsequently others (Atlan et al, 1968; Interiano
et al, 1972; Leitch et al, 1976), sampled arterial blood
intermittently during the night in patients with chronic obstructive
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airways disease and found that the mean fall in arterial oxygen
tension during sleep ranged from 4 mmHg (Atlan et al, 1968) to 7 mmHg
(Pierce et al, 1966).
Koo, Sax and Snider (1975) extended these observations by showing
that the arterial oxygen tension was lower in REM sleep than in NREM
sleep. However, their observations were also made from intermittent
samples of arterial blood.
The episodic nature of nocturnal hypoxaemia in these patients was
demonstrated conclusively by Flick and Block (1977) who made
continuous measurements of arterial oxygen saturation, using a
Hewlett-Packard ear oximeter (Saunders et al, 1976; Douglas et al,
1979b; see Chapter 2). In 10 patients with severe chronic
obstructive airways disease they observed transient falls in arterial
oxygen saturation of 12 - 44% from the baseline during sleep, with
lowest absolute SaC^ levels averaging 68%. These observations were
confirmed and extended by Douglas and colleagues (1979a) who studied
oxygenation during sleep in 12 patients with severe chronic
bronchitis and emphysema, of whom 10 were "blue bloaters" (Dornhorst,
1955) and 2 "pink puffers". All 10 of the "blue bloaters" had
episodes of transient hypoxaemia in which arterial oxygen saturation
fell by more than 10%, and the great majority (23/28) of the
hypoxaemic episodes occurred in REM sleep. The "pink puffers", in
contrast, despite equally severe airflow limitation, had no 10% falls
in oxygen saturation. It was suggested (Flick and Block, 1977;
Flenley, 1978; Douglas et al, 1979a) that these recurrent episodes of
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nocturnal hypoxaemia might lead to cor pulmonale and secondary
polycythaemia, a hypothesis supported by the observation that
pulmonary arterial pressure rises during the hypoxaemic episodes
(Coccagna and Lugaresi, 1978; Douglas et al, 1979a; Boysen et al,
1979; Fletcher and Levin, 1984; Catterall et al, 1985; Connaughton et
al, 1985) and by recent studies in rats, in which repetitive
transient hypoxaemia of similar magnitude increased both right
ventricular weight and red cell mass (Moore-Gillon and Cameron,
1985).
The mechanism of transient nocturnal hypoxaemia in chronic bronchitis
and emphysema has been studied by a number of authors. We and
others have shown that most of the hypoxaemic episodes are associated
not with apnoea, but with hypoventilation (Wynne et al, 1979;
Fleetham et al, 1980; Skatrud et al, 1981; Catterall et al, 1983;
Fletcher et al, 1983). However, there is debate whether the
hypoxaemic episodes are due only to hypoventilation since the fall in
arterial oxygen tension during the episodes is consistently greater
than the rise in arterial carbon dioxide tension. Some authors
(Pierce et al, 1966; Koo, Sax and Snider, 1975; Leitch et al, 1976;
Flick and Block, 1977; Fletcher et al, 1983) have argued that
worsening of ventilation/perfusion balance must also be invoked to
explain the observed changes in arterial gas tensions, but others
(Douglas et al, 1982d; Catterall et al, 1983 and 1985) have argued
that they are compatible with hypoventilation alone, since the
conditions during REM sleep are non steady-state. In order to
clarify this point, we recently designed a simple model of nocturnal
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hypoxaemia (Catterall et al, 1985). Four normal awake subjects
simulated the breathing pattern observed during the hypoxaemic
episodes of REM sleep while breathing a hypoxic gas mixture, and
arterial blood was sampled from an indwelling catheter at 90 second
intervals. We found that the changes in arterial gas tensions were
similar to those observed during the actual nocturnal hypoxaemic
episodes. These results suggest that it is unnecessary to invoke
changes in ventilation/perfusion balance to explain transient
nocturnal hypoxaemic episodes in patients with chronic bronchitis and
emphysema, although they do not exclude such changes (Fletcher et al,
1983).
2(ii) Nocturnal hvpoxaemia in other respiratory disorders
Episodes of hypoxaemia during sleep have also been described in
kyphoscoliosis (Mezon et al, 1980; Guilleminault et al, 1981),
diaphragmatic paralysis (Skatrud et al, 1980), cystic fibrosis
(Muller et al, 1980; Tepper et al, 1983) and interstitial lung
disease (Bye et al, 1984; Perez-Padilla et al, 1985). However,
there is little data on the effects of nocturnal asthma on gas
exchange.
2(iii) Nocturnal oxygenation in asthma
Hetzel and colleagues (1977b) measured arterial gas tensions at 6 am
and 2 pm in 7 asthmatic patients who were convalescing after an acute
attack of asthma and who had morning dips in PEFR of more than 25% of
their highest daily readings. At both times of day, alveolar
arterial oxygen tension gradient was widened and arterial oxygen
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tension correspondingly low. Arterial oxygen tension rose by an
average of 0.5 kPa between 6 am and 2 pm, with an average fall in
arterial carbon dioxide tension of 0.1 kPa, but neither of these
changes was statistically significant.
At the time that the studies in this thesis were first reported,
there had been no continuous measurements of oxygenation during the
night in patients with asthma.
3. Sleep in patients with asthma
Disturbed sleep is a common complaint in patients whose asthma is
poorly controlled. However, there is evidence that even relatively
mild asthmatics have disturbed sleep, as judged
electroencephalographically. Kales and colleagues (1968) compared
the electroencephalographic sleep patterns of 6 young adult
asthmatics with those of age-matched control subjects who had
previously been studied in the same laboratory. The patients
selected were having nocturnal symptoms but they were all out¬
patients and they "were not so disabled that they were not sleeping
or working". The asthmatics had more frequent awakenings than the
control subjects, with a significant reduction in both stage 4 sleep
and total sleep time. A similar disruption of sleep pattern
compared to age-matched control subjects was observed in 10 asthmatic
children, of whom 6 were out-patients and 4 were in a hospital for
asthmatic children (Kales et al, 1970).
However, these studies did not distinguish the effects of asthma
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itself from the effects of the patients' medication, since all of
these patients were regular users of either oral ephedrine,
aminophylline or oral phenobarbital, each of which can affect the
central nervous system and thus probably alter sleep patterns (Rail,
1980; Weiner, 1980; Rhina et al, 1985). The patients were asked to
omit their usual night-time medication but this would not have
removed their effect totally since, on the one hand, the sudden
withdrawal of drugs that affect sleep can itself affect sleep
patterns (Jaffe, 1980), whilst on the other hand phenobarbital has a
long half-life (mean 86 hours in adults; Alvin et al, 1975) and may
therefore still have been present in effective concentrations on at
least some of the study nights. Since ephedrine and phenobarbital
are rarely used to treat asthma nowadays, the current relevance of
these results is uncertain.
In summary, nocturnal oxygenation and breathing patterns have not
been studied in asthma. Electroencephalographic sleep patterns have
been recorded, but most of the data has been collected from children
and the relevance of that data to current practice is uncertain for
the patients were receiving drugs that are now rarely used to treat
asthma.
The next three chapters contain the results of studies of breathing
patterns, oxygenation and electroencephalographic sleep stages at
night in patients with asthma. The investigation described in
chapter 6 involved the study of 20 patients with relatively stable
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asthma throughout a night's sleep. Their electroencephalographic
sleep patterns, breathing patterns and arterial oxygen saturation
were compared with those of 34 age-matched normal subjects (chapter
4) and those of 20 patients with severe chronic bronchitis and
anphysema.
Chapter 7 contains an account of similar studies in a patient with
persistent daytime hypoxaemia due to asthma. I wished to know
whether this patient had more severe nocturnal hypoxaemia than other
asthmatic patients.
The study described in chapter 8 was designed to determine the effect
of ketotifen on oxygenation, breathing patterns and sleep patterns in
asthma. Ketotifen is a relatively new drug for the treatment of
asthma, but it also causes drowsiness. Since sleep is associated
with hypoxaemia in patients with chronic airflow limitation, I was
concerned that ketotifen might aggravate nocturnal hypoxaemia in
patients with asthma.
Chapter 6
BREATHING AND OXYGENATION DURING SLEEP
IN PATIENTS WITH CHRONIC STABLE ASTHMA
In this study, arterial oxygen saturation, breathing patterns and
EEG sleep stage were monitored throughout the night in 20 patients
with asthma. The results were compared with those of similar
studies in:
(a) The 34 healthy subjects described in Section I who were of
similar age to the asthmatic patients.
(b) 20 patients with chronic bronchitis and emphysema. The studies
of these bronchitic patients were initiated by Dr N J Douglas




The patients with asthma (15 men, 5 women) were aged 18 - 59 (mean
36.9) yr (table 4). They were recruited from the asthma clinics of
the Royal Infirmary and City Hospital, Edinburgh independent of any
symptoms of nocturnal asthma. All had reversible airways
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TABLE 4
















1 18 M 2.4 4.2 Pos Yes Yes S
2 18 M 1 .3 4.3 Pos No No S B
3 21 M 2.3 3.5 Pos No Yes s B
4 21 M 2.6 4.1 Pos Yes No s B
5 22 M 0.7 3.8 Pos Yes No s P
6 23 F 1 .2 3.0 Pos No No s B
7 27 M 0.5 2.8 Pos No Yes s B, P
8 30 F 1 .0 1 .7 Pos Yes No s I,P
9 34 F 2.3 3.7 Neg No No s B
10 34 M 1 .5 4.4 Neg Yes No s B
11 37 M 0.9 1.9 Pos Yes Ex s B j P
12 39 F 1 .0 2.0 Pos No No s B j P
13 40 M 1 .5 2.9 Neg Yes Yes s B,T
14 50 M 1 .2 2.5 Pos Yes Ex s B, 0
15 50 M 1 .0 2.7 Pos No Ex s C
16 51 F 0.6 1 .9 Pos Yes Ex s B, C,1, 0
17 53 M 0.5 2.7 Pos Yes Ex s B
18 56 M 0.9 2.0 Neg No No s B
19 56 M 1 .2 2.6 Neg No Ex s B
20 59 M 0.5 1 .3 Pos No No s I > B, P
M, male; F, female; Lowest and highest FEV^ recorded at clinical
during preceding 1-2 years; Pos, positive skin prick tests to at
least 2 common allergens; Neg, negative skin prick tests; FH,
family history; S, inhaled beta-2 agonist; B, inhaled
corticosteroid; I, inhaled ipratropium; C, inhaled disodium
cromoglycate; P, oral prednisolone. 5-10 mg daily, T, oral
theophylline; 0, oral beta-2 agonist.
obstruction with a documented increase in FEV^ of more than 20% after
inhalation of bronchodilators. Fifteen had positive skin prick
tests to Dermatophagoides pteronyssinus and/or grass pollens
(Bencard, Brentford, Middlesex) and 10 had a family history of atopy.
The patients were in a stable state with a mean diurnal variation in
PEFR (measured four times daily for 3 days before and 3 days after
the study in 13 patients) not exceeding 30% (mean 14%) of the
highest daily value, and none had had an acute attack of asthma in
the previous 6 weeks. Fifteen had a history of nocturnal wheeze, 6
were regular users of oral prednisolone (5 or 10 mg daily), 16 took
inhaled corticosteroids regularly, and 2 used inhaled disodium
cromoglycate regularly (table 4). These were discontinued during
the study, each at an unchanged dose, but oral theophyllines
(regularly taken by 1 patient) and oral beta sympathomimetic agents
(2 patients) were withdrawn 24 hours before the study. Inhaled beta
sympathomimetic agents (used by all patients) and ipratropium bromide
(3 patients) were each withheld for 6 hours before the study.
The age-matched control subjects were the 34 subjects described in
Section I who were under 60 yr of age (table 2). Their mean age was
38.5 yr (range 18-58 yr).
The 2 0 patients with chronic bronchitis (Medical Research Council,
1965) and emphysema all had severe irreversible airways obstruction
(FEVj < 1 litre) and none had had an acute exacerbation of their
disease for at least 6 weeks prior to being studied. Thirteen of
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the patients fulfilled our criteria for being "blue and bloated"
[type B (Burrows et al, 1964), non-fighters (Robin and O'Neill,
1963)], having daytime arterial hypoxaemia (Pa02 < 8 kPa) and
hypercapnia (Pa(X>2 > 6 kPa), pulmonary hypertension (mean pulmonary
arterial pressure > 18 mmHg) and secondary polycythaemia (red cell
mass > 28 ml/kg). Seven patients were termed "pink and puffing"
(type A, fighters), having relatively mild arterial hypoxaemia (Pa02
> 8 kPa) and a normal PaC02 (< 6 kPa) when awake. Both the "blue
bloaters" (mean age 58.4 yr) and the "pink puffers" (mean age 63.6
yr) were older than the asthmatic patients (table 5).
Recording and analysis of EEG sleep stage, breathing patterns and
arterial oxygen saturation
The patients slept in a quiet darkened room on two consecutive
nights, with the first night for acclimatisation.
Electroencephalographic sleep stage, breathing patterns and arterial
oxygen saturation were recorded and analysed by the Tnethods described
in Section II.
«
Breath-bv-breath analysis of breathing patterns
In 12 subjects (6 asthmatic patients and 6 control subjects), the
magnetometer signal was analysed on-line throughout the night by a
PDP 11/23+ computer (Digital Equipment Corporation, Maynard, MA, USA)





Breath period (Ttot = Ti + Te)
Respiratory duty cycle (Ti/Ttot)
Amplitude of chest movement, this being a semi-quantitative measure
(see Chapter 2) of tidal volume ("Vt")
"Inspiratory flow rate" ("Vt"/Ti)
"Minute ventilation" ("Vt/Ttot)
Arterial oxygen saturation (SaC^)
The computer was programmed for this analysis by Dr P K Wraith
(Department of Respiratory Medicine, University of Edinburgh), with
my assistance. The computer analysis was compared with hand
analysis in one normal subject when awake over 50 breaths during
which the breathing pattern was varied. For each of the independent
variables measured (Ti, Te and "Vt") the slope of the relationship
between the values obtained by computer analysis and the values
obtained by hand analysis was within 4% of unity, with a correlation
coefficient > 0.98 (fig 8).
Artefacts due to body movement were excluded by hand analysis of the
magnetometer signal record. Some body movements were also
associated with an obvious change in the calibration of the
magnetometer, a change which persisted after the actual movement.
This limited the interpretation of changes in "tidal volume" during
the night, as explained below.
To compare the effects of (i) time of night and (ii) REM sleep (both
of which may be associated with significant bronchoconstriction in
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Fig 8 Comparison between measurements obtained by hand analysis
and measurements obtained by computer analysis for
inspiratory time, expiratory time and amplitude of chest
movement for each breath during 50 breaths in 1 normal
subject.
asthmatic patients; see Chapter 11) on these breath-by-breath
measurements, the following periods were selected for analysis:
1. Breathing during the first 10-15 minute period of uninterrupted
NREM sleep after 1 am was compared with breathing during the
first 10-15 minute period of uninterrupted NREM sleep after
4 am. Since the calibration of the magnetometer sometimes
varied during the night (due to body movement), it was not
possible to compare "tidal volumes" at these two times - only
respiratory timing could be compared.
2. Breathing during 10-15 minutes of uninterrupted REM sleep was
compared with breathing during an immediately preceding 10-15
minute period of uninterrupted NREM sleep, irrespective of the
time of night. Sections were chosen for analysis only if they
contained no obvious change in the calibration of the
magnetometer (recognised by a sudden change in the amplitude of
the signal following body movement) throughout the 20-30 minute
period, a criterion that was met in 5 asthmatics and 5 control
subjects. Thus, in this analysis, it was possible to assess
changes in "tidal volume".
Calculation of arteriail oxygen tensions
The ear oximeter measures arterial oxygen saturation. Arterial
oxygen tensions were calculated (Severinghaus, 1966) from the
arterial oxygen saturation when awake and from the lowest saturation
during sleep, assuming:
(i) a similar oxyhaemoglobin dissociation curve in all subjects
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(ii) an arterial hydrogen ion concentration, [H+] of 40 nmol/1
(iii) a body temperature of 37°C
Errors due to the first assumption are probably small (Tweeddale et
al, 1976 and 1977). The second and third assumptions are also
unlikely to be associated with large errors, since arterial hydrogen
ion concentrations rise during sleep whereas temperature falls at
night and these changes have opposite effects on the oxyhaemoglobin
dissociation curve. Measurements of arterial hydrogen ion
concentration during sleep have not been made in asthmatic patients,
but in patients with chronic bronchitis and emphysema the mean values
recorded in three studies (Koo et al, 1975; Leitch et al, 197 6;
Douglas et al, 1979a) averaged 49 nmol/1. Kreider and colleagues
(1958) found the mean lowest temperature at night to be 36.2°C. If
these values of [H+] (49 nmol/1) and temperature (36.2°C) are used to
calculate PaC^ from, say, the lowest SaC>2 during sleep in the
asthmatic patients (mean 85.5%), the resulting PaC^ would be 7.1 kPa,
compared with a PaC>2 of 6.7 kPa if [H+] is assumed to be 40 nmol/1
and temperature 37°C, i.e. the error of these two assumptions in this
example would be 6%.
The largest source of error in this method of determining arterial
oxygen tension lies in the measurement of arterial oxygen saturation
by the ear oximeter, particularly at the higher levels of SaC^. In
non-smokers (ie when the carboxyhaemoglobin level is < 3%), the ear
oximeter has an error of ^4% (Douglas et al, 1979b). At the highest
level of SaC>2 recorded in any asthmatic patient (98%), an error of
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+4% in the oxygen saturation would mean an error of +66% in the
calculated Pa02 (Pa02 corresponding to Sa02 of 98%, assuming [H+] of
40 nmol/1 and a temperature of 37°C, = 15.5 kPa; Pa02 corresponding
to Sa02 of 94% = 9.3 kPa), whereas a +4% error at the lowest average
Sa02 recorded during sleep in the asthmatic patients (mean 85.5%)
would mean a +10% error in the calculated Pa02 (Pa02 corresponding to
Sa02 of 85.5% = 6.7 kPa; Pa02 corresponding to Sa02 of 81.5% = 6.1
kPa). These are the worst possible errors that would be anticipated
in an individual asthmatic patient, and in a group of patients the
average error would almost certainly be much less.
Thus the transformation from arterial oxygen saturation to arterial
oxygen tension is only an approximation. However, direct
measurement of oxygen tension would have involved the insertion of an
arterial catheter, a procedure that could not have been justified
ethically in most of our subjects. Furthermore, it is very
difficult to sample arterial blood at exactly the lowest oxygen
saturation during sleep since it is impossible to predict exactly
when this is going to occur. To estimate the maximal change in Pa02




1. Requests to use inhalprs during the night in the asthmatic
patients
Five of the asthmatic patients asked to use a brcnchodilator inhaler
during the night - at 5.55 am (patient 2), 1.30 am (patient 8), 5.35
am (patient 10), 4.40 am (patient 14), and 5.15 am (patient 15).
Three of these awakenings were from NREM sleep (two from stage 2
sleep and one after 10 minutes of stage 1 sleep following a period of
stage 2 sleep) and one was from REM sleep. The other request to
use an inhaler was made after 15 minutes of wakefulness. Thus there
was no clear relationship between requests to use a bronchodilator
inhaler and either the time of night or the EEG sleep stage. After
using an inhaler each patient was allowed to return to sleep.
2.- Overnight fall in FEV^ in the asthmatic patients
All the asthmatic patients showed a fall in FEV^ overnight. The
FEVj before sleep averaged 2.3 1 and the FEVj after sleep (taken as
the level on waking during the night in the five patients who used a
bronchodilator inhaler in the night, and as the level at "lights on"
in the remaining patients) averaged 1.5 1 (p < 0.001; appendix, table
19). All of these measurements were made before the use of a
bronchodilator inhaler. One patient had used an inhaler before a
measurement was taken and his FEV^ measurements were therefore
excluded from the analysis.
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3. Sleep
3(i) Asthmatics vs normal subjects: The asthmatic patients slept
less well than the normal subjects (table 5, fig 9). Time in bed
was similar in the two groups (table 5), but the asthmatics spent
more of that time awake than did the normal subjects (table 5), with
less time in stage 2 sleep (p < 0.001), less time in slow wave sleep
(stages 3 + 4; p < 0.02) and less time in REM sleep (p < 0.01) than
the normal subjects (table 5). Total sleep time was on average 84
minutes less in the asthmatics than in the normal subjects (p <
0.001; table 5).
When expressed as a percentage of each subjects' total sleep time,
the durations of each sleep stage were similar in the asthmatics and
normal subjects, with the exception of stage 1 sleep which occupied a
significantly greater proportion of total sleep time (TST) in the
asthmatics (mean 12.1% of TST) than in the normal subjects (mean 7.1%
of TST; p < 0.02).
3(ii) Asthmatics vs patients with chronic; bronchitis and emphysema:
Despite their difference in age (Williams et al, 1974), the asthmatic
patients and the "pink puffers" had a similar duration and quality of
sleep (table 5; fig 9). Total sleep time in the asthmatic patients
was significantly shorter than in the "blue bloaters" but there was
no significant difference between the asthmatics and the "blue
bloaters" in either the sleep efficiency index or the duration of any
individual sleep stage (table 5; fig 9).
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TABLE 5 (cont'd)
ASTHMA NORMAL CHRONIC BRONCHITIS AND EMPHYSEMA
(n-20) (n=34) Pink puffers Blue bloaters
(n=7) (n=13)
Mean Mean Mean Mean
*SE tSE + SE + SE
Arterial oxveen saturation
Sa02 awake (%) 9 5.4+0 .5 97 .0+0.2****' 94.0+0.6 78.2+3.0****
Lowest SaOo asleep
(%) OO OS 0
1+ 1—1 • 1—' 92 .8+0.4****■ 81 .3+2.6 52.4+14.00****
No. of hypoxaemic
episodes 2.3+0.5 0 .4+0. 1****■ 3.6+0.9 > 50****
Maximal Sa02 fall 9.4+0 .9 4.2+0.7**** 12.9+2.8 25 .9+2.5****
Calculated Pa02
fall (kPa) 3.6+0.3 3 .8+0 .3 3.2-+0.6 2.2+0.8***
% Pa02 fall 43+10 29+2 33^5 36+3
Maximal SaC^ fall = SaC^ awake - lowest SaC^ asleep.
Calculated PaC^ fall = PaC>2 awake (calculated) - lowest Pa02 asleep
(calculated).
% Pa02 fall = (Maximal Pa02 fall/Pa02 awake) x 100.
The number of hypoxaemic episodes (ie Sa02 falls > 4%) in the "blue
bloaters" was not counted accurately.
Results without asterisk were not significantly different from those in
the asthmatics.
* Different from asthma, p < 0.0 5.
** Different from asthma, p < 0.02.
*** Different from asthma, p < 0.01.
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Fig 9 Sleep efficiency index in 20 stable asthmatics, 34 age-
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10 Relationship between the overnight fall in forced expiratory
volume in 1 second (FEVj) and total sleep time in 18 stable
asthmatics. The overnight change in FEV^ is expressed in
litres in the upper figure and as a percentage of the pre-
sleep FEVj in the lower figure. The regression (solid) line
and 95% confidence limits for the measurements (dashed line)
are indicated.
3(iii) Relation between overnight fall in FEV^ and sleep in the
asthmatic patients: Although the asthmatic patients slept less well
than their age-matched control subjects, there was no clear
relationship between the overnight change in FEV^ (expressed either
in litres or as a percentage of the pre-sleep FEV^) and either the
total sleep time (fig 10) or the sleep efficiency index.
4. Amoea and hvpocnoea during sleep
As in normal subjects (see Chapter 6), apnoea and hypopnoea occurred
much more frequently in the asthmatics than did hyperpnoea.
Although episodes of hyperpnoea followed by a respiratory pause
(possibly representing sighs) were seen in three of the asthmatic
patients during intervening periods of wakefulness, only two episodes
of hyperpnoea, both in the same subject, were observed during actual
sleep and they were not associated, with any significant change in
arterial oxygen saturation or in EEG sleep stage. Hyperpnoea is
therefore not considered further.
The prevalence of apnoea and hypopnoea in the asthmatic patients
showed the normal tendency to increase with age, 253 of the 329
episodes of apnoea and hypopnoea recorded in the 20 asthmatic
patients occurring in the 8 subjects over the age of 40 yr (p <
0.001). As in the normal subjects there was no sex difference in
the prevalence of apnoea and/or hypopnoea during sleep.
4(i) Asthmatics vs normal subjects: During the time spent asleep,
there was no significant difference between the asthmatics and the
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normal subjects in either the number of apnoeas, the number of
hypopnoeas, the total number of apnoeas plus hypopnoeas or the number
of minutes of irregular breathing, either per night or per hour of
sleep (table 5).
4(ii) Asthmatic patients vs patients with chronic bronchitis and
emphysema: Breathing patterns during sleep were similar in the
asthmatic patients and bronchitic patients, with no significant
difference in the prevalence of apnoea and/or hypopnoea, or the total
duration of irregular breathing, either between the asthmatic
patients and the "pink puffers" or between the asthmatic patients and
the "blue bloaters" (table 5).
5. Arterial oxygen saturation
The prevalence of nocturnal hypoxaemia in the asthmatic patients
showed the normal tendency to increase with age', 30 of the 45
hypoxaemic episodes (67%) in the asthmatic patients occurring in the
8 subjects over 40 years of age (p < 0.01). As in normal subjects
there was no sex difference in either the number of hypoxaemic
episodes per night or the lowest arterial oxygen saturation during
sleep.
5(i) Asthmatics vs normal subjects: The mean arterial oxygen
saturation when awake averaged 95.4% (range 91 - 98%) in the
asthmatics, but 97.0% (range 94 - 99%) in the age-matched healthy
subjects (p < 0.001; table 5). Hypoxaemia during sleep was both
more common and more pronounced in the asthmatics. Hypoxaemic
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episodes occurred 0-7 (mean 2.3) times per night in the asthmatics
and 0-5 (mean 0.4; p < 0.001) times per night in the normal
subjects (table 5). The mean lowest SaC>2 during sleep was 86.0%
(range 77 - 94%) in the asthmatics, whereas this was 92.8% (range 72
- 96%; p < 0.001) in the healthy controls (table 5; fig 11). The
mean fall in SaC^ from the level awake to the lowest level during
sleep was 9.4% (4 - 19%) in the asthmatics and 4.2 (2 - 24%; p <
0.001) in the control subjects (table 5).
5(ii) Asthmatic patients vs patients with chronic bronchitis and
emphysema: The SaC>2 awake, the maximal fall in SaC^ during sleep,
the number of hypoxaemic episodes, and the lowest SaC>2 recorded
during sleep were each similar in the asthmatic patients and the
"pink puffers" (table 5; fig 11). In contrast, the "blue bloaters",
who had lower levels of arterial oxygen saturation when awake (mean
78.2%, range 60 - 89%) than the asthmatic patients (mean 95.4%, range
91 - 98%; p < 0.001), had much greater falls in SaC>2 during sleep
(mean 25.9%, range 18 - 47%) than did the asthmatics (mean 9.4%,
range 4 - 19%; p < 0.001; table 5; fig 11). The lowest Sa02 during
sleep in the "blue bloaters" averaged 52.4% (range 30 - 75%) compared
to 86.0% (range 77 - 94%; p < 0.001) in the asthmatic patients (table
5; fig 11).
These results suggested that the largest falls in arterial oxygen
saturation during sleep tended to occur in the subjects who had the
lowest levels of SaC>2 when awake. The relationship between the
level of oxygenation during wakefulness and the lowest level of
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oxygenation during sleep was therefore explored further, using data
from all 80 subjects studied in this way i.e. all 40 normal subjects
described in Section II, together with the 20 asthmatic patients and
the 20 bronchitic subjects.
6. Relationship between the level of oxygenation when awake and the
lowest level of oxygenation during sleep
When the data for the normal subjects, the asthmatics, the "pinK
puffers" and the "blue bloaters" were plotted together, there was a
clear and curvilinear relationship between the arterial oxygen
saturation during wakefulness and the lowest arterial oxygen
saturation measured during sleep (fig 12a). When the calculated
arterial oxygen tensions were plotted, there was a significant linear
correlation (p < 0.001; fig 12b) between the calculated Pa02 during
wakefulness and the lowest calculated Pa02 during sleep, with the
equation:
Pa02 asleep (kPa) = 0.58 x Pa02 awake (kpA) +1.06
n = 80; r = 0.83; p < 0.001
7. Arterial oxvaen tension
The calculated maximal fall in arterial oxygen tension during sleep
in the asthmatic patients was 3.6 1 0.3 kPa. This was not
significantly different from that of either the normal subjects, or
the "pink puffers", and it was actually greater than the calculated
Pa02 fall in the "blue bloaters" (table 5). When expressed as a
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Fig 11 Lowest arterial oxygen saturation during sleep (ear
oximeter) in 20 stable asthmatics, 34 age-matched healthy
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12a Relationship between the arterial oxygen saturation (SaC^)
when awake and the lowest SaC>2 during sleep in 40 healthy
subjects, 20 stable asthmatics and 20 patients with chronic
bronchitis and emphysema.
Calculated ftiC>2 awake (kRa)
12b Relationship between the calculated arterial oxygen tension
(PaC>2) when awake and the lowest calculated PaO? during
sleep in 40 healthy subjects, 20 stable asthmatics and 20
patients with chronic bronchitis and emphysema. The
regression (solid) line and 95% confidence limits for the
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Fig 13 Relationship between the overnight fall in FEV-, (FEV^ before
sleep - FEVj after sleep) and the overnight fall in arterial
































14 Relationship between breathing patterns and arterial oxygen
desaturation (ear oximeter) in asthmatic patients. Each
point represents a hypoxaemic episode. The fall in
arterial oxygen saturation is from the stable level during
sleep.
Pa02 in the asthmatics was no different from that of any of the other
three groups of subjects (table 5).
8. Relationship between nocturnal hvpoxaemia and overnight fall in
FEV^ in the asthmatic patients
There was no correlation between the maximal fall in arterial oxygen
saturation during sleep and the overnight change in FEV^ in the
asthmatic patients (fig 13).
9. Sleep stage during hypoxaemic episodes in the asthmatic patients
Most (30/45) of the hypoxaemic episodes (67%) occurred during REM
sleep which occupied, on average, 15.8% of total sleep time. In
only two patients was the rate of occurrence of hypoxaemic episodes
in NREM sleep greater than in REM sleep (p < 0.001). Thirteen of
the remaining 15 hypoxaemic episodes occurred during stage 2 sleep
and one during stage 1 sleep (appendix; table 19).
10. Breathing pattern during hypoxaemic episodes in the asthmatic
patients
Most (32/43) of the hypoxaemic episodes (74%), including those with
the greatest falls in arterial oxygen saturation (fig 14), occurred
during hypopnoea (20 episodes) or apnoea (12 episodes). In 6 of the
remaining 11 episodes, the breathing pattern showed a cyclical
pattern with recurrent falls in the amplitude of chest movement, but
these reductions in chest movement were not sufficient to satisfy our
strict criteria for hypopnoea. During two of the hypoxaemic
episodes, the breathing pattern could not tie determined because the
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magnetometer trace was of poor quality.
11. Computer analysis of breathing pattern
Examples of the frequency histograms obtained from the computer
analysis of the breathing patterns are shown in fig 15. The results
for all the patients studied in this way are summarised in figs 16
and 17.
11 (i) Changes between NREM sleep and REM sleep; During REM sleep,
there was a fall in the amplitude of chest movement ("Vt") compared
with NREM sleep, but this change was similar in the asthmatics and
the control subjects (fig 16a). There was no significant change in
respiratory timing in either group (fig 16a).
In both groups the breathing pattern became more variable during REM
sleep, as shown by an increase in the coefficient of variation
(mean/standard deviation) of all the variables measured (figl6b).
This variability was similar in the asthmatics and the control
subjects (fig 16b).
11(ii) Changes between NREM sleep at 1 am and NREM sleep at 4 am:
There were no significant changes in any measure of respiratory
timing between NREM sleep at 1 am and NREM sleep at 4 am, either in
the asthmatic patients or in the control subjects (fig 17).
Although the asthmatic patients had evidence of nocturnal
bronchoconstriction (overnight fall in FEV]_ 0.9 1 0.8 1 in these 6
patients), there was no significant increase in expiratory time (Te)
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Expiratory Time (Te)
Fig 15a Frequency histograms of expiratory time for each breath
during a 10-15 minute period of REM sleep and an adjacent
10-15 minute period of NREM sleep in 5 patients with asthma.
See text for details.
Breath Period (Tj-04.)
Fig 15b Frequency histograms of breath period for each breath during
a 10-15 minute period of REM sleep and an adjacent 10-15
minute period of NREM sleep in 5 patients with asthma. See
text for details.
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Fig 15c Frequency histograms of amplitude of chest movement for each
breath during a 10-15 minute period of REM sleep and an
adjacent 10-15 minute period of NREM sleep in 5 patients
with asthma. Hie breaths analysed were the same as those










































16a Breathing patterns during REM and NREM sleep.
The figures shown are the mean values of expiratory time
(Te), breath period (Ttot), respiratory duty cycle
(Tp/T^-Qt), amplitude of chest movements ("Vt"),
"ventilation" ("V^/t^, ) an(j "inspiratory flow rate"
("Vt"/T^) during NREM sleep and an adjacent period of REM
sleep in 5 asthmatics and 5 control subjects. The number
of breaths analysed in the asthmatics was 227 * 12 in NREM
sleep and 246 _12 in REM sleep. The number of breaths
analysed in the control subjects was 208 1 8 in NREM sleep


































16b Breathing patterns during REM and NREM sleep.
The figures shown are the coefficients of variation
(mean/standard deviation) of the variables shown. The
breaths analysed were the same as those in fig 16a.
MEAN
ASTHMA NORMAL





























Fig 17 Breathing patterns at 1 am and 4 am.
The figures shown are the means and coefficients of
variation (mean/standard deviation), of expiratory time
(Te), breath period (TtClt), and respiratory duty cycle
(T^/Tj-qj.) during NREM sleep at 1 am and NREM sleep at 4 am
in 6 stable asthmatics and 6 control subjects. See text
for details. The number of breaths analysed in the
asthmatics was 227 * 12 at 1 am and 190
_ 8 at 4 am. The
number of breaths analysed in the control subjects was 225 +
10 at 1 am and 214 ^ 12 at 4 am.
during the night. Mean Te/Ttot decreased by an average of 8%
between 1 am and 4 am; this was not different from the 12% in the
control group.
DISCUSSION
The asthmatic patients in this study slept less well and became more
hypoxaemic during sleep than did healthy subjects of the same age.
However, their nocturnal breathing patterns were normal.
sleep
The pattern of sleep disruption in our asthmatic patients was similar
to that reported in previous (Kales et al, 1968) and concurrent
(Montplaisir et al, 1982) studies of stable adult asthmatics. The
main abnormalities were an increase in the amount of time spent
awake, a decrease in sleep efficiency and a decrease in total sleep
time. There was also an increase in the percentage of total sleep
time spent in stage 1 sleep at the expense of deeper stages of sleep,
although the percentage of total sleep time spent separately in each
of stages 2, 3, 4 and REM was not significantly different in the
controls and asthmatics. As in other studies (Kales et al, 1968 and
1970; Kontplaisir et al, 1982; Issa and Sullivan, 1985), there was no
clear relationship between EEG sleep stage and the requests from
patients to use their inhalers during the night. All of our
patients were in a relatively stable condition at the time of the
study. Formal EEG recordings of sleep have not been made during
acute attacks of asthma, but patients' own reports and clinical
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observation suggest that they sleep even less well when they are
acutely ill.
The consequences of sleep disruption in patients with asthma have not
been studied. Studies in normal subjects indicate that sleep
deprivation causes impaired daytime vigilance (reviewed in Parkes,
1985), and this could be a potential problem in asthmatics,
especially asthmatic children who are still at school. Sleep
disruption for 24 hours can also reduce ventilatory drive (Cooper and
Phillips, 1982; White et al, 1983; Schiffman et al, 1983). During
acute attacks of asthma, when patients often have several worsening
nights with little or no sleep, such a blunting of drive could be a
factor, along with fatigue and continuing bronchospasm, in the
subsequent development of hypoxaemia and hypercapnia in some of these
patients (Tai and Read, 1966; McFadden and Lyons, 1968).
The modest nocturnal hypoxaemia in our patients was unlikely to be
the cause of their sleep disruption, for the arousals did not occur
during episodes of hypoxaemia. There is debate whether severe
hypoxaemia can disrupt sleep (Brezinova et al, 1982; Calverley et al,
1982; Fleetham et al, 1982), but studies in normal human subjects
(Berthon-Jones and Sullivan, 1982; Douglas et al, 1982b; Gothe et al,
1982) and in animals (Phillipson et al, 1978; Bowes et al, 1980;
Nebauer et al, 1981), indicate that modest hypoxaemia very rarely
causes arousal. It is more likely that sleep disruption in the
asthmatic patients was a direct conseqence of their bronchospasm
since Montplaisir and colleagues (1982) found that asthmatics slept
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better when their overnight bronchoconstriction was relieved. Not
all bronchodilators improve sleep, however. Theophyllines can
actually disrupt sleep in patients with airflow limitation (Fleetham
et al, 1983; Rhind et al, 1985). The effects of bronchodilator
drugs on sleep, breathing and oxygenation at night in patients with
asthma are discussed in chapter 9.
Breathing patterns
The asthmatic patients had no more apnoea and hyponoea during sleep
than their age-matched healthy control subjects, an observation which
has also been made in concurrent studies in other laboratories
(Montplaisir et al, 1982; Neagley et al, 1986). As in normal
subjects, the prevalence of apnoea and hypopnoea increased with age
and was the same in both sexes.
One of the clinical signs of an acute attack of asthma is relative
prolongation of expiration (Batten, 1978; Fraser and Parre, 1979),
and lengthening of expiratory time has also been described, using
respiratory inductive plethysmography, during bronchoconstriction
induced by histamine (Stewart et al, 1984a). I postulated,
therefore, that it might be possible to detect bronchoconstriction
during sleep without waking asthmatic patients, by studying their
spontaneous breathing patterns. However, there were no significant
changes in expiratory time, inspiratory time or breath period, between
1 am and 4 am in the asthmatics, despite overnight
bronchoconstriction. These results do not totally exclude changes
in spontaneous breathing pattern during sleep resulting from
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nocturnal bronchoconstriction, however, since we did not actually
measure bronchoconstriction while the patients were asleep.
Furthermore, our patients had only moderate overnight changes in
FEVj, and we measured only chest movement. Issa and Sullivan
(1985), using a respiratory inductive piethysinograph to measure both
thoracic and adominal movement, recently demonstrated phase changes
between the chest and abdomen during acute attacks of asthma in four
sleeping subjects. Morgan and colleagues (1986), in a similar study
of nine asthmatic patients, found no phase changes during sleep but
their patients apparently had less severe nocturnal asthma than those
of Issa and Sullivan for none woke with acute attacks of asthma
during the study, although they did show an overnight fall in FEV^
from a mean of 2.6 litres to a mean of 1.9 litres. Spontaneous
breathing patterns, therefore, seem unlikely to be useful for
assessing mild or moderate bronchoconstriction during sleep. It is
possible that studies of thoraco-abdominal movement may be useful in
detecting the onset of severe nocturnal asthma, but further studies
will be needed to confirm this.
The reduction in chest movement, and corresponding falls in
"inspiratory flow rate" and "minute ventilation", which occurred
during REM sleep were also unlikely to be due to REM-related
bronchoconstriction in the asthmatic patients (see chapter 11), since
similar changes in breathing pattern were seen in the normal subjects
during REM sleep. Paradoxical indrawing of the rib cage has been
described during REM sleep in adolescent asthmatics, aged 12-15
years (Tabachnik et al, 1981), but this has not been confirmed in
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adult stable asthmatics (Morgan et al, 1986). This question of
paradox could not be addressed in the present study, since only chest
movement was measured, at the level of the third intercostal space
anteriorly.
For the same reason, tidal volume and ventilation could not be
assessed accurately in this study (see Chapter 2). Nevertheless,
the results of both hand analysis and computer analysis of the
magnetometer signal clearly suggested that there was hypoventilation
during REM sleep, without alteration in respiratory rate, both in the
asthmatics and the normal subjects. This finding is in agreement
with concurrent studies of ventilation during sleep in asthmatics,
(Tabachnik et al, 1981; Morgan et al, 1986) and normal subjects
(Douglas et al, 1982, Krieger et al, 1983b; Stradling et al, 1985).
In contrast, Hudgel and colleagues (1984), in a study of six normal
adults, found no changes in ventilation, tidal volume or breath
frequency between NREM and REM sleep, and Tabachnik and co-workers
(1981a), in nine normal adolescent subjects, found that tidal volume
and ventilation tended to increase from NREM to REM. Both these
studies involved respiratory inductive plethysmography but the
results were based on analysis of epochs of only 20 breaths (Hudgel
et al, 1984) or one minute (Tabachnik et al, 1981a). Analysis based
on such short epochs could lead to errors in the estimation of
ventilation during REM sleep, for, in our experience the periodicity
of the typical breathing pattern in REM sleep (waxing and waning of
chest movement), is often greater than one minute.
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Oxygenation
The observation that stable asthmatics have modest, but nevertheless
abnormal, arterial oxygen saturation during sleep is in agreement
with the results of concurrent studies in both asthmatic children
(Smith and Hudgel, 1980) and asthmatic adults (Montplaisir et al,
1982). In the present study, the falls in arterial oxygen
saturation during sleep in the asthmatic patients were greater than
those of normal subjects, similar to those of "pink puffers", and
less than those of "blue bloaters". However, the calculated changes
in arterial oxygen tension were similar in all four groups. In each
group, most of the hypoxaemic episodes were associated with hypopnoea
during REM sleep. In asthma, therefore, as in chronic bronchitis
and emphysema (Catterall et al, 1985), nocturnal hypoxaemia in REM
sleep is probably due mainly to hypoventilation, although the present
study does not exclude co-existent changes in ventilation/perfusion
balance (Fletcher et al, 1983). Such hypoventilation is normal in
REM sleep (Douglas et al, 1982; Stradling et al, 1985), and patients
with asthma and chronic bronchitis and emphysema have greater falls
in arterial oxygen saturation than normal subjects mainly because
they start the night at a lower point on the oxyhaemoglobin
dissociation curve. Although asthmatic patients bronchoconstrict
overnight, with possible worsening of the bronchoconstriction during
REM sleep (see Chapter 11), this did not appear to cause significant
additional hypoxaemia in our relatively stable asthmatics, at least
as assessed by the maximal overnight fall in arterial oxygen tension.
There was no clear relationship between the overnight fall in FEV^
and the maximal fall in arterial oxygen saturation in the asthmatic
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patients.
The observation that there is a linear relationship between the
lowest oxygen tension during sleep and the oxygen tension during
wakefulness has a number of implications.
First, these results mean that it is probably unnecessary to perform
sleep studies on patients with asthma or chronic bronchitis and
emphysema to see how much they desaturate - within moderately wide
limits (fig 12) that can be predicted from their arterial oxygen
tension when awake. There may be exceptions to this, however, since
the sleep apnoea syndrome can occasionally coexist with obstructive
pulmonary disease (Guilleminault et al, 1980; Goldstein et al, 1984;
Flenley, 1985). Patients suspected of having both these conditions
- because of daytime hypersomnolence (Guilleminault et al, 1980) or
because of morning headaches after receiving nocturnal oxygen
(Goldstein et al, 1984) - should have studies of breathing and
oxygenation during sleep because they may benefit from relief of
their sleep apnoea, e.g. by continuous nasal positive airways
pressure (Sullivan et al, 1981). The sleep apnoea syndrome has not
yet been described in a patient with asthma, but there appears to be
no reason why the two conditions could not coexist.
Second, it confirms that sleep hypoxaemia is a continuum from health
to disease. During acute attacks of asthma, therefore, when
patients often have daytime hypoxaemia (Tai and Read, 1966; McFadden
and Lyons, 1968; Rees et al, 1968), patients would be expected to
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have greater falls in arterial oxygen saturation during sleep than
were recorded in this study, and such hypoxaemia could contribute to
the rare but tragic nocturnal deaths from acute asthma. However,
there have been no actual measurements of oxygenation during sleep in
patients who are hypoxaemic due to acute asthma. Ideally, such
studies would involve patients who were breathing air without
supplemental oxygen, and this would be difficult to justify ethically
during acute attacks of asthma. Furthermore, sleep studies are
complex, with numerous pieces of equipment, and they would pose many
practical problems in asthmatic patients who are acutely ill.
Studies of a patient with chronic daytime hypoxaemia due to asthma
are described in chapter 7.
Third, these results suggest that any treatment which improves
daytime oxygenation would be expected to reduce nocturnal hypoxaemia.
Thus, they emphasise the importance of regular daytime treatment in
asthma, a principle which also applies to the prevention of overnight
bronchoconstr iction (Horn et al, 1985, see Chapter 1-3).
Bronchodilators given only at night have not been shown to improve
oxygenation during sleep in asthma (Catterall et al, 1983; Stewart et
al, 1984; Rhind et al, 1985; Neagley et al, 1986). From figure 12,
it would also be predicted that oxygen could be used to reduce
nocturnal hypoxaemia in asthma, as it is known to do in hypoxic
chronic bronchitis and emphysema (Douglas et al, 1979a). This point
is also addressed in chapter 7.
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Chapter 7
BREAMING AND OXYGENATION DURING SLEEP IN AN ASMMATIC
PATIENT WITH PERSISTENT DAYTIME HYFOXAEMIA
The stable asthmatics studied in chapter 6 had relatively normal
levels of oxygenation during wakefulness, with modest falls in
arterial oxygen saturation during sleep. It was postulated that
asthmatics who were more hypoxaemic when awake would have greater
falls in arterial oxygen saturation during sleep. However, this
hypothesis was based largely on observations in patients with hypoxic
chronic bronchitis and emphysema. This chapter contains studies of
a patient with chronic daytime hypoxaemia due to asthma. The
results show that this patient had severe nocturnal hypoxaemia,
which occurred during periods of hypoventilation in REM sleep.
Because of the unusual severity of this patient's hypoxaemia together
with carbon dioxide retention and cor pulmonale, we also studied his
ventilatory responses to oxygen and carbon dioxide when awake.
Patient
A 20 year old man was referred so that his suitability for
domiciliary oxygen therapy could be assessed. In early childhood he
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had developed intermittent wheeze and nocturnal cough, with severe
flexural eczema. Despite treatment with sodium cromoglycate, and
later with inhaled salbutamol and inhaled beclomethasone, he had
rarely been free of symptoms. He had lost time from school each
year because of asthma, and his best FEV^ recorded up to the age of
19 had been 1.0 litre.
Six months prior to referral, at the age of 19, he had been admitted
to hospital with an exacerbation of asthma, associated with
hypoxaemia, hypercapnia, and clinical evidence of right ventricular
failure. Although the FEV^ had risen to 1.9 litres with nebulised
bronchodilators and oral prednisolone, it had subsequently fallen
again after discharge and he had remained hypoxaemic with carbon
dioxide retention.
At the time of referral his symptoms we re relatively stable. He
gave no family history of respiratory illness and he denied ever
having smoked. He did not have regular sputum production and there
was no history of previous pneumonia, whooping cough, haemoptysis or
calf pain. His regular medication consisted of inhaleo
beclomethasone, inhaled salbutamol, frusemide with supplemental
potassium, and digoxin.
On examination he was plethoric but had no signs of cardiac failure.
The chest was hyperinflated and there were a few scattered high
pitched rhonchi.
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The chest radiograph showed enlargement of the pulmonary conus but no
cardiomegaly and no pruning of peripheral blood vessels. The
electrocardiogram showed incomplete right bundle branch block.
While breathing air, the arterial oxygen tension was 7.3 kPa with an
arterial carbon dioxide tension of 7.0 kPa and a hydrogen ion
concentration of 44 nmol/1. While breathing 30% oxygen, the
arterial oxygen tension rose to 9.4 kPa, with an arterial carbon
dioxide tension of 7.4 kPa. Haemoglobin concentration in the
peripheral blood was 19.3 g/dl, the white cell count was 8.7 x 10^/1
of which 11% were eosinophils, and the red cell mass was 34.6 ml/kg
(normal 22-28 ml/kg). Pulmonary arterial pressure (PAP) was 40/15
mmHg, mean 22 mmHg (normal mean 12-18 mmHg). The FEV^ was 1.3
litres (predicted 4.1, SD 0.5 litres) and the FVC 1.6 litres
(predicted 4.8, SD 0.6 litres). Total lung capacity measured by
helium dilution was normal but the residual volume and the residual
volume/total lung capacity ratio (RV/TLC) were each approximately
twice normal. The transfer factor for carbon monoxide was low
normal at 8.4 mmol/min/kPa (predicted 11.3, SD 1.7). Skin prick
tests to six allergens including Dermatophagoides pteronyssinus,
Aspergillus fumigatus, and cat fur were strongly positive. Tests
for Aspergillus precipitins were negative. The sweat test for
cystic fibrosis was normal (sodium 26.9 mmol/1, potassium 10.8
mmol/1) and the serum level of alpha-1 antitrypsin was normal at
3.0 g/1 (reference range 1.8-4.0 g/1).
Studies of breathing and oxygenation during sleep
Electroencephalographic sleep stage, chest movement, oronasal
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airflow, and ear oxygen saturation were monitored non-invasively as
described in Section II, on three consecutive nights. The first
night was for acclimatisation only. On the second night, the
patient breathed air at 2 1/min by nasal prongs and on the third
night oxygen at the same flow rate, in a single blind protocol.
Studies of ventilatory control when awake
These studies were performed by Dr P Calverley, with my assistance.
On the morning before the first night's sleep study the ventilatory
response to progressive isocapnic hypoxia was measured in duplicate
at the patient's resting end-tidal carbon dioxide tension, using the
method of Weil and colleagues (1970) as modified by Calverley and co¬
workers (1983). The ventilatory response to hypercapnia was
measured during steady state conditions in a background of hyperoxia
(end-tidal oxygen tension > 25 kPa) with an inspired carbon dioxide
concentration of 2% and subsequently 5% (Lloyd et al, 1958). The
^results are expressed as instantaneous minute ventilation (Vt x f =
Ve inst) per percentage fall in ear oxygen saturation (Ve/SaC^) or
per kilopascal rise in end-tidal carbon dioxide tension (Ve/PETCC>2).
«
Studies with medroxyprogesterone acetate
Both the sleep studies and the studies of ventilatory control were
repeated after four weeks of treatment with the ventilatory stimulant
medroxyprogesterone acetate (MPA) 20 mg eight-hourly. The sleep





In all the studies the patient's total sleep time, and the percentage
of REM sleep were similar to those of other asthmatic patients
(Chapter 6; table 6).
When breathing air, SaC>2 fell from 92% during wakefulness to 76% at
the lowest level during sleep. There were numerous 4% falls in SaC>2
(see chapter 5), and on three occasions during the night (two of them
in REM sleep) SaC^ fell transiently by 10% or more (fig 18; table 6).
Treatment with medroxyprogesterone acetate had no significant effect
on nocturnal oxygenation (table 6). When breathing oxygen, however,
the arterial oxygen saturation remained above 91% throughout the
night. There were no episodes of sleep apnoea either before or
after therapy, and all the hypoxaemic episodes occurred during
periods of recurrent hypopnoea as defined in Section II. Hypopnoea
was as frequent during the oxygen treatment nights as during the air
studies.
Ventilatory control studies
The ventilatory response to hypoxia, both before and after treatment
with medroxyprogesterone acetate, was well below the average for
normal subjects (Douglas et al, 1982b; Calverley et al, 1983). The
ventilatory response to carbon dioxide doubled after treatment with
MPA for four weeks, but even at this level, it was at the lower limit
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18 Arterial oxygen saturation (ear oximeter) and EEG sleep stage
throughout the night in a 20 year old asthmatic patient who
was hypoxic when awake.
TABLE 6
OXYGENATION, NOCTURNAL SLEEP, AND VENTILATORY CONTROL
MEASUREMENTS BEFORE AND AFTER MEDROXYPROGESTERONE ACETATE
IN AN ASTHMATIC PATIENT WITH PERSISTENT DAYTIME HYPOXAEMIA
Stable Lowest 10% TST REM Ve/ Ve/
SaOo Sa02 falls in (min) (% of Sa02 PETCO2
awake asleep Sa02 TST) (1/min) (l/min)
Pre-progesterone
(air night) 92.0 76.0 3 410 20.1 0.07 3.67
Pre-progesterone
(02 night) 97.0 91.5 0 423 17.6
After 4 weeks
progesterone
(air night) 91.0 77.0 1 375 20.2 -0.10 7.62
After 8 months
progesterone 90.0 75.2 4 343 21.2
Sa02, ear oxygen saturation (%); TST, total sleep time; REM, rapid
eye movement sleep, Ve/Sa02, change in ventilation per unit % fall in
Sa02; Ve/PETC^, change in ventilation per kPa rise in end-tidal CO2.
Follow-up
Because of the response to oxygen treatment, the patient was given
domiciliary oxygen, to take for 15 hours daily, including the
sleeping hours (Medical Research Council Working Party, 1981). He
felt less tired with this treatment but his condition continued to
deteriorate slowly and he died, out of hospital, 28 months after
starting oxygen treatment. Permission for autopsy was declined.
DISCUSSION
Despite the youth of this patient, and despite the fact that he was
in a stable condition, he had more severe nocturnal hypoxaemia than
any of the asthmatic patients described in Chapter 6. Apart from
the night that he received oxygen, the patient showed a relatively
constant pattern of nocturnal hypoxaemia, with arterial oxygen
saturation falling to an average lowest value of 76%, corresponding
to an arterial oxygen tension of 5.5 kPa (assuming normal body
temperature and pH, see Chapter 6). These values are more commonly
seen in patients with hypoxic chronic bronchitis and emphysema or
patients with recurrent sleep apnoea.
In Chapter 6, I postulated that nocturnal falls in arterial oxygen
saturation could be much more marked during acute attacks of asthma -
when patients are hypoxaemic by day - than during relatively stable
periods. I also postulated that oxygen would be effective in
relieving such nocturnal hypoxaemia. A study to confirm these
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postulates would be difficult to justify on ethical grounds, however,
since it would involve denying oxygen to patients at night during
acute attacks of asthma. The patient described above had asthma,
with no evidence of other respiratory disease, and he also was
hypoxaemic by day. Although the daytime hypoxaemia of this patient
was due to chronic disease rather than an acute attack of asthma, his
large nocturnal falls in SaC^ and their correction by oxygen lend
support to the above postulates.
As in other subjects (Chapter 4, 6), the nocturnal hypoxaemic
episodes in this patient were associated with reduced chest movement.
The fact that he continued to hypoventilate despite marked nocturnal
hypoxaemia suggests that his ventilatory response to hypoxia was
reduced during REM sleep. There have been no measurements of
ventilatory drive during sleep in asthmatic patients, but studies in
normal subjects indicate that the ventilatory responses to both
hypoxia (Berthon-Jones and Sullivan, 1982; Douglas et al, 1982b;
Hedemark and Kronenberg, 1982) and hypercapnia (Birchfield et al,
1959; Bulow, 1963; Gothe et al, 1981; Douglas et al, 1982c) are
reduced during sleep, with the most marked decreases occurring in REM
sleep. This patient had blunted ventilatory responses to hypoxia
and hypercapnia when awake, and these blunted responses presumably
played a permissive role in the pathogenesis of his marked nocturnal
hypoxaemia. Patients with hypoxic chronic bronchitis and emphysema,
who also have large falls in arterial oxygen saturation during sleep,
also tend to have low ventilatory responses to hypoxia (Flenley et
al, 1970; Kepron and Cherniack, 1973) and hypercapnia (Kepron and
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Cherniack, 1973; Matthews, 1977; Bradley et al, 1979) when measured
during wakefulness.
Hudgel and Weil (1974) also reported a teenage asthmatic boy with a
low hypoxic ventilatory drive, and their patient also had persistent
hypoxaemia with carbon dioxide retention and cor pulmonale. In
their patient, there was evidence for a hereditary deficiency in
ventilatory drive and the authors suggested that this may have pre¬
dated the onset of severe airways obstruction. There is also
evidence from other studies that the ventilatory responses to hypoxia
(Collins et al, 197 8) and hypercapnia (Mountain et al, 1978) may be
strongly influenced by genetic factors. We attempted to pursue this
possibility in our patient, by approaching members of his immediate
family for study of their ventilatory drives. However, they did not
wish to undertake such studies. We cannot say, therefore, whether
the low ventilatory responses to hypoxia and hypercapnia in our
patient were due to hereditary factors or whether they were a
consequence of prolonged hypoxia, as described in patients living at
altitude (Severinghaus et al, 1966; Milledge and Lahiri, 1967) and in
I
patients with cyanotic congenital heart disease (Sorensen and
Severinghaus, 1968; Edelman et al, 1970).
Cor pulmonale is rare is asthma. In chronic bronchitis and
emphysema, there is evidence that nocturnal hypoxaemia may contribute
to the pathogenesis of cor pulmonale (see Chapter 5). We did not
measure pulmonary arterial pressure during the night in this patient,
but it seems likely that the recurrent nocturnal hypoxaemic episodes
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in this patient contributed to the development of pulmonary
hypertension and subsequent right ventricular failure.
Medroxyprogesterone acetate stimulates ventilation during wakefulness
in normal subjects (Skatrud et al, 1978; Zwillich et al, 1978) and in
patients with chronic obstructive pulmonary disease (Skatrud et al,
1980; Dolly and Block, 1983). It has also been shown to improve
oxygenation during sleep in patients with chronic mountain sickness
(Kryger et al, 1978) and to raise the arterial carbon dioxide tension
during NREM sleep in patients with chronic obstructive pulmonary
disease (Skatrud et al, 1981). I was therefore interested to know
whether medroxyprogesterone acetate would improve nocturnal
oxygenation in this patient. Treatment with medroxyprogesterone
acetate for four weeks, at a dose which has been shown to stimulate
ventilation during wakefulness and NREM sleep in chronic obstructive
pulmonary disease (Skatrud et al, 1981), was associated with a
doubling of his ventilatory response to hypercapnia during
wakefulness, but it had no effect on either the hypoxic ventilatory
drive when awake, or on the severity of nocturnal hypoxaemia. Even
after four further weeks of treatment, the nocturnal hypoxaemia was
unchanged. Medroxyprogesterone acetate has also proved to be
disappointing in the treatment of nocturnal hypoxaemia in patients
with chronic bronchitis and emphysema. In a recent double-blind
controlled trial of the drug in 19 patients with chronic obstructive
pulmonary disease (Dolly and Block, 1980), there was no significant
difference in either the number of episodes of desaturation or the
lowest arterial oxygen saturation during sleep between the active
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drug and placebo.
On the other hand, nocturnal oxygen was effective in reducing
nocturnal hypoxaemia in this patient, and he was therefore given
domiciliary oxygen. He died 28 months after starting this
treatment. In the recent UK Medical Research Council trial of
domiciliary oxygen in hypoxic chronic bronchitis and emphysema
(Medical Research Council Working Party, 1981), approximately 60% of
male patients receiving oxygen 15 hours daily survived longer than
this, and in the American trial of home oxygen therapy (Nocturnal
Oxygen Therapy Trial Group, 1980), 50% of bronchitic patients
receiving nocturnal oxygen, and 75% receiving continuous oxygen,
survived longer than 28 months. Thus, our patient's survival time,
following commencement of domiciliary oxygen, was similar to that of
many patients with severe chronic bronchitis and emphysema after
starting this treatment.
It must be stressed that although this patient had asthma, with
evidence of no other respiratory disease, the course of his illness
was atypical. Nevertheless, the studies described above illustrate
that severe nocturnal hypoxaemia can occur in asthma, in association




THE EFFECTS OF KETCTTFEN IN NOCTURNAL ASTHMA
Assessment of the efficacy of drugs in nocturnal asthma has largely
been restricted to measurements of airway calibre (Soutar et alf
1975; Milledge and Morris, 1979; Reinhardt et al, 1980; Fairfax et
al, 1980; Connolly, 1981; Barnes et al, 1982; Carpentiere et al,
1983; Horn et al,1984), with the recent exception of a study by
Davies and colleagues (1984) who used a subjective scoring system to
assess sleep quality in patients receiving theophyllines. It would
clearly be of interest also to know the effects of such drugs on EEG
sleep patterns and sleep related hypoxaemia in asthmatic patients,
particularly as some bronchodilators can have direct effects on the
central nervous system. Beta agonists and theophyllines, for
example, are central nervous system stimulants and could therefore
disrupt sleep directly, whilst ketotifen, a relatively new drug which
has been advocated for the treatment of asthma, often causes
drowsiness and potentially, therefore, could aggravate hypoxaemia.
These drugs have recently been studied in our laboratory to determine
their effects on sleep, breathing patterns and oxygenation at night
in patients with asthma. The studies with ketotifen are described
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in this chapter. The other studies - with choline theophyllinate
(Rhind et al, 1985), terbutaline (Stewart et al, 1984) and disodium
croinoglycate (Morgan et al, 1985) - will not be described in detail
in this thesis as they were performed mainly by other workers.
METHCDS
Non-invasive measurements of EEG sleep stage, breathing patterns,
arterial oxygen saturation (Sa02), and overnight change in FEV]_ were
made during nocturnal sleep in 10 adult patients with stable asthma,
in a double-blind crossover trial of ketotifen.
Patients
The patients (9 men and 1 woman), aged 18 - 55 years all had airways
obstruction that was reversible and varied spontaneously. During
the two years before the study the lowest FEV^ recorded in these
subjects at the out-patient clinic ranged from 0.5 to 1.9 1 and the
highest spontaneous FEV^ from 1.7 to 4.2 1. Eight of the patients
had positive skin prick test responses to at least two common
allergens, and six had a family history of atopy. A11 the patients
used a beta2 agonist inhaler, six took beclomethasone dipropionate by
inhalation and three took regular oral prednisolone in a dose of 5
mg daily. None of the patients was receiving sodium cromoglycate,
antihistamines, theophyllines, hypnotics, or sedatives. Most (7) of
the patients had never been studied in the sleep laboratory before,
but three had taken part in the study described in chapter 6 at least




The trial was designed so that half the patients received placebo
before ketotifen and half received ketotifen first. The patients
slept in a quiet darkened room on two pairs of two consecutive nights
(the first night in each pair serving as an acclimatisation night)
separated by two to four weeks.
On the night of the study beta2 agonists were withheld from 5 pm.
The patients arrived in the laboratory at 9.30 pm and, after the
apparatus had been set up and the FEV^ measured, they were given one
tablet of either placebo or ketotifen ten minutes before the lights
were switched off. During the night EEG sleep stage, chest
movement, oronasal airflow and arterial oxygen saturation were
measured as described previously (Section IT). In the morning the
FEVj was measured when the patient woke up.
Differences between placebo and ketotifen nights were analysed by the
paired Student's "t" test. Values are given as mean * standard
errors of the mean.
RESULTS
Arterial oxygen saturation
Sa02 during sleep was unaltered by ketotifen. The change in SaOg
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from the level before sleep (ketotifen nights 96.4 + 0.7%; placebo
nights 95.6 * 0.9%) to the lowest level during sleep (ketotifen 88.4
t. 1.2%; placebo 88.1 1 1.6%) was the same after the drug (8.0 ~t 1.1%)
and after placebo (7.8 _ 1.2%). Significant episodes of hypoxaemia
(SaC>2 falls of at least 4% from the immediately preceding stable
Sao2) occurred in six patients from 1 to 9 times (mean 2.4 times) per
night on placebo. The number of episodes was not significantly
different on ketotifen nights, when 6 patients had from 1-12 (mean
2.6) hypoxaemic episodes per night.
Irregular breathing
The cumulative duration of irregular breathing during sleep (apnoeas
and hypopnoeas; chapter 5) was the same on ketotifen and placebo
nights averaging 42 1 12 min after the active drug and 37 t 7 min
after placebo. Most (99%) of this irregular breathing was
hypopnoea. In all ten subjects only 9 episodes of apnoea occurred
after placebo and 11 after ketotifen.
EEG sleep stages
Total sleep time occupied 387 * 8 min on ketotifen nights but only
336 t. 19 min on placebo nights (p < 0.02). When expressed as a
percentage of time in bed (sleep efficiency index), this true sleep
occupied 95 * 1.1% of time in bed on the ketotifen nights but only 85
1 3.8% of time in bed on the placebo nights (p < 0.04). On
ketotifen nights, less time was spent in EEG sleep stages 0 (p <
0.05) and 1 (p < 0.03), and more time in EEG sleep stages 2 (p <






















Fig 19 Duration of different EEG sleep stages in 10 stable
asthmatics studied during sleep after taking placebo (open











20 Forced expiratory volume in 1 second (FE\M measured before
sleep and after sleep on placebo nights (left) and when the
patients had taken 1 mg ketotifen (right). On the
ketotifen nights, all the FEVj measurements after sleep were
those made at the time of final awakening. On the placebo
nights, 6 of the "after sleep" FEVi measurements were made
at the time of final awakening and 4 were made when the
patients woke during the night.
taken to fall asleep averaged 28 min on placebo nights compared to 12
min on ketotifen nights, but this was not a significant difference.
The duration of stage 3 sleep (mean 21 min) and the duration of REM
sleep (mean 55 min) were similar after drug and placebo (fig 19).
Overnight change in FEV^
The FEVj before sleep averaged 2.9 _ 0.4 1 on ketotifen nights and
2.9 1 0.4 1 on placebo nights. In all patients the lower of these
values was within 30% of the higher. After taking ketotifen none of
the patients asked to use an inhaler during the night. After taking
placebo, however, 4 of the 10 patients asked to use their beta2
agonist inhalers (p < 0.1, Chi^ test for small numbers; Swinscow,
1976). After using their inhalers they went back to sleep. Three
of these awakenings occurred between 3 and 3.30 am and the other at
5.35 am. The FEV^ recorded at these times was on average 1.0 1
(range 0.3 - 1.7 1) lower than the FEVj before sleep. In the other
six patients the FEV^ was on average 0.6 1 lower after sleep than
before sleep when they had taken placebo, compared with a fall of
0.9 1 with ketotifen. This difference (fig 20) was not significant.
DISCUSSION
The main purpose of this study was to determine whether ketotifen has
adverse effects on breathing patterns and oxygenation during sleep in
patients with asthma. The results show that ketotifen does not
affect nocturnal breathing patterns and oxygenation, at least in
stable asthmatics, when given as a single 1 mg dose.
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However, ketotifen also had no significant effect on the overnight
change in FEVj_ in this study. Ketotifen has been described as
protecting against acute antigen challenge (Pauwells et al, 1978;
Wuethrich et al, 1978; Wells et al, 1979; Craps, 1981) and histamine
challenge (Craps et al, 1978; Mattson et al, 1979; Beumer et al,
1979; Lisboa et al, 1985; Craps, 1981) in asthmatic patients but
there is debate whether it provides effective prophylaxis against
asthmatic attacks in clinical practice (Gobel, 1978; Lane, 1980;
Dyson and Mackay, 1980; Petheram et al, 1981; Monie et al, 1982;
Tinkelman et al, 1985). The observations of this study extend those
of Dyson and Mackay who found that ketotifen in a daily dose of 2 mg
for four weeks had no effect on patient's nocturnal dyspnoea, as
assessed by diary cards.
Although ketotifen had no effect on oxygenation, breathing patterns
or overnight change in FEVj, it did help the patients to sleep. The
patients slept longer and spent more time in the deeper stages of
sleep after taking ketotifen than after taking placebo. It seems
most likely that this is a direct effect on the central nervous
system, for ketotifen has antihistaminic properties (Martin and
Romer, 1978). Antihistamines in therapeutic dosage often cause
somnolence (Harvey, 1975) but their effect on EEG sleep stages is
poorly documented. Diphenhydramine, in contrast to ketotifen in
this study, suppresses REM sleep (Rawl, 1980) but it is not known
whether other antihistamines do the same.
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Beta2 agonists were withheld on the nights of the study, to separate
the effects of ketotifen from those of sympathomimetic drugs.
Whether ketotifen would have the same effects on EEG sleep stage when
given in combination with beta agonists is not known. It is also
not known whether the hypnotic effect of ketotifen persists in
patients taking the drug for prolonged periods. It is probable that
it does not, for daytime drowsiness in association with ketotifen
usually resolves after two to three months' treatment (Craps, 1981;
Tinkelman et al, 1985). In any event this hypnotic effect is
unlikely to have a therapeutic application. Most if not all (Clark
et al, 1971; Caddie et al, 1972; Editorial, 1972) sedative drugs can
depress respiration and although this would not be important in most
stable asthmatics, it could aggravate respiratory failure during
acute attacks of asthma. Although it is desirable to relieve the
disturbed sleep of asthmatic patients (Chapter 6), I believe that, if
possible, this should be achieved by agents which also relieve
bronchoconstriction.
The oral drugs most frequently used to control the symptoms of
nocturnal asthma are theophyllines and oral beta agonists. Although
these agents reduce the overnight change in FEV^ in asthmatic
patients (Milledge and Morris, 1979; Fairfax et al, 1980; Barnes et
al, 1982), they do not improve sleep (Fleetham et al, 1980; Stewart
et al, 1984; Rhind et al, 1985), probably because of a direct
stimulant effect. Indeed, recent studies in this laboratory (Rhind
et al, 1985) indicate that theophyllines cause even more disruption
of sleep than usual (see Chapter 6) in asthmatic patients. There
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is a need for a bronchodilator which will remain effective throughout
the night, and which will also relieve the disturbed sleep of
asthmatic patients. This problem is discussed further in chapters
12 and 13.
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SDMMARY - PART III
The main aims of this part of the thesis were (i) to determine
whether asthmatic patients become hypoxaemic at night and whether
they have abnormal breathing patterns during sleep, (ii) to study the
effects of asthma on sleep.
Three studies were performed:
1. Ear oxygen saturation (SaC^), oronasal airflow, chest movement and
electroencephalographic sleep stage were monitored throughout an
undisturbed night's sleep in 20 stable asthmatic patients and the
rsults compared with those of similar studies in 34 age-matched
healthy subjects. Since the asthmatic patients were more
hypoxaemic than the normal subjects when awake, their nocturnal
Sa02 falls were also compared to those of 20 patients with chronic
bronchitis and emphysema.
2. In order to explore further the relationship between daytime
oxygenation and oxygenation during sleep in asthma, studies were
also performed in an asthmatic patient who was persistently
hypoxaemic when awake.
3. In the third study, involving 10 patients, the effects of
ketotifen on nocturnal oxygenation and breathing patterns in
asthma were investigated.
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The following results were obtained:
1. The patients with asthma became more hypoxaemic during sleep, with
greater falls in SaC^, than normal subjects of the same age.
2. The nocturnal SaC>2 falls in the asthmatic patients were similar to
those recorded in the "pink puffers" with chronic bronchitis and
enphysema but much smaller than those recorded in "blue bloaters".
3. When expressed in terms of oxygen tension, the asthmatics, the
normal subjects, the "pink puffers" and the "blue bloaters" all
had similar changes in arterial oxygenation at night.
4. When the data for the normal subjects, the asthmatics, the "pink
puffers" and the "blue bloaters" were plotted together, there was
a linear relationship between the arterial oxygen tension when
awake and the lowest arterial oxygen tension during sleep.
I
5. The asthmatic patient with persistent daytime hypoxaemia had much
greater falls in SaC^ during sleep than other stable asthmatics of
his age. This nocturnal hypoxaemia was corrected by oxygen but
not by medroxyprogesterone acetate.
6. There was no clear relationshsip between the nocturnal fall in
Sa02 and the overnight change in PEFR in the asthmatic patients.
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7. Despite nocturnal bronchoconstriction, the asthmatic patients had
normal breathing patterns during sleep, both in terms of the
number of apnoeas and hypopnoeas per night and the duration of
inspiration and expiration for each breath.
8. The patients with asthma slept less well than healthy subjects of
the same age. They spent less of the night asleep, and the
proportion of total sleep time spent in drowsiness (EEG sleep
stage 1) was increased at the expense of the deeper stages of
sleep.
9. Ketotifen, given in a single 1 mg dose at night, increased the
duration and depth of sleep in asthmatic patients without
affecting oxygenation or breathing patterns. However, it did not
alter bronchoconstriction.
The implications of these results are as follows:
1. Patients with asthma become more hypoxaemic during sleep than
healthy subjects of the same age because they start the night on a
steeper part of the oxyhaemoglobin dissociation curve than normal.
2. Most stable asthmatic patients have relatively small nocturnal
falls in SaC>2 but patients with asthma who are hypoxaemic when
awake may become markedly hypoxaemic during sleep. Nocturnal
hypoxaemia in asthma can be corrected by oxygen.
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3. Expensive studies of breathing and oxygenation during sleep do not
appear to be indicated in the assessment of patients with asthma
or chronic bronchitis and emphysema unless there is a coexistent
sleep apnoea syndrome, since these patients have normal breathing
patterns during sleep and the degree of nocturnal hypoxaemia can
be predicted from the oxygen tension when awake.
4. There is a need for a bronchodilator which will act throughout the
night without disrupting sleep.
US
Part IV




REVIEW OF THE LITERATORE
The idea that sleep may adversely affect asthma was stated clearly by
Maimonedes, in the twelfth century. In his treatise on asthma,
Maimonedes wrote:
"Sleep in this disease is rather harmful...Those
afflicted should therefore sleep as little as possible."
However, Maimonedes did not distinguish the effects of sleep itself
from those of other circadian changes, nor could he attempt to
distinguish an effect of sleep on bronchoconstriction itself from,
say, sleep-related hypoventilation which also occurs in asthmatics
(see chapter 6) or sleep-related hypoxaemia (chapter 6), since the
concept of bronchoconstriction in asthma was not introduced until
five centuries later (Willis, 1679).
In this chapter I shall review previous studies which have attempted




There is now considerable evidence that nocturnal bronchoconstriction
in asthmatic patients represents an exaggeration of the normal
circadian variation in airway calibre (see Chapter 1).
Amplification of the normal rhythm is related to hyperreactivity of
the airways, and there is a close relationship between the amplitude
of "morning dipping" and bronchial reactivity to inhaled histamine
(Ryan et al, 1982). This implies that the marked circadian change
in bronchomotor motor tone in asthmatic patients is the result of
their bronchial hyperreactivity, and that the underlying mechanism of
nocturnal bronchoconstriction in asthma is likely to be the same as
that which determines the overnight change in airway calibre of
normal individuals.
Bronchial reactivity itself shows a circadian variation.
Bronchoconstrictor responses to histamine (De Vries et al, 1962), to
actetyl choline (Reinberg and Gervais, 1972) and to inhaled allergens
(Gervais et al, 1977) are all lowest in the afternoon and greatest in
the early morning or late at night. However, this circadian rhythm •
is unlikely to be the sole cause of nocturnal asthma since the
circadian change in bronchial reactivity is no greater in asthmatics
than in normal subjects (Reinberg and Gervais, 1972).
Many possible explanations for nocturnal asthma have been considered
and it now seems likely that the pathogenesis of nocturnal
bronchoconstriction is multifactorial (Barnes, 1984; Douglas 1985).
This review will be confined to the relationship between nocturnal
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bronchoconstriction ana sleep. A more detailed review of nocturnal
asthma (Douglas, 1985) and a recent symposium on this subject (Royal
Society of Medicine, 1984), have been published elsewhere.
2. Does sleep cause bronchoconstriction?
Salter (1859) believed that sleep caused both an increase in reflex
bronchoconstriction and a decrease in awareness of airflow
limitation, and he attributed the efficacy of strong coffee in asthma
to its stimulant effects. Writing on the "treatment of asthma by
stimulants" he made the following observations (Salter, 1859):
"One of the commonest and best-reputed remedies of
asthma is strong coffee.
....About the modus operandi of this remedy I was
long puzzled; I could not make it out; and it is only
lately that I have stumbled upon it.
....This fact is, that sleep favours asthma - that
spasm of the bronchial tubes is more prone to occur
during the insensibility and lethargy of sleep than during
the waking hours, when the senses and will are active.
....Anything that rouses the asthmatic to a state of
wakefulness will put a stop to asthma".
It was more than a century before Salter's hypothesis (that sleep
disruption will improve nocturnal bronchoconstriction) was tested.
Clark and Hetzel (1977) studied five asthmatic shift workers and
found that the change from day shift to night shift was rapidly
accompanied by inversion of the circadian rhythms in peak flow and
that this "was complete by the time the first natural sleep had taken
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place as each shift started". The inversion of the
bronchoconstricting rhythm was felt to be more rapid than that
reported for "basic" circadian rhythms such as body temperature or
hormone levels (Perkoff et al, 1959), and the authors concluded that
nocturnal bronchoconstriction is intimately related to sleep.
However, the authors did not actually measure circulating hormone
levels in relation to bronchoconstriction in these shift workers.
Connolly (1981) reported similar findings.
Two years later, Hetzel and Clark (1979) reported another study in
which they attempted to determine whether sleep causes
bronchoconstriction. They studied patients in hospital who were
recovering from an acute attack of asthma. The investigation
contained three separate protocols, each involving sleep disruption.
In the first part of the study, five patients were woken .for 15
minutes at 2 am and then allowed to go back to sleep. This did not
affect the overnight fall in peak expiratory flow rate. However,
this result does not exclude an effect of sleep on airway calibre,
since the protocol involved only a very short period of sleep
disruption.
In the second part of the study, five patients were woken at 2-hourly
intervals to estimate the time of onset of the nocturnal fall in
PEFR. On a subsequent night they were woken 1 hour before that
time, exercised for 15 minutes, and then allowed to go back to sleep*.
This procedure also failed to prevent a fall in PEFR by 6 am, but
124
again the study only involved partial disruption of sleep.
In the third part of the study by Hetzel and Clark, eleven asthmatic
patients were kept awake until 3, 4, or 5 am and then were allowed to
sleep until 6 am. In six patients the "morning dip" in peak flow
occurred prior to sleep, but in the other five most of the decrease
in flow rate occurred during the 1 to 3 hours when sleep was allowed.
Interpretation of this study is complicated by the fact that during
the "awake" period the subjects "went to bed at 22.00 h and adopted
the sleeping posture .... reading or listening to the radio". Most
people would find it difficult to avoid snoozing when left like this
until 5 am and it is not clear how scrupulously the patients were
oberved. The most that can be concluded from this part of the study
is that sleep may be important in the pathogenesis of nocturnal
bronchoconstriction in some patients, and that very short periods of
sleep might be sufficient to produce these effects.
The authors of this complex study (Hetzel and Clark, 1979) concluded
that sleep disruption is unlikely to be of value in the treatment of
nocturnal asthma. However, they were unable to exclude a causal
relationship between sleep and nocturnal bronchoconstriction.
Reinhardt and colleagues (1980), in contrast, were able to abolish
nocturnal bronchoconstriction in seven asthmatic children by keeping
them awake all night. However, their study was also inconclusive
for it contained no details as to how wakefulness was assessed, nor
is it clear how the children were prevented from sleeping at night.
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It would be important to know, for example, whether they were given
coffee to keep them awake, since this can act as a bronchodilator
over and above any indirect effect through sleep deprivation (Salter,
1859; Rail, 1980; Becker et al, 1984).
3. Is nocturnal bronehoconstriction related to sleep stage?
Several groups have recorded electroencephalograms in sleeping
asthmatics and noted the sleep stage when patients awoke with attacks
of asthma. Ravenscroft and Hartman (1968) studied three asthmatics
during 21 subject nights and found that 20 of the 37 asthmatic
attacks occurred during REM sleep (P <0.001 on Chi-square test).
However, this work was reported only in abstract form and these
results were not confirmed in subsequent studies. In the largest
of these studies, including 93 "asthmatic episodes" recorded in
twelve patients on a total of 35 study nights, Kales and colleagues
(1968) found that asthmatic attacks were randomly distributed
throughout the stages of sleep in proportion to the amount of time
spent in each sleep stage. The results of two smaller studies, one
in asthmatic children (Kales et al, 1970) and the other in adults
(Montplaisir et al, 1982), suggested that deep sleep (stages 3 and 4)
may protect against asthmatic attacks.
However, the interpretation of all these studies is complicated by a
number of factors. First, in each of these studies, the definition
of an "asthmatic episode" was based on the patients' use of
bronchodilator inhalers. In only one of the investigations
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(Montplaisir et al, 1982) was bronchoconstriction documented by
measurements of FEVj and even in that study, a nocturnal attack was
defined on the basis of symptoms.
Second, none of these investigators distinguished the effects of
sleep stage on bronchoconstriction itself from possible sleep stage
effects on arousal from asthmatic attacks. Most experiments in
animals (Steriade and Hobson, 1976) and experiments in man using non¬
respiratory stimuli (Savin et al, 1973) have shown that it is more
difficult to arouse patients from REM sleep than stage 2 sleep, but
two recent experiments in man have shown that arousal with airway
occlusion (Issa and Sullivan, 1983) and with hypercapnia (Berthon-
Jones and Sullivan, 1984) is more rapid from REM sleep than NREM
sleep. The effects of sleep stage on the arousal threshold to
bronchoconstriction are unknown.
Finally, these investigations contained insufficient data to conclude
that sleep stages 3 and 4 protect against asthmatic attacks, for slow
wave sleep took up only a small proportion of total sleep time in the
studies.
Montplaisir and colleagues (1982) noted that the most marked falls in
FEVj, and also the lowest SaC^ levels, usually occurred in the later
hours of sleep, coinciding with the time when most REM sleep occurs,
but as these authors pointed out, this does not prove any
relationship between bronchoconstriction and sleep stage.
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Interest in the possible effect of sleep stage on airway calibre has
also been stimulated by observations in laboratory animals.
Sullivan and colleagues (1979) monitored changes in tracheal smooth
muscle tone during different sleep stages in four tracheostomised
dogs by measuring the pressure in the water-filled cuff of their
endotracheal tubes. During REM sleep, tracheal smooth muscle tone
fluctuated markedly and erratically, as reflected by changes in cuff
pressure as large as 90 cm water, although the changes were largely
random with no consistent tendency to either bronchoconstriction or
bronchodilatation. Partial blockade of the vagus nerves, by cooling
exteriorised cervical vagal loops, decreased or abolished the
fluctuations in tracheal smooth muscle tone during REM sleep at
temperatures that did not abolish resting tone, demonstrating that
changes in tone during REM sleep were related to variability in
neural control of airway smooth muscle.
It is unclear, therefore, whether sleep causes bronchoconstriction in
asthma. The results of previous studies involving sleep deprivation
are difficult to interpret because of uncertainty that the patients
were kept awake, whilst in other studies relating asthmatic attacks
to EEG sleep stage the results have depended not only on
bronchoconstriction but also on arousal from sleep, and on the
eagerness of individual patients to use their inhalers during the
night. In an attempt to overcome these problems, I performed three
studies, which are described in the following chapters. The first
involved measurements of peak expiratory flow in asthmatic patients
kept awake all night. In this study, the patients were carefully
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scrutinised throughout the night to ensure that they did not fall
asleep, and wakefulness was confirmed electroencephalographically.
In the second study, patients were woken briefly from known sleep
stages and the degree of bronchoconstriction immediately assessed
objectively by measurements of peak expiratory flow rate. In the
third study, I attempted to determine whether changes in vagal tone
are important in the pathogenesis of nocturnal bronchoconstriction,
by studying the effect of the inhaled anticholinergic agent,
ipratropium, on overnight changes in peak expiratory flow.
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Chapter 10
EFFECT OF SLEEP DEPRIVATION ON NOCTURNAL BRCNOOXNSTRICriON
In this study 12 asthmatic patients who reported nocturnal wheezing
were kept awake all night to see whether this altered their nocturnal




Clinical details of the 12 asthmatic patients studied (9 men and 3
women, aged 22-58 yr) are given in table 7 (patients 1-12). All had
documented nocturnal bronchoconstriction with peak expiratory flov;
rate (PEFR) recorded four times daily in the week prior to study
showing an average circadian change (highest PEFR - lowest
PEFR/highest PEFR) of 29% (range 10 - 68%). Eight had positive skin
prick test responses to at least two common allergens and seven had a
family history of atopy. Six were lifelong non-smokers, four (two
atopic) were ex-smokers, and two (both atopic) smoked 10-15
cigarettes per day. All patients had been attending our clinic for
at least one year but none had had an acute attack of asthma in the
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1 23 M 4.2 2.0 27 Pos Yes No S,C
2 54 M 3.5 1 .8 37 Pos Yes No S, B
3 63 M 2.2 1.3 31 Neg No No S, B
4 18 F 3.3 0.9 68 Pos Yes Ex S, B, C
5 35 F 3.6 1.3 11 Pos No No S,B,T
6 21 F 3.9 1 .5 21 Pos Yes Yes S,B,T
7 20 M 4.4 2.1 10 Pos Yes No S,C
8 24 M 4.6 3.6 10 Neg No No S,C
9 26 M 4.0 2.3 42 Pos Yes Ex S j B, I, P
10 57 M 2.7 1 .2 25 Pos Yes Ex S, B
11 57 M 2.7 1.3 31 Pos No Ex S,P,T
12 58 M 2.1 1 .4 31 Neg No No S, B, P
13 31 F 3.8 1 .3 39 Pos Yes No S , B, D
14 37 F 3.0 1 .5 ND Pos Yes No S,B,T
15 21 M 3.1 1 .9 ND Pos Yes No S,B,C
16 46 M 2.8 1 .4 13 Pos Yes Ex S,B,C, I
17 51 M 2.2 1 .3 21 Pos Yes Ex S, B, I
18 34 M 4.4 1 .5 ND Neg Yes No S, B
19 50 M 2.7 1.0 ND Pos No Ex S,C
20 59 M 2.4 1 .6 ND Neg No Ex S,B,I,P,T
21 64 M 3.2 1 .6 ND Neg No No S,B,P,T
M, male; F, female, FEV-p forced expiratory volume in one second; H,
highest FEV^ in last year recorded at clinic; L, lowest FEV^ in last
year; PEFR, peak expiratory flow rate; Pos, positive skin prick tests
to at least two common allergens; Neg, negative skin prick tests; FH,
family history; S, inhaled beta-2 agonist; B, inhaled corticosteroid;
I, inhaled ipratropium; C, inhaled disodium cromoglycate; P, oral
prednisolone 5-10 mg daily; T, oral theophylline; 0, oral beta-2
agonist; ND, not determined.
six weeks before the study. All used beta2 agonist inhalers and one
an anticholinergic inhaler, nine inhaled corticosteroids, and four
inhaled sodium crcmoglycate. Three patients took 5-10 mg daily of
oral prednisolone and five were taking oral theophyllines. The
theophyllines were discontinued 24 hours before each study night and
the beta2 agonist and anticholinergic inhalers six hours before each
study night. The corticosteroids and sodium cromoglycate were
continued at an unchanged dose.
Procedure
Each patient was studied on two occasions, an "awake night" and an
"asleep night" 7-14 days apart, the order of the two nights being
randomly determined.
On the "asleep night", which was preceded by a night of
acclimatisation under the same conditions, each patient slept
undisturbed in a quiet, darkened room. PEFR was recorded in the
seated position before sleep at 10 pm, after sleep at 7 am, and also
if the patient awoke during the night asking to use an inhaler. All
PEFR measurements on each night were made by the same technician
using the same instructions. Sleep was scored (Rechtschaffen and
Kales, 1968) from an electroencephalogram, electrooculogram and
electromyogram, as outlined in chapter 2.
On the "awake night" the patients played cards or board games and
watched non-stimulating films; they were permitted to walk slowly
around the sleep laboratory complex but were not allowed out of
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doors, and such mild exertion was always less than 15 minutes a
night. They were denied substances containing caffeine as these are
bronchodilators (Pall, 1980; Becker et al, 1984). They were
supervised constantly by two members of staff, who ensured that they
did not sleep; and whenever they were seated or lying wakefulness was
confirmed electroencephalographically. On the awake night, PEFR was
recorded at 2-hourly intervals, again with the subjects seated. At
7 am after each study night bronchial reactivity to histamine was
assessed (Chai et al, 1975) to see whether overnight wakefulness
blunted bronchial reactivity.
Before each study the subjects performed a normal day's work and were
instructed not to sleep. Venous blood was drawn at the beginning of
each study; it contained very low concentrations of caffeine (less
than 0.9 ug/ml) in all patients and detectable theophyllines in only
five patients - in each case the theophylline level was < 3.3 ug/ml.
In the last four patients studied venous blood was sampled hourly
throughout the night, both on the awake night and the asleep night, a
venous catheter having been inserted at the elbow at the start of the
study. The blood was collected into cold heparinised syringes and
immediately spun in a refrigerated centrifuge. The plasma was then
frozen at -70°C for subsequent analysis for 11-hydroxycorticostercid
and catecholamine levels. On the awake night the four patients
rested supine for 15 minutes prior to each blood sample. The plasma
samples were transported in dry ice to the Department of Materia
Medica, University of Glasgow, and there analysed radioenzymatically
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(Da Prada and Zurcher, 1975) for 11-hydroxycorticosteroid and
catecholamine levels under the supervision of Professor J L Reid.
The significance of differences was assessed by Student's t test for
paired data or by analysis of variance and Duncan's multiple
comparison test (Snedechor and Cochrane, 1980).
RESOLTS
EEG sleep stage
On the awake night all patients remained awake throughout the night.
On the asleep night the sleep period time averaged 413 * 14 (SEM)
min, during which there were 55 _ 16 min of wakefulness, 21 * 4 min
of stage 1 sleep, 172 1 11 min of stage 2, 43 * 5 min of stage 3, 56
t 9 min of stage 4, and 66 * 10 min of REM sleep.
Overnight brQnchoconstriction
The results are shown in figs 21-23. Full details of the results
frcm the individual studies are shown in fig 31 in the appendix.
Seven of the 12 patients did not use an inhaler on either night;
three did so only on the sleep night (at 2.40, 4.00 and 5.30), and
two used their inhalers on both nights (at 1.00 and 4.20 on the
asleep night and at 3.00 and 6.00 respectively on the awake night).
Thus no patient used his inhaler earlier on the awake night than on
the asleep night. In the seven patients who did not use inhalers,
the overnight changes in PEFR were compared on the basis of the 7 am
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values. In the other five patients, the pre-inhaler PEFR on the
asleep night was compared with the nearest time-matched PEFR on the
awake night (fig 21) .
All patients showed overnight bronchoconstriction both on the asleep
night and on the awake night (fig 21). The PEFR fell to lower values
on the asleep night (270 1 46 1/min) than on the awake night (371 t 43
1/min; p < 0.01). The overnight fall in PEFR was significantly
greater on the asleep night than on the awake night, both in terms of
absolute fall in PEFR (asleep night 148 1 28, awake night 84 t. 13
1/min; p < 0.02) and as a percentage fall in PEFR (asleep night 38 +
6%, awake night 20 1 4%; p < 0.01). PEFR at 10 pm on the awake night
(465 + 43 1/min) tended to be higher than on the asleep night (418 1 40
1/min), but this was not a significant difference (0.1 > p > 0.05).
Plasma hormone levels
In the four patients in whom venous blood was sampled there was no
consistent change in 11-hydroxycorticosteroid levels between the
awake and asleep night. In all four subjects, plasma adrenaline was
higher throughout the asleep night than on the awake night, and there
was a trend for plasma noradrenaline also to be higher on the asleep
night (fig 22).
Bronchial reactivity to histamine
In 11 patients bronchial reactivity to histamine was assessed at 7 am
after both the asleep night and the awake night. The 12th patient
was excluded from histamine challenge because his morning value of
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p<0-01
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21 Peak expiratory flow rates at night and in the morning in 12
patients on a night when they slept (left) and a night when
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Fig 22 Peak expiratory flow rates and plasma noradrenaline and
adrenaline levels in 4 asthmatic patients on a night when




























Fig 23 The concentration of histamine required to reduce forced
expiratory volume in 1 second (FE\M by 20% (PCog) in 11asthmatic patients after a night when they slepE (left) and
a night when they were kept awake (right).
FEV^ was less than 1 litre (Pepys and Davies, 1977) on both mornings.
There was no difference between the awake night and the asleep night
in the bronchial reactivity to histamine, as assessed by the
concentration of histamine which reduced FEV-j_ by 20% (fig 23), even
though the pre-histamine FEV^ was lower after the asleep night.
DISCUSSION
This study shows that patients with nocturnal asthma develop
bronchoconstriction at night even if they are kept awake. However,
the patients in this study showed greater falls in peak flow on the
night when they slept. Furthermore, five patients had to use their
bronchodilator aerosols during the asleep night but only two during
the awake night, and both of these used the inhaler later on the
awake night than on the asleep night. Thus the study shows that
sleep, while not essential for nocturnal bronchoconstriction, has a
role in airway narrowing at night. In this study approximately half
ofthe overnight fall in peak flow was prevented by keeping the
patients awake. There was no change in bronchial reactivity after
overnight wakefulness.
This is the first study of the effect of sleep deprivation on
nocturnal asthma which has documented wakefulness by
electroencephalography and which has excluded the ingestion of
caffeine (a bronchodilator) which would confuse the results. Our
observations, therefore, extend those of Hetzel and Clark (1979) who
attempted to keep asthmatics awake until the early morning and found
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that most, but not all, showed their usual degree of nocturnal
bronchoconstriction before going to sleep. However,
electroencephalograms were not recorded in that study as discussed in
chapter 9. Conflicting evidence came from the study of Reinhardt
and colleagues (1980), who found that nocturnal bronchoconstriction
in asthmatic children was abolished by sleep deprivation, although it
is not clear how the children in that study were kept awake.
The finding in the current study that sleep contributes to the
pathogenesis of nocturnal bronchoconstriction in asthma is supported
by studies in asthmatic shift workers (Clark and Hetzel, 1977;
Connolly, 1979) in whom the time of sleep determined the time of the
fall in peak flow, irrespective of the time of day.
Why were higher peak flow rates obtained after the awake night?
Other differences between the awake night and the asleep night were
minimised but cannot totally be excluded as factors. Both nights
were spent in the same rooms at the same temperature (Chen and Chai,
1982) and precautions were taken to keep the house dust mite count
low (Platts-Mills et al, 1982). It was not feasible for the
patients to be lying down throughout the night they were kept awake,
as we would have been unable to keep these volunteer patients fully
awake as defined electroencephalographically. Posture effects are
unlikely to explain the differences in peak flow, however, since
nocturnal bronchoconstriction is unchanged whether patients are
ambulant by day or are kept lying in bed throughout the 24 hour
period (Clark and Hetzel, 1977).
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There was a trend for PEFR at 10 pm to be higher on the awake night
than on the asleep night. This trend is difficult to explain. It
was necessary for the patients to know in advance which night they
were going to be awake so that they could arrange work schedules; but
if they had had a nap (which each denied) before coming in on the
awake night the PEFR would be expected to have been lower at the
start of that night, whereas the trend was towards the reverse.
This non-significant trend seems unlikely to be the reason for the
significantly smaller falls in both absolute and percentage PEFR on
the awake night.
It seems more likely that sleep itself influences nocturnal asthma.
Such an effect of sleep could be either direct or indirect.
Direct effects of sleep on breathing, such as changes in breathing
pattern (Chapters 4, 6) and ventilatory control (Douglas et al,
1982b, c), are transient and on arousal return to the patterns of
those found in wakefulness. The effect of sleep on nocturnal asthma
is clearly different from these effects as nocturnal
bronchoconstriction persists after awakening.
Indirect mechanisms might include the role of sleep in controlling
circadian rhythms of hormones (Soutar et al, 1977; Barnes et al,
1980), body temperature (Chen and Chai, 1982), autonomic nervous
activity (Baust and Bohnert, 1969; Gaultier et al, 1977) or other
factors. The sleep-wake cycle is important in synchronising
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circadian rhythms, ana disruption of this cycle by enforced overnight
wakefulness would alter such rhythms. It has been suggested that
nocturnal asthma results from overnight falls in circulating
adrenaline (Soutar et al, 1977; Barnes et al, 1980) and the results
of our study could be explained were circadian changes in adrenaline
concentrations altered by overnight wakefulness. Previous studies
in normal subjects have found no consistent changes in circulating
catecholamines during overnight wakefulness (Prinz et al, 1984), and
the hormone results in the four subjects in this study similarly
provide no evidence that the effect of sleep on nocturnal asthma is
mediated through either catecholamine or Cortisol levels. In fact,
the catecholamines tended to be lower when the asthmatics were awake.
This study does not address the issue of whether the non-sleep
determined component of nocturnal asthma is caused by circadian
changes in catecholamines (Soutar et al, 1977; Barnes et al, 1980) or
circulating corticosteroids (Soutar et al, 1975).
In order to clarify the effects of sleep on bronchoconstriction in
asthma, another study was performed to determine whether changes in
peak flow are related to individual sleep stages. This study is
described in the next chapter.
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Chapter 13-
TBE RELATIONSHIP BETWEEN NOCTURNAL BRONCBOCONS'miCnON
AND EEG SLEEP STAGE
In this study, 8 adult asthmatics who complained of nocturnal wheeze
and age-matched control subjects were wakened at different times
during the night, from known EEG sleep stages, and their FEV^ and
PEFR measured immediately. The protocol was designed to determine
whether there was any difference in airway calibre between REM and
NREM sleep in adult asthmatics and to compare any such difference
with underlying circadian changes.
METHODS
Subjects
Eight patients with asthma (5 male, 3 female) were studied,
including four who had also taken part in the sleep deprivation study
(Chapter 10) the interval between the two studies for each patient
being at least 3 months. Their clinical details are given in table
7 (patients 2, 4, 7, 9, 11, 13-15). Their mean age was 30 yr
(range 15 - 54 yr) and all were within 15% of their ideal body weight
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(Documenta Geigy, 1970). All had reversible airways obstruction
with at least one FEV^ during the preceding year that was within 1.5
standard deviations of predicted. Seven had positive skin prick
tests to D. pteronyssinus and/or grass pollens. All complained of
nocturnal wheeze and had documented "morning dips" in peak expiratory
flow rate (PEER). None had had an acute attack of asthma in the six
weeks prior to the study. Two took regular inhaled sodium
cromoglycate and two oral prednisolone (5 and 10 mg/daily). All
used beta2 sympathomimetic agents but these were withheld for six
hours before the study. Each patient was matched for age and sex
with a healthy subject with no history of respiratory disease who was
studied on the same night as the patient.
Protocol
Each subject slept for three consecutive nights in the sleep
laboratory, the first serving as an acclimatisation night. On each
night they were awoken from sleep on three occasions and immediately
asked to perform forced expiratory manoeuvres so that PEFR and FEVj_
could be measured. The timing of their wakenings on the second and
third nights was designed to differentiate temporal from sleep stage
related changes in airway calibre (fig 24).
On one night (night A) the patients were awoken 10 minutes after the
end of the first REM period and again 60 minutes later, before the
start of the next REM period (fig 24), i.e. both awakenings were from
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Fig 24 Schematic diagram of times of wakening on second and third
nights. Broken lines indicate second randomisation, in
which wakenings from REM and NREM (non-REM) sleep were
random.
On the other night (night B) the patient was awoken 60 minutes after
sleep onset, prior to the first REM period, and 5-7 minutes after the
start of (i.e. during) the second REM period. Thus there was a REM
period between the two awakenings and, furthermore, the second
awakening was made during a REM period (fig 24). The order of night
A and night B was randomised so that half the paients did each night
first.
The third awakening on both nights was designed to give "time-
matched" measurements of airway calibre in REM and NREM sleep.
Thus, on one night, the third awakening was made from the first REM
period after 4 am, and on the other night it was made during the
first NREM period after 4 am. The order of these nights was
randomised independently of the night A/night B randomisation (fig
24) .
On both nights measurements of FEVp forced vital capacity and PEFR
were also made at: 9.30 pm; at 11 pm just before lights out;
immediately on final awakening in the morning; and finally one hour
thereafter. On each of these occasions and following imposed
wakenings, the PEFR was measured first with the subject supine, then
FEVj was measured with the subject sitting on the bed and finally
both PEFR and FEV^ were measured while the subject was standing.
All measurements were made in duplicate except for the standing FEV^
which was measured in triplicate and on each occasion the highest
value was taken.
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Each patient slept in a quiet, darkened room on each night of the
study and EEG sleep stage was determined by the methods previously
described (Rechtschaffen and Kales, 1968).
The actual measurements of FEV^ and PEFR were made by a nurse who was
trained in these measurements and who was blind to the protocol and
who did not know the EEG sleep stage from which the patient had been
woken. The timings of the awakenings on each night were decided by
Dr Shapiro since he had greater expertise in the analysis of EEG
sleep stages than I. This is the only study in the thesis in which
I did not collect the majority of the data myself. However, I did
initiate the study and I designed the study with the assistance of Dr
Shapiro. I also recruited the patients, and I helped to analyse and
interpret the results with the assistance of Dr G Raab (Department of
Medical Statistics, University of Edinburgh) who performed the
multiple regression analysis (see below).
Results are quoted as means 1 standard error of the mean.
Statistical analysis was by Students "t" test for paired comparisons.
The Wilcoxon signed rank test was used for the pooled information
depicted in figure 25. All the data obtained when the subjects were
awakened were analysed by multiple regression methods (Baker and





Despite the three deliberate awakenings, the subjects spent most of
the time asleep , and there was a tendency for the asthmatics to
sleep less well than the control subjects. Total sleep time
averaged 427 min in the normal subjects, compared with 398 min in the
asthmatic patients, but this was not a significant difference. The
normal subjects spent less time awake (mean 44 min) than did the
asthmatics (64 min; p < 0.05) and they also spent more time in stage
2 sleep (234 min) than did the asthmatics (201 min; p < 0.05). The
mean durations of stage 1 sleep (normal, 29: asthma, 36 min) stage 3
sleep (normal, 27: asthma, 23 min), stage 4 sleep (normal, 50:
asthma, 51 min) and REM sleep (normal, 87: asthma, 87 min) were each
similar in the two groups in this study.
Forced expiratory manoeuvres
The results are in figs 25 and 26. Detailed results from each study
are shown in figs 32a-d in the appendix.
Normal subjects
In the eight normal subjects there was no significant
bronchoconstriction overnight, eg PEFR supine was 413 1 38 1/min pre
sleep and 400 * 40 1/min at each individual's lowest PEFR during the
night. There was also no difference in time-matched REM and NREM
measures in the normal subjects, eg FEVj standing was 3.5 1 0.4 1 and
3.5 * 0.4 1 on awakening from REM and NREM sleep respectively.
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Asthmatic patients
Every patient bronchcconstricted overnight, eg PEER supine was 410 *
50 1/min pre -sleep and 186 1 49 1/min at the lowest level overnight.
One patient (patient 2; fig 32, appendix) used a bronchodilator
inhaler after the first wakening on night B. The subsequent data
from that night has been excluded frcm the analysis.
(i) Changes in PEFR and FEV^ with and without intervening REM sleep:
All measurements of forced expiratory flow rate (PEFR both lying and
standing, FEV^ both sitting and standing) decreased significantly
more (range of p values 0.04 - C.02; table 8) when there had been
intervening REM sleep periods (night B) than when there was no
intervening REM sleep (night A). However, the intervals containing
REM Sleep were significantly longer (190 1 26 min) than the intervals
without any REM sleep (61 * 3 min). Thus this comparison cannot
fully distinguish effects of sleep stage from those due to time.
(ii) PEFR and FEV^ during "time-matched" awakenings from REM and
NREM sleep:
To examine predicted sleep stage effects while reducing any temporal
effects, we compared the measurements of FEV^ and PEFR made during
the first NREM period after 4 am with those made during the first REM
period after 4 am ("time-matched" measurements). There was no
significant difference between the measurements made during wakenings
from REM sleep compared with those during wakenings from NREM sleep,
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TABLE 8
HEAR CHARGE IK PEER AHD FEVj WITH AHD
WITHOUT INTERVENING REM SLEEP
Without intervening
REM sleep
(night A; n = 7)
With intervening
REM sleep
(night B; n = 7)
Duration of interval
between measurements (min) 61 190
PEFR lying (1/min) -9 -74
PEFR standing (l/min) -39 -120
FEVjl sitting (1) COo•o1 •o1
FEV^ standing (l) -0.02 -0.7
but for all parameters of forced expiratory flow (PEFR lying and
standing, FEVj sitting and standing) the REM measurements tended to
be lower than the MREM measurements.
However, this analysis was complicated by a number of factors, viz:
(i) patient 2 (fig 32) used his inhaler on one night (see above) and
on the other night did not enter REM sleep after 4 am; (ii) in
patient 3 (fig 32), the second wakening on night B was after 4 am;
and (iii) on night B, patient 6 did not fall asleep after 4 am.
To obtain more data for this analysis, covering a wider time period,
we included "time-matched" measurements made at two other times
during the night and, for this analysis only, we also included
results from the acclimatisation nights whenever this enabled a
"time-matched" comparison to be made that would not have been
possible otherwise. Thus: (1) In five patients FEV-. and PEFR
measurements on final awakening were made from NREM sleep on one
night and from REM sleep on the other night: (2) The second
awakening on. night A (from NREM sleep) was compared with the second
awakening on night B (from REM sleep) in each patient. Taking all
19 "time-matched" measurements (seven at the second awakening on each
night, seven at 4 am and five on final awakening), the REM
measurements were on average 21 * 8 (range -4 to +69) minutes later
than the matched NREM measurements.
Averaging the two or three "time-matched" measures for each subject






















Fig 25 Peak expiratory flow rate and forced expiratory volume in 1
second in postures indicated after patients were woken from
REM and NREM (non-REM) sleep. Each line represents average
of 3 time-matched comparisons (5 patients) or 2 time-matched
awakenings (2 patients). For all measures, p < 0.05.
TIME
Fig 26 Forced expiratory volume in 1 second (FE\M measured
standing after wakening from REM or NREM (non-REM) sleep at
times indicated: values are means * SEM in 7 patients using
data from both night A and night B. Solid lines join data
obtained in the subjects on the same night: broken lines
indicate when data were from different nights owing to the
two separate randomisation procedures.
all measurements of forced expiration after awakenings from REM sleep
were significantly lower (p < 0.05) than the measurements following
"time-matched" NREM awakenings (fig 25). The data obtained from
this "time-matched" comparison of wakenings from REM and NREM sleep
were plotted against the time of night (fig 26). The overall
decrease in FEV^ overnight was much greater than the difference in
FEV^ between REM and NREM sleep.
(iii) Regression analysis:
Since the above "time-matched" awakenings for REM sleep were on
average later than those from NREM sleep, they could not fully
differentiate sleep effects from temporal effects. Furthermore, the
above analysis of "time-matched" values did not use all the data
collected to separate the effects on forced expiration of time of
night from those due to sleep stage. This was achieved by fitting a
regression model to all the data obtained in each patient, using the
statistical package GLIM (Baker and Nelder, 1978). In the final model
(table 9) for all four measurements of forced expiration (FEV^ and
PEFR each in two postures) the most important influence was that of
time (p < 0.01). Taken over the whole night, the effect of REM
sleep was significant for one of the respiratory measures (PEFR
lying, p < 0.05) but not significant (0.1 > p > 0.05) for the other
measures. However, when a model was fitted which allowed the
influence of REM sleep to decline with time of night, this gave a
significantly better fit for all four expiratory manoeuvres (p <
0.05). The effect of REM sleep was greatest early in the night and
declined towards morning for all forced expiratory measurements.
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TABLE 9
EFFECT OF RAPID EYE MOYIMEET SLEEP OH BROHCHOCOHSTRICTIOK
Fitted values of the variables in the linear equation derived from
all the data from the 8 asthmatics:
Y = Pi~tSi " DREM + ^t_2)SREM
where
Y = FEVj (or PEFR) in each posture
P^ = FEV^ (or PEFR) in NREM sleep at midnight in the ith patient
t = time after midnight (hours)
Si = slope of FEV^ (or PEFR) decline with time in the ith patient
Drem = decrease in FEV^ (or PEFR) due to REM sleep at 2 am
Srem = change in effect of REM sleep on FEV^ (or PEFR) with time
Y
, Pi . ,Si , DREM SREMMean (Range) Mean (Range)
PEFR 1/min 1/min/hr 1/min 1/min/hr
standing 362 (200-534) 14 (-2 - 50) 82 19
sitting 322 (162-454) 13 (2 - 38) 74 21
FEV-l 1 1/hr 1 1/hr
standing 2.72 (1.61-3.72) 0.11 (0.02-0.28) 0.46 0.12
sitting 2.58 (1.50-3.54) 0.10 (0.01-0.24) 0.39 0.10
DISCUSSION
This study suggests that nocturnal brcnchocontsriction in adult
asthmatics may be associated with rapid eye movement sleep, but that
there is also a major effect of time.
In Chapter 10, asthmatic patients were found to have smaller
overnight falls in peak expiratory flow when they were kept awake all
night than on nights when they slept. However, it was not clear
whether this was due to disruption of the sleep-wake cycle, with its
attendant effects on other circadian rhythms which might affect
airway calibre, or to loss of time in one or more EEG sleep stages.
The results of the present study extend those observations by
establishing that the REM stage of sleep may be associated with
bronchoconstriction independent of temporal effects. However, this
REM effect was relatively small compared with the overall nocturnal
bronchoconstriction, and was only significant in the early part of
the night.
The lower flow rates found after awakening from REM sleep could be
explained by impaired expiratory muscle function on wakening from
REM, which is a sleep stage characterised by voluntary muscle
hypotonia. However, the subjects were fully awake at the time of
performing the expiratory manoeuvres with normal submental
electromyogram tone. Further, the difference in forced expiratory
flow rates was seen in each of the four sequential types of forced
expiratory flow manoeuvres, and thus there was no evidence that the
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effect was transient following awakening. Other studies of the
performance of voluntary tasks on wakening from different sleep
stages suggest that the worst performance occurs on wakening from
stages 3 and 4 sleep, with no significant difference between stage 2
sleep - from which most of the NREM awakenings were made - and REM
sleep (Wilkinson and Stretton, 1971). Further, the normal controls
would be expected to show such a performance effect and they did not.
Thus we conclude that the significant effects of REM sleep in
asthmatic patients on measurements of forced expiration reflect
alterations in airway calibre. Asthmatics respond more than normal
subjects to a wide variety of bronchoconstricting influences and this
study suggests that REM sleep is another such stimulus.
REM sleep could either cause bronchoconstriction by a direct "on-off"
effect or by producing a lasting effect which persists after the REM
period has finished. The results from the modelling procedure and
from the "time-matched" comparison both suggest that REM sleep has a
direct effect on asthmatic airway calibre, but whether REM sleep has
a persisting effect on airway tone is unclear. It is possible that
the effect of REM sleep was underestimated in this study since the
overnight decline may have resulted partially from an accumulative
effect of REM sleep periods throughout the night. However, a
decline in airway calibre was also observed between the awakenings
without intervening REM sleep, suggesting that there is a time effect
independent of the REM sleep effect.
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The results of this study - suggesting that REM sleep causes
bronchoconstriction - require confirmation as we studied relatively
few subjects and by awakening them necessarily interrupted the
variable under study, ie REM sleep. There have been no satisfactory
measurements of bronchomotor tone in sleeping asthmatics (see Chapter
2), perhaps because oesophageal intubation is required for
conventional measurement, and patients with nocturnal asthma sleep
poorly (Chapter 6) even without such instrumentation. One study
(Kales et al, 1970) used a tape-recording of breath sounds to try to
detect bronchoconstriction, and found no relationship between REM
sleep and bronchoconstriction in asthmatic children, but as
ventilation is on average lower in REM sleep than NREM sleep (Douglas
et al, 1982a; Straaling et al, 1985), wheeze might even decrease in
REM despite bronchoconstriction. Nevertheless, the data presented
above does suggest that REM sleep may be associated with
bronchoconstriction.
The mechanism of bronchoconstriction in REM sleep requires
elucidation. In dogs, the variability in bronchial smooth njuscle
tone during REM sleep can be abolished by cooling the vagus nerve
(Sullivan et al, 1979). I therefore studied the effects of inhaled
anticholinergic agents on nocturnal bronchoconstriction. These
studies are described in the next chapter.
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Chapter 12
THE EFFECT OF AHWAY VAGAL BLOCKADE
ON NOCTURNAL BRCNCnOCCNSTRICTTON
In the foregoing study, REM sleep was shown to be signficantly
associated with bronchoconstriction in asthma. Since REM-related
fluctuations in airway calibre in dogs can be abolished by cooling
the vagus nerves (Sullivan et al, 1979), and because of evidence that
vagal activity increases at night both in cats (Baust and Bohnert,
1977) and human subjects (Gaultier et al, 1977; Postma et al, 1985),
I attempted to study the effects of vagal blockade on nocturnal
bronchoconstriction in patients with asthma, using the inhaled
• atropine-like drug ipratropium bromide.
METHODS
Patients
The asthmatic patients (8 men, 2 women) were aged 21 - 51 (mean 39.8)
years (table 7; patients 2, 3, 7, 11, 16 and 21). None had had an
acute exacerbation of asthma for at least six weeks. All complained
of nocturnal wheeze, with a mean circadian change in PEFR (measured
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four times daily for 5-7 days as an out-patient in six) averaging
22 percent (range 13 - 42 percent) of the highest daily value. All
had reversible airways obstruction with a documented increase in FEV^
of more than 20 percent after inhalation of bronchodilators. Seven
had positive skin prick tests to at least two common allergens and
seven had a family history of atopy. Three patients took a regular
dose of prednisolone 5-10 mg daily, eight patients took inhaled
corticosteroids regularly and two patients used inhaled sodium
cromoglycate regularly. These were continued during the study,
each at an unchanged dose, but oral theophyllines (used by three
patients), oral salbutamol (two patients) and inhaled ipratropium
bromide (two patients) were withdrawn 24 hours before the study.
All patients used inhaled betasympathomimetic agents and these were
withdrawn six hours before the study.
Dose response to ipratropium
One week prior to the night time study, a cumulative dose response
curve to nebulised ipratropium was performed mid-morning in five of
the patients, measuring FEV^ after 50, 250, 500 and 1,000 ug of
ipratropium. 250-500 ug produced maximal bronchodilatation (fig
27). The dose of ipratropium chosen for the study was 1 mg.
Protocol
The patients were studied on three consecutive nights, the first for
acclimatisation. On the second and third nights they received
either nebulised ipratropium (1 mg) or nebulised normal saline in
random order, double-blind (fig 28).
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Fig 27 Effect of inhaled ipratropium on forced expiratory volume in
1 second in 5 patients with asthma: cumulative dose-
response curve.
They arrived in the laboratory at 9.3 0 pm. At 10 pm, their peak
expiratory flow was measured and the nebulised solution (either
placebo or ipratropium) was administered. Ninety minutes later the
peak flow was re-measured. They were allowed to sleep, but were
wakened at 2 am when a peak flow rate was recorded and a further
nebulisation of the same solution given. The patients were wakened
again at 6 am, their peak flows were measured, and then, on both
nights, they were given nebulised ipratropium 1 mg. After a further
90 minutes, the peak flow was measured again. Finally, on both
nights, each patient received 5 mg of terbutaline by nebulisation and
the peak flow was recorded 30 minutes later (fig 28).
At 10 pm, 11.30 pm, 2 am and 6 am, the pulse rate was measured during
wakefulness before the peak flow measurements and before the
administration of the nebulised solutions.
In six subjects, electroencephalographic sleep stage was recorded
throughout the night as described in Chapter 2. Owing to technical
problems, however, complete sleep data for both nights was recorded
in only four subjects.
Additional study to determine the effect of nocturnal ipratropium on
the response to methacholine challenge at 6 am
To determine whether ipratropium (1 mg) administered at 10 pm and 2
am blocked pulmonary cholinergic receptors throughout the night, four
of the ten patients were restudied on a further two nights. On one
152
night they received 1 ma ipratropium at 10 pm and 2 am, and the on
the other night they received nebulised saline at these times,
double-blind and in random order as in the main study, but at 6 am,
instead of receiving an ipratropium inhalation, they underwent a
standard methacholine challenge (Chai et al, 1975). On each night,
the concentration of methacholine which produced a 20% fall in FEVj
(PC20) was determined.
Differences were assessed by the paired "t" test.
RESULTS
Requests to use additional bronchodilators
One patient woke between 1 am and 2 am on both study nights and asked
to use a bronchodilator. On each occasion, he was given the test
nebuliser solution (either placebo or ipratropium) but in neither
instance did he feel that this was sufficient to control his
symptoms. He became anxious and requested that no further
measurements be made. He was given nebulised terbutaline (5 mg)
with relief of symptoms, and eventually returned to sleep. No
measurements were made in this patient after 2 am, but measurements
up to and including the 2 am (pre-terbutaline) measurement are
included in the peak flow results below. When the code was broken,
his peak flow at 2 am was found to be 220 1/min on the ipratropium
night and 150 1/min on the placebo night.





























Fig 28 Overnight change in peak expiratory flow rates in asthmatic
patients on a night when they inhaled ipratropium (closed
circles) and a night when they inhaled placebo (open
circles). Ipratropium or placebo was administered at 10
pm, 2 am and 6 am. At 7.30 am, the patients received
inhaled terbutaline.
bronchodilators on either night.
Effect of ipratropium on peak expiratory flow
The PEFR at 10 pm was similar on the placebo night (376 * 29 1/min)
and ipratropium night (376 * 31 1/min; NS; fig 28). Following
placebo there was no change in PEFR (363 t 33 1/min; MS; fig 28), but
the PEFR did rise after ipratropium (415 * 33 1/min; p < 0.02; fig
28). This bronchodilating effect of ipratropium persisted, the PEFR
measurements at 2 am and 6 am also being higher (p < 0.01 and < 0.02
respectively) on the ipratropium night than on the placebo night (fig
28).
Effect Qf ipratropium on the overnight fall in peek expiratory flow
Although ipratropium increased nocturnal peak flow rates
significantly, it had no effect on the overnight change in peak flow.
Significant bronchoconstriction occurred overnight on- both the
ipratropium night (PEFR drop from 11.30 pm level to lower of 2 am or
6 am levels 86 1 17 1/min; p < 0.001; fig 29) and the placebo night
(PEFR drop 103 * 23 1/min; p < 0.01; fig 29) and these decreases in
peak flow were not significantly different on the two nights (p >
0.2; fig 29).
Effect of ipratropium on peak expiratory flow before and after sleep
There was no significant difference between the bronchodilatation at
6 am on the placebo night and the initial bronchodilatation at 10 pm
on the ipratropium night (PEFR rise at 10 pm 46 t 12 1/min: at 6 am
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Fig 29 Maximal overnight fall in peak expiratory flow rate in 10
asthmatic patients on a night when they received ipratropium
































Fig 30 Change in peak expiratory flow rate with ipratropium before
sleep and after sleep in 9 patients with asthma. The
"before sleep" measurements (closed circles) were made at 10
pm on the ipratropium night. The "after sleep"
measurements (open circles) were made at 6 am on the placebo
night.
Effect of ipratropium on FEFR at 6 am
Ipratropium at 6 am on the placebo night produced a significant
increase in PEFR of 83 1 17 1/min (before ipratropium 283 1 21 1/min:
after ipratropium 366 1 32 1/min; p < 0.01). On the ipratropium
night, however, ipratropium did not produce significant additional
bronchodilatation at 6 am (before ipratropium 347 1 37 1/min: after
ipratropium 369 * 40 1/min; p > 0.1).
Pulse
The pulse rate at the start of the study (10 pm) was not
significantly different from the pulse rate at either 11.30 pm, 2 am
or 6 am on either the placebo night or the ipratropium night.
Effect of terbutaline after maximal bronchodilatation with
ipratropium
On both nights, the inhaled terbutaline at 7.30 am produced
significant bronchodilatation over and above that brought about by
ipratropium. Peak flow rose from 368 * 25 1/min before terbutaline
to 443 * 25 1/min after terbutaline (p < 0.001).
Effect of nocturnal ipratropium on the response to metacholine
ehaT|pnqe at 6 am
In the additional study involving methacholine challenge, ipratropium
again raised the overnight peak flow readings. PEFR at 6 am in
these four patients averaged 298 * 21 1/min on the ipratropium night
and 163 1 42 1/min on the placebo night (p < 0.05).
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TABLE 10
THE EFFECT OF IPRATROPIUM (1 mg), ADMINISTERED AT 10 pm AMD 2 a*,
ON THE RESPONSE TO METHACHOLINE CHALLENGE AT 6 am
IB FOUR PATIEHTS WITH ASTHMA
Subject ^20 ^or methacholine at 6 am (ug/ml)
No
Ipratropium night Placebo night
5 8 < 0.05
11 • 0.05 < 0.03
16 0.5 0 .1
20 1.8 < 0.03
The subject number is taken from table 7.
In one subject, the FEV^ at 6 am on the placebo night was only 0.9 1.
Since methacholine challenge is contraindicated in patients with a
pre-challenge FEV^ of less than 1 litre (Pepys and Davies, 1977),
this patient was given 2 puffs (500 ug) of terbutaline before
performing the challenge. This raised the pre-challenge FEV^ on the
placebo night to 2.1 1 in this patient.
The effect of ipratropium (1 mg) given at 10 pm and 2 am was to
increase the dose of methacholine necessary to produce a 20% fall in
FEVj at 6 am. On average, the PC20 f°r methacholine was
approximately 10 times greater on the ipratropium night than on the
placebo night (table 10).
Sleep
In the four subjects whose EEG sleep stages were recorded throughout
both nights, time in bed was similar on the ipratropium night (400 _
3 min including the interruption at 2 am) and placebo night (398 * 4
min; NS). There was a tendency for patients to spend more time
awake on the placebo night (128 * 31 min) than the ipratropium night
(89 1 13; p > 0.05) but this difference did not reach statistical
significance with the small number of patients involved. Total
sleep time (ipratropium 312 t 11 min: placebo 273 t 35 min) and time
spent in stage 2 sleep (ipratropium 93 t 16 min: placebo 73 * 9 min)
tended to be greater on the ipratropium night than the placebo night,
although these again were not significant differences. The number
of minutes spent in EEG sleep stage 1 (ipratropium 17 1 4 min:
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placebo 17 1 2 min; MS), slow wave sleep (EEG sleep stages 3 plus 4,
ipratropium 131 1 14 min: placebo 133 t 20 min; NS) and REM sleep
(ipratropium 64 + 6 min: placebo 66 1 11 min; MS) were each similar
on active drug and placebo.
DISCUSSION
The main purpose of this study was to determine whether nocturnal
bronchoconstriction in asthma is due to increased vagal tone at
night. The results suggest that it is not. Ipratropium did
increase nocturnal peak flow rates in these patients, but the effect
of ipratropium was no greater during the night than before sleep.
To maximise vagal blockade throughout the night in this study, the
patients were given 1,000 ug of ipratropium (2-4 times the dose which
produced maximal bronchodilatation in these patients) and the drug
was administered both before sleep and halfway during the night.
This regimen of ipratropium protected against methacholine challenge
at 6 am (table 10), with, on average, more than a ten fold increase
in the PC2Q for methacholine on the ipratropium night compared to the
placebo night. Further evidence that there was overnight vagal
blockade was provided by the results of the 6 am ipratropium
inhalation (fig 28). On the night that the patients received 1 mg
of the active drug, they showed no significant additional
bronchodilatation at 6 am, whereas ipratropium at the end of the
placebo night produced a highly significant rise in peak flow (fig
30). Taken together, these results suggest that there was
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substantial blockade of resting vagal tone of the airways in these
patients throughout the night that they received ipratropium. Since
there was no greater fall in peak flow on the ipratropium night than
on the placebo night, changes in airway vagal tone seem unlikely to
be important in the pathogenesis of nocturnal bronchoconstriction.
In the cardiovascular system, vagal blockade can be assessed during
sleep by measurement of heart rate or of sinus arrhythmia (Soutar et
al, 1977; Postma et al, 1985). In this study, heart rate was not
significantly different on the ipratropium and placebo nights, but
this would not be expected since ipratropium is very poorly absorbed
into the systemic circulation, when given by inhalation (Deckers,
1975; Rominger, 1979).
Despite maximal bronchodilatation with ipratropium, the beta-agonist
terbutaline produced an additional rise in peak expiratory flow.
This rise in peak flow was unlikely to be due to spontaneous
bronchodilatation, for it was a large increase over a period of only
30 minutes.
These results - suggesting no increase in airway vagal tone at nicht
in adult patients with asthma - are at variance with those of
Gaultier and colleagues (1977) who studied healthy children. They
found that ipratropium had greater effects on lung resistance at 8 am
than at 11 pm and that ipratropium abolished circadian changes in
dynamic compliance. The results of Gaultier and colleagues are
difficult to interpret, hov/ever, because measurements were made 10
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minutes after ipratropium inhalation whereas the peak effect is at 60
- 120 minutes (Gross, 1975; Douglas et al, 1979c; Bruderman et al,
1983).
Other suggestions that increased vagal tone at night might contribute
to nocturnal bronchoconstriction have been based on more
circumstantial evidence. Reinhardt and colleagues (1980) found that
urinary cyclic guanosine monophosphate (c-GMP) levels increase at
night in asthmatic children and they suggested that this may reflect
increased vagal tone at night. However, the relationship between c-
GMP levels and vagal tone is uncertain. Soutar and colleagues
(1977) postulated an increase in vagal tone at night to explain their
observation that nocturnal peak flow changes paralleled heart rate
changes in three of seven asthmatics, and vagal factors were also
implicated by Postma and colleagues (1985) who found that eight
patients with chronic airflow limitation and nocturnal
bronchoconstriction had slower heart rates and longer sinus
arrhythmia gaps than healthy control subjects, the differences being
maximal at night. Whilst the results of all these studies are
consistent with an increase in vagal tone at night, at least in the
heart, they are not proof of this, nor do they establish a causal
relationship between vagal activity and nocturnal
bronchoconstriction.
Although ipratropium did not alter the magnitude of the "nocturnal
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dip" (Turner-Warwick, 1977) in these patients, it did cause a
substantial improvement in the absolute level of peak flow during the
night. This could have useful implications for the treatment of
nocturnal asthma. Since quaternary ammonium atropine derivatives
such as ipratropium have a longer duration of action (4-6 hours)
(Gross, 1975; Ulmer, 1975; Douglas et al, 1979c; Coe and Barnes,
1986) than the beta2 agonist inhalers, and since the combination of
ipratropium and a beta2 agonist usually produces better and more
prolonged bronchodilatation that either drug alone (Kebog, 1975;
Lightbody et al, 1978; Douglas et al, 1979d; Ruffin et al, 1982;
Lefcoe et al, 1982; Elwooa et al, 1982; Eruderman et al, 1983), it
seems likely that ipratropium given at night might reduce the need
for oral bronchodilators (theophyllines and oral beta2 agonists) in
some patients. However, further studies will be needed to test this
hypothesis, since the duration of action of ipratropium is not quite
so long as that of many oral preparations and an additive effect
between anticholinergic agents and inhaled beta2 agonists has not
been demonstrated during the night (Cox et al, 1984). The results
of two recent studies (Cox et al, 1984; Coe and Barnes, 1986), both
performed concurrently with the present investigation, suggest that
anticholinergic agents given as a single dose before sleep may indeed
improve nocturnal bronchoconstriction, at least in some asthmatic
patients (Coe and Barnes, 1986).
There was a tendency for ipratropium to improve the duration and
depth of sleep in these patients. If this is confirmed in larger
numbers of patients, it would be another potential advantage of
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ipratropium over oral bronchodilators (see Chapter 8). However, it
must be stressed that more studies will be need to clarify the
effects of inhaled ipratropium on sleep, since patients were
deliberately wakened during this study in order to give them an
additional nebulisation at 2 am.
In 1870, Thorowgood emphasised the nocturnal occurrence of asthma and
recommended strammonium or belladonna "especially given at night in a
full dose" as the most effective treatment. The results of this
study suggest that changes in vagal tone are unlikely to account for
nocturnal changes in airway calibre. However, they confirm that
anticholinergic agents can relieve bronchoconstriction at night, and
suggest the need for further clinical studies of ipratropium at night
in combination with other inhaled therapjy.
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SUMMARY - PART IV
The purpose of this part of the thesis was to clarify the effects of
sleep on bronchoconstriction in patients with nocturnal asthma.
This involved the following studies:
1. To determine whether sleep is essential for the development of
nocturnal bronchoconstriction, 12 patients with nocturnal asthma
were studied on two nights - one when they slept and another when
they were kept awake. Peak expiratory flow rate fell on both
nights, but both absolute and percentage fall in PEFR were greater
when the patients slept.
2. In 4 of these patients, venous levels of catecholamines and
corticosteroids were measured thfoughout the two nights. There
was no consistent change in 11-hydroxycorticosteroid levels
between the awake night and the asleep night. Adrenaline and
noradrenaline levels tended to be higher on the asleep night.
3. To determine whether nocturnal bronchoconstriction is associated
with a particular stage of sleep, a further study was performed in
which PEFR measurements were made after waking patients from known
EEG sleep stages. Eight patients with nocturnal asthma were
studied, each on three nights. PEFR was lower after wakenings
from REM sleep than after time-matched wakenings from NREM sleep,
but this difference was small in relation to total overnight
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bronchoconstriction and was only significant in the early part of
the night.
4. Since REM-related changes in airway tone in dogs may be mediated
vagally, the effects of vagal blockade on nocturnal
bronchoconstriction were studied. In a double-blind placebo-
controlled trial of ipratropium, involving a further 10 patients
with nocturnal asthma, nebulised ipratropium increased nocturnal
peak flow rates, but this bronchodilating effect was no greater
during the night than before sleep.
The following conclusions were drawn:
1. Sleep is not essential for the development of nocturnal asthma but
it does appear to aggravate overnight bronchoconstriction.
2. Patients with asthma may bronchoconstrict more in REM sleep than
in NREM sleep. However, this REM effect on airway calibre appears
to be small in relation to total overnight bronchoconstriction.
3. The bronchoconstricting effect of sleep is unlikely to be mediated
by changes in the circulating levels of corticosteroids or
catecholamines.
4. Nocturnal bronchoconstriction in asthma is probably not caused by
changes in airway vagal tone.
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5. Although ipratropium does not abolish overnight
bronchoconstriction in asthma, it can raise peak expiratory flow
rates during the night as well as during the day. In view of the
long duration of action of ipratropium, further studies should be




CLINICAL IMPLICATIONS AND CONCLUSIONS
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Chapter J.3
THE CLINICAL IMPLICATIONS OF THESE STUDIES
The results of this thesis are discussed in detail after each
individual study. This chapter contains a brief resume of their main
clinical implications.
1. The indications for studies of breathing and oxygenation during
sleep
In routine patient care, the major indication for studying breathing
and oxygenation during sleep is to confirm a clinical suspicion of
the sleep apnoea syndrome. The results of this thesis suggest that
expensive sleep studies are not necessary to predict the level of
hypoxaemia during REM sleep in patients with either asthma or chronic
bronchitis and emphysema, for the lowest oxygen tension during sleep
can, within moderately tolerance limits, be predicted from the oxygen
tension when awake in these patients (Section III). It must be
remembered, however, that obstructive airways disease and sleep
apnoea can occasionally coexist, and sleep studies should be
performed in patients suspected of having both conditions.
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Recent guidelines (Martin et al, 1985) endorsed by the American
College of Chest Physicians and the Association of Sleep Disorders
Centers, suggest that cardiopulmonary sleep studies may be indicated
in patients with chronic obstructive pulmonary disease or asthma if
they have sleep-related respiratory symptoms (nocturnal cough or
choking, wheezing, sputum production or dyspnoea). However, the
asthmatic patients studied in this thesis had normal breathing
patterns during sleep, both in terms of the number of apnoeas and
hypopnoeas and the duration of inspiration and expiration for each
breath. They also had similar falls in oxygen tension during sleep
to the normal subjects and bronchitic patients, even though they had
nocturnal wheeze, dyspnoea or cough at night, with documented
nocturnal bronchoconstriction.
In asthma, therefore, most respiratory symptoms at night do not in
themselves appear to be an indication for complex measurements of
breathing patterns and oxygenation during sleep, although further
studies in larger numbers of patients will be needed to confirm this.
For the most part, sleep studies should be restricted to patients who
have symptoms suggestive of a sleep apnoea syndrome, (e.g. daytime
somnolence, personality change, sexual impotence, morning headache,
loud snoring) irrespective of the presence or absence of co-existing
lung disease.
It should be stressed, however, that these considerations apply only
to the complex studies of breathing and oxygenation described in
sections I - III of this thesis. Measurements of circadian changes
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in airway calibre (FEV^ and PEFR) are simple, inexpensive, and very
useful in the assessment of patients with airflow limitation (Turner-
Warwick, 1977).
Furthermore, these comments apply only to routine patient care.
Nocturnal asthma remains poorly understood, and its treatment
unsatisfactory, and these problems will be resolved only by further
research.
2. The interpretation of studies of breathing and oxygenation during
sleep
The results reported in section II indicate that there is a wide
normal range of apnoea, hypopnoea and oxygen desaturation during
sleep, especially in subjects over the age of 50 yr. Indeed, some
of our asymptomatic subjects had more than the 30 apnoeas per night
required to diagnose a sleep apnoea syndrome (Guilleminault et al,
1978), yet they did not develop symptoms of the syndrome over a
follow-up period of six years.
Although the currently accepted definition of a sleep apnoea syndrome
is adequate in most clinical settings, these observations suggest
that it may not always be applicable, especially over the age of
50 yr. These results suggest, therefore, that the sleep apnoea
syndrome should be diagnosed only in patients who have both symptoms
suggestive of this syndrome and documented breathing abnormalities
during sleep.
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These results also emphasise the importance of age-matched controls
in studies of breathing and oxygenation during sleep.
In sections II and III of the thesis, hypoxaemia during sleep was
shown often to result from hypopnoea rather than apnoea, yet sleep
hypopnoea has received little attention in clinical studies. Recent
studies suggest that there may be a "sleep hypopnoea syndrome" in
which recurrent hypopnoea during sleep - but not apnoea - is
associated with clinical features normally found in the sleep apnoea
syndrome (Gould et al, 1986). If this observation is confirmed,
clinical studies should take into account not only the number of
apmoeas during sleep but also the number and duration of hypopnoeas.
3. The management of nocturnal asthma
Patients with bronchial asthma v/ho complain of nocturnal wheeze are
often treated with oral theophyllines or oral beta sympathomimetic
agents. Although these agents are often necessary to achieve
adequate relief of nocturnal symptoms, this approach to treatment is
unsatisfactory from both practical and theoretical viewpoints.
Practically, these agents are often poorly tolerated and they are not
always effective. On theoretical grounds, they are unsatisfactory
because they provide symptomatic relief only and do not correct the
underlying abnormality. Ideally the treatment of nocturnal asthma
should involve a more systematic approach, as outlined below:
3(i) Reduction of bronchial hyperreactivity
Nocturnal asthma is an exaggeration of the normal reduction in airway
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calibre at night. It therefore reflects bronchial hyperreactivity
and indicates that the patient's asthma is inadequately controlled.
The initial treatment of choice for nocturnal wheeze, therefore, is
to increase conventional daytime maintenance treatment with
prophylactic agents and, if necessary, inhaled beta2~agonists
(Connolly, 1981; Horn et al, 1984).
Bronchial hyperreactivity, with parallel improvement in morning peak
expiratory flow, can be achieved by rigorous exclusion of inhaled
allergens for prolonged periods (Platts-Mills et al, 1982), but this
is rarely feasible in practice.
The studies in this thesis do not address the question of bronchial
hyperreactivity directly, but it should be the primary consideration
in the treatment of all patients with asthma.
3(ii) Identification and reversal of the factors which lead to
airway narrowing at niaht
Another approach to the treatment of nocturnal asthma would be to
identify the change or changes which lead to airway narrowing at
night and to reverse them in patients with asthma. Since nocturnal
bronchoconstriction in asthma is an exaggeration of the normal
variation in airway calibre at night, it is likely, although not
proven, that the immediate cause or causes of nocturnal
bronchoconstriction are physiological.
There have been many attempts to identify the nature of these changes
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(Douglas, 1983 and 1985; Barnes, 1984) and the studies in section IV
- in which I attempted to define the relationship between sleep and
bronchoconstriction - fall into this category.
The study in chapter 10 demonstrated that partial relief of nocturnal
bronchocontriction could be achieved by keeping patients awake all
night, but clearly this has no direct practical application.
Furthermore, it did not distinguish the effects of sleep itself from
those of other circadian changes which might have been affected by
disruption of the sleep-wake cycle. A further study established a
relationship between bronchoconstriction and REM sleep, but the
effect of REM sleep was small compared to the overall nocturnal
change in peak flow and was only significant in the early part of the
night. Although it might have been possible to reduce the amount of
REM sleep by giving patients the tricyclic antidepressant
proptryptiline, an approach that has been shown to improve symptoms
(Brownell et al, 1982; Conway et al, 1982), nocturnal oxygenation
(Brownell et al, 1982; Smith et al, 1982) and the number of apnoeas
(Clark et al, 1979; Conway et al, 1972; Smith et al, 1982) in
patients with the obstructive sleep apnoea syndrome, I was reluctant
to use this approach since the REM effect on airway calibre was small
and this agent sometimes has adverse anticholinergic effects, even
when used at night (Conway et al, 1982). Instead, I postulated that
the REM effect on airway calibre (and also some of the overnight
bronchoconstriction that was not associated with REM sleep) might be
due to increased vagal tone. However, I found no evidence for this.
Although the inhaled anticholinergic agent ipratropium improved
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airway calibre overall, the overnight effect of ipratropium was no
greater than its effect at 10 pm, before sleep.
Other studies attempting to define the mechanism of nocturnal
bronchoconstriction have also been disappointing in their practical
application. Reinberg and colleagues (1969) noted that circulating
catecholamines showed circadian changes with a nocturnal nadir.
These observations were extended by Soutar and colleagues (1977) who
found that urinary catecholamine excretion fell to a minimum
coincidental with the lowest peak flow rates in seven asthmatics, and
by Barnes and co-workers (1980) who demonstrated a temporal
relationship between the circulating catecholamine level and
nocturnal bronchoconstriction. Barnes and colleagues also showed
that nocturnal peak flow rates could be improved by infusion of
adrenaline but the adrenaline was infused for only 10 minutes on
three separate occasions and the authors did not report the resulting
plasma adrenaline levels. It is uncertain, therefore, whether the
effect of the infused adrenaline was due only to reversal of the
nocturnal fall in circulating adrenaline or whether the adrenaline
levels were supraphysiological. Other studies have shown that,
although supraphysiological doses of betasympathomimetic agents may
help nocturnal asthma, they do not abolish morning dipping (Turner-
Warwick, 1977; Milledge and Morris, 1979; Fairfax et al, 1980;
Fairfax, 1984).
Reinberg and colleagues (1963) showed that nocturnal breathlessness
in asthmatic patients was most marked when the urinary excretion of
172
17-hydroxycorticosteroids was at its lowest. Soutar and colleagues
(1975) confirmed that peak flow rates paralleled changes in
circulating corticosteroids, but proved that this was not a causal
relationship by showing that overnight fall in peak flow was
unchanged if 11-hydroxycorticosteroid levels were kept constant
overnight by infusion of hydrocortisone. Thus circadian changes in
circulating Cortisol seem unlikely to be the immediate cause of
nocturnal bronchoconstriction. There is evidence that regular
treatment with corticosteroids will reduce morning dipping (Eorn et
al, 1984) but this is presumably an effect on overall airway
stability (see above) rather than a pure nocturnal effect.
Nocturnal cooling of the airways (Chen and Chai, 1982),
gastrooesophageal reflux at night (Martin et al,1982; Davis et al,
1983; Hughes et al, 1983; Inouye et al, 1984) and impairment of
mucociliary clearance during sleep (Bateman et al, 1978) have all
been postulated as possible causes of nocturnal bronchoconstriction
but in none of these studies has the evidence been conclusive
(Douglas, 1985) and at present there is no indication that correction
«
of these factors has any practical clinical application.
To date, therefore, attempts to identify and correct the immediate
cause of nocturnal bronchoconstriction have been disappointing, with
little direct benefit to the patient. It is possible that nocturnal
bronchoconstriction could result from a combination of factors, each
of differing importance in different individuals. This emphasises
the importance of dealing with the underlying abnormality in
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nocturnal asthma, i.e. the increased bronchial hyperreactivity,
discussed above.
3(iii) Symptomatic treatment
The studies in section III of the thesis showed that asthmatic
patients not only bronchoconstrict at night, but also that they sleep
less well and become more hypoxaemic at night than healthy control
subjects. The ideal treatment regimen for nocturnal asthma should
restore all of these changes to normality. Unfortunately, however,
neither oral theophyllines nor oral beta agonists - which can reduce
the overnight fall in peak flow (Milledge and Morris, 1979; Fairfax
et al, 1980; Barnes et al, 1982; Davies et al, 1984; Fairfax, 1984) -
improve the quality of sleep in asthma (Phind et al, 1985; Stuart et
al, 1984). Indeed, theophyllines actually disrupt sleep in both
asthmatic patients (Rhind et al, 1985) and patients with chronic
obstructive pulmonary disease (Fleetham et al 1983). " A recent
report (Stewart et al, 1984) indicates that oral terbutaline does not
affect the duration and quality of sleep in asthma. If this is
confirmed, at equal levels of bronchodilataticn, oral beta agonists
may have an advantage over oral theophyllines for the treatment of
nocturnal asthma, but this is uncertain at present.
In this thesis I studied the effects of ketotifen in patients with
nocturnal asthma. A single 1 mg dose of ketotifen improved sleep
without impairing oxygenation but it did not alter the overnight fall
in FEVj. Since there is doubt about the effectiveness of this agent
as a bronchodilator in clinical practice, even when given for periods
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of 4 - 8 weeks (Dyson and Mackay, 1980; Petheram et al, 1981; Monie
et al, 1982), ketotifen cannot be recommended for the treatment of
nocturnal asthma on current evidence.
In general, inhaled therapy for asthma is preferable to oral therapy,
since similar levels of bronchodilation occur with much lower doses
and thus adverse systemic effects are minimised (Larsson and Svedmyr,
1977; Rossing et al, 1980; Williams et al, 1981; McFadden, 1986).
The main reason for using oral agents to treat nocturnal asthma is
their longer duration of action than inhaled beta agonists. The
observation (Chapter 12; Cox et al, 1984; Coe and Barnes, 1986) that
ipratropium increases nocturnal peak flow rates is of interest in
this context, for this agent also has a longer duration of action
than inhaled beta agonists (Gross, 1975; Ulmer, 1975; Douglas et al,
1979c). However, the role of inhaled anticholinergic bronchodilators
in nocturnal asthma has still to be defined.
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gEsnSIQNS
These investigations have helped to clarify some of the
interrelations of asthma and sleep. As noted above, they have also
helped to define the role of sleep studies in the management of
patients with respiratory disease and they have established normal
reference ranges for irregular breathing and oxygenation during
sleep.
Sleep is not essential for the development of nocturnal asthma, but
it does appear to aggravate bronchoconstriction at night. Patients
with asthma may bronchoconstrict more in REM sleep than in non-REM
(NREM) sleep, but the bronchoconstricting effect of REM appears to be
small in relation to total overnight change in airway calibre.
Other mechanisms by which sleep aggravates bronchoconstriction are
poorly understood. Nocturnal bronchoconstriction in asthmatic
patients does not appear to be due to an increase in airway vagal
tone at night.
REM sleep is also associated with hypoventilation, both in asthmatic
patients and normal subjects. The consequent falls in arterial
oxygen saturation are small in most stable asthmatics, but nocturnal
hypoxaemia in REM sleep is probably more pronounced in patients who
are hypoxaemic when awake, including those with severe asthma or
patients recovering from acute attacks. Such episodes of nocturnal
hypoxaemia could contribute to the rare but well-recognised nocturnal
deaths from asthma.
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These studies have also confirmed that asthma disrupts sleep. lack
of sleep is a common finding in asthma and may lead to impaired
performance at work or school in some patients. The ideal treatment
regimen in asthma should therefore improve sleep as well as airway
calibre. This will best be achieved by the liberal use of
prophylactic agents - to reduce bronchial hyperreactivity - and by




Tables 11 - 19 and figures 31 and 32
TABLE 11
SLEEP QUALITY I® 19 HEALTHY MEM DURING STUDIES OF HOCTURHAL





















1 23 43 0 419 97 8 5 38 29 16 11
2 25 430 410 95 4 4 40 7 30 19
3 27 405 367 85 15 10 67 6 8 10
4 27 460 408 89 12 9 54 8 7 22
5 27 468 410 88 17 3 55 5 9 28
6 28 450 423 94 7 5 48 7 17 23
7 28 40 5 376 93 15 9 58 3 4 26
8 37 374 354 95 6 15 43 8 19 16
9 40 400 373 93 3 10 39 6 16 29
10 42 452 366 81 28- 17 • 46 9 6 23
11 45 421 405 96 12 7 64 5 6 18
12 45 410 396 97 12 14 47 5 7 21
13 51 42 5 347 82 19 4 66 5 2 23
14 52 473 413 87 8 8 51 7 16 23
15 55 395 294 74 22 11 61 6 10 12
16 57 363 287 79 29 7 59 13 1 19
17 58 425 394 93 10 10 47 8 12 23
18 60 428 223 52 6 6 66 5 6 17
19 68 43 5 309 71 7 24 58 12 4 2
TIB, time in bed; TST, total sleep time; SEI, sleep efficiency index;
SOL, sleep onset latency. See table 3 for summary of results, for
comparisons between sexes, and for comparisons beween older and
younger subjects.
TABLE 12
SLEEP QUALITY IN 21 HEALTHY WOME® DURING STUDIES OF
NOCTURNAL BREATHING PATTERNS AND OXYGENATION
Sub je ct Age TIB TST SEI SOL
0
/I of TST in EEG s leep stage
No (yr) (min) (min) (%) (min) 1 2 3 4 REM
1 22* _ — — — _ — - - -
2 23 405 376 93 12 3 37 30 23 7
3 24 420 391 93 6 1 42 17 26 14
4 25 445 404 91 9 4 51 10 21 14
5 26 455 404 89 14 6 51 13 9 21
6 26 420 397 95 5 6 47 3 18 26
7 27 385 346 90 41 6 58 10 10 16
8 32 472 444 94 17 4 60 3 13 19
9 38 448 399 89 17 9 67 3 6 15
10 42 458 409 89 6 6 50 14 9 21
11 46 439 382 87 9 15 53 17 10 5
12 49 445 425 96 2 5 46 7 24 18
13 50 370 333 90 4 6 54 10 11 19
14 50 457 424 93 7 6 51 6 10 27
15 53 400 386 96 11 5 54 6 9 26
16 55 403 298 74 10 10 58 9 7 16
17 55 450 309 69 54 10 60 18 0 12
18 60 438 413 94 5 9 69 5 4 15
19 63 398 351 88 6 8 59 6 8 19
20 64 3 86 369 96 2 5 68 6 0 20
21 64 436 409 94 16 3 50 11 5 31
*The EEG, EOG and EMG traces were of poor quality in this subject.
TIB, time in bed; TST, total sleep time; SEI, sleep efficiency
index; SOL, sleep onset latency. See table 3 for summary of
results, for comparisons between sexes and for comparisons between
older and younger subjects.
TABLE 13
BREATHING PATTERNS DURING SLEEP IN 19 HEALTHY EON-OBESE MEN
Subject Age Weight Apnoeas Hypopnoeas Irregular breathing (min)
No (yr) (% average) Total In sleep stages:
1 2 3+4 REM
1 23 100 0 0 0 0 0 0 0
2 25 99 0 4 5 0 0 0 5
3 27 91 0 2 1 0 0 0 1
4 27 104 0 0 0 0 0 0 0
5
*
27 100 0 2 1 0 0 0 1
6 28 102 0 0 0 0 0 0 0
7 28 104 0 0 0 0 0 0 0
8 37 100 1 0 1 0 1 0 0
9 40 89 6 0 9 0 0 0 9
10 42 87 3 1 5 0 0 0 5
11 45 100 0 0 0 0 0 0 0
12 45 102 2 0 2 0 0 0 2
13 51 94 45 • 40 123 17 26 4 76
14 52 95 2 8 18 1 4 0 13
15 55 99 1 2 4 0 0 0 4
16 57 101 0 4 6 0 0 0 6
17 58 105 10 11 28 0 7 0 21
18 60 101 2 9 14 0 2 0 12
19 68 88 13 54 68 12 50 0 6
Average body weights taken from Documenta Geigy, 1970.
See table 3 and figure 6 for summary of results, for comparisons
between sexes and for comparisons between older and younger subjects.
TABLE 14
BREATHING PATTERNS DURING SLEEP IN 21 HEALTHY NON-OBESE HOME®
Subject Age Weight Apnoeas Hypopnoeas Irregular breathing (min)
No (yr) (% average) Total In sleep stages:
1 2 3+4 REM
1 22 104 0 2 2 0 0 0 2
2 23 102 0 7 12 0 2 0 10
3 24 94 0 1 1 0 0 0 1
4 25 105 0 0 0 0 0 0 0
5 26 100 1 0 1 0 1 0 0
6 26 105 0 0 0 0 0 0 0
7 27 101 0 0 0 0 0 0 0
8 32 105 0 0 0 0 0 0 0
9 38 85 0 0 0 0 0 0 0
10 42 97 0 3 6 0 0 0 6
11 46 105 1 2 4 0 0 0 4
12 49 98 1 2 4 0 0 0 4
13 50 100 0 0 0 0 0 0 0
14 50 87 1 0 1 0 0 0 1
15 53 93 0 2 3 0 0 0 3
16 55 91 0 9 17 0 0 0 17
17 55 102 9 11 36 2 16 0 18
18 60 95 75 9 120 12 59 0 49
19 63 100 1 35 47 2 10 0 35
20 64 112 0 4 6 0 0 0 6
21 64 88 4 13 21 0 0 0 21
Average body weights taken from Documenta Geigy, 1978.
See table 3 and figure 6 for summary of results, for comparison
between sexes, and for comparison between older and younger subjects.
TABLE 15
















1 23 98 93 0
2 25 96 94 0
3 27 98 96 0
4 27 98 96 0
5 27 99 93 0
6 28 95 90 0
7 28 96 94 0
8 37 99 93 0
9 40 98 93 1 1 1
10 42 98 93 0
11 45 98 92 0
12 45 98 95 0
13 51 98 93 3 3 2 1
14 52 96 92 0
15 55 94 89 0
16 57 98 94 1 1 1
17 58 97 93 0
18 60 95 88 2 1 1 1 1
19 68 95 71 6 5 1 3 3
Sa02j arterial oxygen saturation (measured by ear oximetry) awake or
at lowest level during sleep; H.E., hypoxaemic episode; Reg, regular
breathing; Hy, hypopnoea; Ap, apnoea. See table 3 and figure 7 for
summary of results, for comparison between sexes, and for comparison
between older and younger subjects.
TABLE 16
ARTERIAL 0XYGE3J SATURATION DURING SLEEP IE 21 HEALTHY EOH—OBESE HOME®
SaO 2 No of H.E.'s in H.E.'s with
Subject Age Awake Lowest H.E.'s sleep stage:
No (yr) (%) (%) 1 2 REM Reg Hy Ap
1 22 95 93 0
2 23 97 90 1 1 1
3 24 97 93 0
4 25 98 94 0
5 26 97 93 0
6 26 97 95 0
7 27 97 95 0
8 32 98 94 0
9 38 99 96 0
10 42 97 93 0
11 46 97 90 1 1 1
12 49 95 93 0
13 50 97 92 0
14 50 96 93 0
15 53 96 94 0
16 55 97 90 1 1 1
17 55 95 87 1 1 1
18 60 96 11' 4 2 2 3 1
19 63 97 78 5 2 3 1 4
20 64 95 94 0
*
21 64 96 92 2 2 2
Sa02> arterial oxygen saturation (measured by ear oximetry) awake or
at lowest level during sleep; H.E., hypoxaemic episode; Reg, regular
breathing; Hy, hypopnoea; Ap, apnoea. See table 3 and figure 7 for
summary of results, for comparison between sexes, and for comparison
between older and younger subjects.
TABLE 17
SLEEP QUALITY IN 20 INDIVIDUAL PATIENTS WITH CHRONIC ASTHMA
DURING STUDIES OF NOCTURNAL BREATHING PATTERNS AND OXYGENATION
Patient Age FEV^ TIB TST SEI SOL % Total sleep time in EEG stage:
No (yr) (%) (min) (min) (%) (min) 1 2 3 4 REM
1 18 29 397 310 78 19 4 70 8 0 8
2 18 63 420 346 77 50 4 53 6 22 15
3 21 27 437 389 89 19 11 56 6 9 18
4 21 12 324 268 83 18 4 59 5 26 7
5 22 42 431 370 86 12 9 48 7 18 18
6 23 50 436 332 63 37 15 60 4 8 13
7 27 38 416 360 86 24 17 45 5 26 7
8 30 38 3 56 257 72 16 22 51 5 2 20
9 34 14 420 342 81 32 7 62 4 18 9
10 34 52 388 218 69 23 23 41 6 14 16
11* 37 - 550 266 48 145 13 40 9 14 24
12 39 27 570 284 50 189 14 66 8 4 8
13 40 11 3 82 270 71 8 11 43 6 12 28
14 50 33 403 165 41 23
'
18 50 5 3 24
15* 50 - 417 293 51 70 18 53 8 8 13
16 51 23 406 320 80 4 1 51 6 0 31
17 53 35 433 245 57 51 13 46 12 20 9
18 56 19 403 354 88 6 13 71 7 0 11
19 56 39 410 344 84 11 23 52 5 3 17
20 59 44 360 206 57 8 16 46 8 19 11
Patients 11 and 15 used a bronchodilator inhaler before the FEV^ was
measured.
FEV-^% = FEV^ before sleep - lowest FEV^ x 100%;
FEV^ before sleep
see table 19 for absolute values of FEV^.
TIB, time in bed; TST, total sleep time; SEI, sleep efficiency index;
SOL, sleep onset latency.
TABLE 18
BREATHING PATTERNS DURING SLEEP IN 20 PATIENTS WITH ASTHMA
Subject Age FEV-^ Apnoeas Hypopnoeas Irregular breathing (min)
No (yr) (%) Total In sleep stages
1 2 3+4 REM
1 18 29 0 0 0 0 0 0 0
2 18 63 0 3 6 0 0 0 6
3 21 27 0 0 0 0 0 0 0
4 21 12 0 5 8 0 0 0 8
5 22 42 0 0 0 0 0 0 0
6 23 50 0 3 4 1 0 0 3
7 27 38 0 2 4 4 0 0 0
8 30 38 0 0 0 0 0 0 0
9 34 14 - - - - - - -
10 34 52 0 0 0 0 0 0 0
11* 37 - 8 17 33 9 0 0 24
12 39 27 0 6 10 0 5 0 5
13 40 11 4 30 57 0 0 0 52
14 50 33 2 44 74 21 27 0 26
1 5* 50 - 0 7 13 9 0 0 4
16 51 23 41 8 44 3 15 0 36
17 53 35 13 2 18 14 0 0 4
18 56 19 38 5 52 4 25 1 22
19 56 39 36 4 42 28 9 0 5
20 59 44 9 10 27 18 6 3 0
* Patients 11 and 15 used a bronchod ilator inhaler before the FEV^
was measured.
FEV-^% = FEV^ before sleep - lowest FEV^ x 100;
FEV-^ before sleep
see table 19 for absolute values of FEV^.
TABLE 19
ARTERIAL OXYGEN SATURATION DURING SLEEP IN 20 PATIENTS
WITH CHRONIC ASTHMA
Subject Age FEV-^ Sa02 No of H.E's in H.E's





Awake Lowest 1 2 REM Reg Hy Ap
1 18 4.2 3.0 98 93 0
2** 18 3.8 1.4 95 85 2 2 2
3 21 3.3 2.4 98 92 0
4 21 4.2 3.7 93 83 2 2 1 1
5 22 1 .9 1.1 95 89 0
6 23 3.2 1.6 94 88 1 1 1
7 27 1 .3 0.8 98 94 0
8** 30 1 .3 0.8 94 83 1 1 1
34 3.6 3.1 97 87 1 1 - - -
10** 34 3.3 1.6 98 89 3 3 3
11* 37 0.8 - 93 86 4 1 3 4
12 39 1.5 1 .1 92 85 1 1 1
13 40 1.8 1 .6 95 87 4
-
4 1 3
14** 50 1 .2 0.8 96 83 5 3 2 2 3
15 50 1 .4 - 97 86 2 2 2
16*** 51 1.3 1.0 95 78 6 2 4 1 4
17 53 2.3 0.8 91 83 1 1 1
18 56 1.6 1.3 97 77 7 1 3 3 1 2 4
19 56 2.3 1.4 95 84 4 4 1 3
20 59 0.9 0.5 96 88 1 1 1
Sa02, arterial oxygen saturation (ear oximeter) awake or at lowest
level during sleep; H.E., hypoxaemic episode; Reg, regular breathing;
Hy, hypopnoea; Ap, apnoea.
* Patients 11 and 15 used a bronchodilator inhaler before the lowest
FEV^ was measured.
** Patients 2, 8, 10 and 14 woke early and used a bronchodilator
inhaler.
*** The magnetometer trace was unsatisfactory in patient 9 and also
during one hypoxaemic episode in patient 16.
Fig 31 Peak expiratory flow rates in 12 asthmatic patients on a
night when they slept (continuous line) and throughout a





































































32a PEFR lying in 8 asthmatic patients after deliberate
wakenings from REM and NREM sleep*. The two lines for each
patient represent two separate nights of study and the
wakenings from REM sleep are marked with an asterisk. For

























32b FEVj sitting in 8 asthmatic patients after deliberate
wakenings from REM and NREM sleep on two nights. For








































































32c PEFR standing in 8 asthmatic patients after deliberate
wakenings from REM and NREM sleep on two nights. For





































Fig 32d FEV-^ standing in 8 asthmatic patients after deliberate
wakenings from REM and NREM sleep on two nights. For
details, see chapter 11.
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Summary Breathing patterns, ear oxygen satur¬
ation (Sa02), and EEG sleep-stage
throughout an undisturbed night's sleep were compared in
ten adult stable asthmatics and ten age-matched healthy
subjects. The two groups slept equally long (5-0-7-2, mean
6-2 h), but the asthmatics slept less well; they had more
periods of wakefulness and drowsiness and irregular
breathing than did the healthy subjects. They also had greater
and more frequent falls in Sa02. Most hypoxaemic episodes
occurred in the rapid-eye-movement phase of sleep and were
associated with hypopnoea or apnoea, but no patient had a
classical sleep-apnoea syndrome. The severity of nocturnal
hypoxaemia was related to the level ofSa02 when the subjects
were awake, but did not correlate with the fall in forced
expiratory volume recorded in eight out of ten asthmatics
after sleep.
Introduction
although nocturnal wheeze in asthma was clearly
described by Dr John Floyer (himselfan asthmatic) in 1698,'
it has only recently been associated with a reduced peak
expiratory flow rate (PEFR) in the early hours of the morning
(the morning dip).2"4 The wide prevalence of this symptom
becomes apparent when asthmatics are asked how they sleep.
Furthermore, although death during an asthmatic attack is
rare, some,5,6 but not all,7,8 surveys have suggested that such
deaths are commoner at night.
Recent interest in disordered breathing during sleep6,10 has
revealed profound transient nocturnal hypoxaemia in
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patients with the "blue and bloated" pattern of chronic
bronchitis and emphysema.11,12 If hypoxaemia also occurred
in asthmatics with nocturnal wheeze, it could contribute to
the disturbed sleep and to the occasional death that occurs in
attacks. To see if asthmatics become hypoxaemic during
sleep, we examined the relationships between EEG sleep
stage, breathing irregularities, and ear oxygen saturation in
ten adult patients with chronic stable asthma and compared
the results with corresponding observations in ten healthy
subjects. Controls were age-matched with subjects, since
sleep disordered breathing becomes commoner as age
advances,13,14 even in health.
Methods
We used non-invasive methods to monitor arterial oxygen
saturation (Sa02) and breathing pattern throughout a night's sleep
in ten adult asthmatics (seven males, three females; aged 22-59
years, mean 41-2); the same studies were done in ten healthy age-
matched subjects (six males, four females; aged 27-57 years, mean
40 • 5) who had no history of respiratory disease and a normal chest
radiograph, forced expiratory volume in 1 s (FEV,), lung volumes,
and transfer factor for carbon monoxide (Tco).15 All subjects were
within 15% of their desired weight,16 and all but one (a 56-year-old
asthmatic man whose control was a 55-year-old normal woman)
were of the same sex as their controls.
All the asthmatics had reversible airways obstruction, with at least
one normal FEV, within the past year. In the 2 years before the
study the lowest FEV, was 0-5-2-3 litres, and the highest
spontaneous FEV, was 1-3-3-5 litres. Seven had positive prick
tests to Dermatophagoides pteronyssinus and/or grass pollens, and
five had a family history of atopy. All were in a stable state with
PEFR varying by not more than 30% (mean 13%) when measured
four times daily for 3 days before and after the study, and none had *
had an attack ofasthma in the previous 6 weeks. Five had a history of
nocturnal wheeze, four took oral prednisolone regularly (5 or 10 mg
dailv), and two inhaled disodium cromoglycate regularly. [S
sympathomimetics were withheld for 6 h before the study.
Each subject slept in a quiet darkened room on 2 consecutive
nights, the first to get the subject accustomed to the equipment.
Only data from the second night were analysed. Thermocouples
were used to detect air flow at nostrils and mouth, and an induction
stethogram at the third intercostal space anteriorly to record
anteroposterior chest diameter.12 The stethograph may not reflect
tidal volume in all sleep stages, particularly since Tabachnik et al.
have described paradoxical inspiratory indrawing of the rib cage
during rapid eye movement sleep (REM) in eight adolescent
asthmatics.17 Ear oxygen saturation was measured by the Hewlett-
Packard 47201A ear oximeter.18 The electroencephalogram (EEG!
was recorded for 30 min before "lights out" and throughout the
night by two midline frontoparietal electrodes; electrooculogram
(EOG) by four electrodes above and outside the outer canthi; and
electromyogram (EMG) by two submental electrodes. Sleep stage
was analysed by standard criteria.19 FEV, was measured before the
subject went to bed and immediately on waking. The subjects gave
informed consent, and the study was approved by the hospitals'
ethical committee. Data were recorded on strip chart recorders,
EEG, EOG, and EMG being recorded separately and linked by time
marks every 15 min to the records of breathing pattern and ear
oxygen saturation. Significance of differences was analysed by the
Wilcoxon 2-sample test. Values are given as mean and range.
Results
EEG Sleep Stage
The total time spent asleep by all subjects averaged 6 • 2 h
(5-0-7-3) and did not differ significantly between the two
groups. There was no significant difference between the two
groups in the duration of REM (mean for the two groups 59
min, range 19-84) or ofnon-REM sleep (NREM; EEG sleep
stages 2, 3, and 4) which averaged 227 min (153-290). The
asthmatics spent more time in wakefulness and drowsiness
(EEG sleep stages 0 and 1; mean 110 min, 61-160) than did
the healthy subjects (mean 64 min, 18-121) (p<0-02).
Breathing Pattern
The breathing pattern was fairly regular for most of the
time spent asleep, as shown by chest wall movement and
oronasal air flow (fig. 1A). Three types of episodes of
breathing irregularity were identified—apnoea,
"hypopnoea", and "hyperpnoea". Apnoea was defined as
complete cessation of oronasal flow for at least 10 s (fig. IB);
hypopnoea as an amplitude ofchest wall movement <50% of
the mean level in the preceding period of regular breathing,
lasting for > 10 s (fig. ID); and hyperpnoea as an episode >10
s when the amplitude ofchest wall movement was >200% of
the previous mean level in regular breathing (fig. 1C).
Hypopnoea thus defined might arise from paradoxical
inspiratory indrawing of the rib cage in REM sleep, as
described in adolescent asthmatics.17 However, our studies of
adult stable asthmatics showed that increase in chest diameter
at the level of the third intercostal space anteriorly was always
in phase with inspiration as recorded by oronasal airflow,
even during hypoxaemia in REM sleep.
Over 98% of episodes of breathing irregularity occurred
repetitively in short bursts, so that periods of irregular
(jreathing were easily recognised. We timed such periods
from the onset ofeither apnoea, hypopnoea, or hyperpnoea to
the start ofthe next full 2 min of regular breathing. We related
these periods to both EEG sleep stage and ear oxygen
saturation. We added up the length ofeach period ofirregular
breathing to obtain the total duration of irregular breathing
for each subject.
Asthmatics spent more time breathing irregularly (mean
52-1 min) than did healthy subjects (mean 24-2 min;
p<0 • 05; fig. 2). In the healthy, hypopnoea accounted for over
99% (70-100) of the irregular breathing, whereas in the
asthmatics hypopnoea accounted for 50-4% (0-100) of the
irregular breathing, apnoea 40 • 1 % (0-97 • 7) and hyperpnoea
9 • 5% (0-24). The 11 apnoeic episodes in the healthy subjects
were all of central type. Seven of the asthmatic patients had
apnoeic episodes, the number of episodes for each of them
being 1,3, 5,8, 35,40, and 71. The frequency ofsleep apnoea
increased with age, 154/163 (94%) of the apnoeic episodes
occurring in the five asthmatics over the age of 40. 151/163
(93%) of the apnoeic episodes in the asthmatics were central,
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Fig. 1—Classification of breathing patterns.
c = chest wall movement; n = airflow at nostril.
x is the amplitude (in arbitrary units) of the chest wall movement in a subject
during stable regular breathing while asleep. In B, an episode of obstructive
apnoea (in which chest wall movement continues despite cessation of air flow)
is shown following an episode ofcentral apnoea (in which both air flow at chest
wall movement cease).
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Regular Apnoea Hyperpnoea Hypopnoea
Fig. 2—Duration of irregular breathing (min, mean± 1 SD) from sleep
onset to final awakening. Fig. 4—Relation between breathing patterns and oxygen
Left: total. Right: in wakefulness and drowsiness (EEG sleep stages 0 and 1); desaturation in asthmatic (•) and healthy (o) subjects,
in non-rapid eye movement sleep (NREM); and in rapid eye movement sleep Each point represents a period ofbreathing. The fall in oxygen saturation is
(REM) in both asthmatic (•) and healthy (o) subjects. from the stable oxygen saturation during sleep.
Although the asthmatics spent more time breathing
irregularly than did the healthy subjects in all EEG sleep
stages (fig. 2), this difference was significant only during
stable wakefulness and drowsiness. Most of the irregular
breathing occurred in REM sleep.
Arterial Oxygen Saturation
The mean Sa02 awake was 95-4% (92'0-97-8 in
asthmatics), but 97-0% (95-0-98-5) in healthy subjects
(p<0 • 01). Hypoxaemia during sleep was both commoner and
more pronounced in asthmatics, and if a hypoxaemic episode
is defined as a fall in Sa02 >4% from the immediately
preceding stable baseline in sleep, such hypoxaemic episodes
occurred in nine asthmatics, but in only four of the healthy
subjects. These episodes occurred 0-7 times a night in
asthmatics, but only 0-1 times a night in the healthy. The
lowest Sa02 during sleep ranged from 77-0-91 -0% (mean
85-0) in the asthmatics, whereas this was 89-3-95-2%
(mean 92-8) in the healthy (p<0-01). The mean fall in Sa02
from the level awake to the lowest level during sleep was
9-7% (4-0-18-9) in asthmatics and 4-3% (2-0-6-2;
p<0-01) in controls (fig. 3).
All 4 hypoxaemic episodes in the controls occurred during
uninterrupted REM sleep; 1 was associated with regular
breathing, 1 with apnoea, and 2 with hypopnoea (fig. 4). In
the asthmatics 16/28 (57%) of these episodes occurred in
uninterrupted REM sleep, 3 (11 %) in uninterrupted NREM
sleep, 6 (22%) in NREM sleep which was interrupted by
short periods of wakefulness and drowsiness (EEG sleep
stages 0 and 1), and 3 (11%) during stable wakefulness and
drowsiness. 8 hypoxaemic episodes in asthmatics were
associated with regular breathing, 8 with apnoea, 1 with
hyperpnoea, and 10 with hypopnoea (fig. 4). On-line
computer recording of chest wall movement and inspiratory
and expiratory time for each breath taken throughout the
night's sleep showed that in three of the four asthmatics in
whom such recording was made expiratory time was longer in
hypoxaemic episodes occurring during REM sleep than
during periods of NREM sleep when the arterial oxygen
saturation was stable (fig. 5). Chest wall movement was also
reduced during these hypoxaemic episodes (fig. 5).
In eight asthmatics the FEV, on waking up in the morning
was below the FEV, on retiring, the mean value falling from
1 • 5 litres before sleep to 1 • 3 litres after sleep. There was no










Fig. 3—Pre-slccp (o) and lowest sleep ( • ) arterial oxygen saturation
(%) in asthmatics and controls.
Lines join measurements in individual subjects.
Discussion
Irregular breathing and episodic hypoxaemia during sleep
were both commoner in adult patients with stable asthma
than in healthy age-matched controls. The asthmatics also
slept less well—they had more intervening drowsiness and
wakefulness than the controls. Although Block et al.14 found
that Sa02 sometimes dropped in healthy subjects during
sleep, this occurred only when the subjects were elderly and
obese. None of our subjects (either asthmatic or healthy) was
obese. The lowest Sa02 values in our asthmatics
(91 • 0-77 • 0%) were similar to those in eight patients with the
"pink and puffing" (type A) chronic bronchitis and
emphysema, but much above the lowest Sa02 in sixteen
"blue and bloated" (type B) bronchitics.12 Most hypoxaemic
episodes were associated with irregular breathing,
particularly hypopnoea and apnoea. Apnoea was commoner
in asthmatics than in controls. Nearly all apnoeic episodes
were central: no patient had a sleep apnoea syndrome.'•10
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Fig. 5—Lower panel, chest wall movement (antero-posterior
diameter at level of third intercostal space anteriorly), in arbitrary
units; and upper panel, expiratory time of all breaths during non-
REM sleep with stable ear oxygen saturation (■) and during REM
sleep with hypoxacmic episodes (fg) in a 51 year old woman with
chronic stable asthma.
We cannot prove that hypoxaemia and hypoventilation
were associated with bronchoconstriction during sleep.
Indeed, paradoxical inspiratory indrawing of the rib cage in
REM sleep, associated with increased diaphragmatic but
reduced intercostal EMG activity, has been found in
adolescent asthmatics.'7 We cannot confirm this, since we
only measured mid-thoracic diameter. However,
prolongation of expiratory time (TE) in three of four of our
adult asthmatics REM who were hypoxic during sleep
contrasts with the shortening ofTE found during REM sleep
in adolescent asthma.17 We believe that this prolongation of
TE, coupled with a fall in amplitude ofchest wall movement,
could arise from subclinical bronchoconstriction during
REM sleep. The increase in airways resistance would cause
the diaphragm, the main inspiratory muscle, to generate a
greater inspiratory pressure, if tidal volume were to be
maintained; however, the increase in lung volume associated
with bronchoconstriction20'21 would further impair its
efficiency as a pressure generator. It is uncertain whether
sleep itself causes bronchoconstriction in man,2,21'22 but our
preliminary results suggest some association, since the
"morning dip" in PEFR is often associated with REM
sleep.25'24 Clearly, better methods of detecting broncho¬
constriction which do not depend upon the patient being
awake are needed to resolve this question.
In our chronic stable asthmatics FEV, measured before and
after sleep was a poor guide to the fall in Sa02 during sleep.
However, this fall in Sa02 correlated with the awake Sa02
(p<0-05) when the results for both asthmatics and healthy
subjects are combined. Conversion of Sa02 values into
corresponding arterial P02 (assuming a normal oxygen
dissociation curve and pH) yields a significant correlation
(n = 20, r = 0-66, pKO-Ol):
Lowest Pa02 asleep (mm Hg)
= 0-35 x Pa02 awake (mm Hg) + 28.
This means that asthmatics have a lower Sa02 during sleep,
partly because they start the night at a lower point on the
oxygen dissociation curve. Our studies do not indicate the
differences in roles played by alveolar hypoventilation and/or
ventilation/perfusion mismatching in producing the
hypoxaemia. To do so will require continuous measurement
of arterial PC02 as well as ear oxygen saturation, but this is
not yet possible by non-invasive means, at least in adults.
Our demonstration of irregular breathing and transient but
modest hypoxaemia during sleep in adults with chronic stable
asthma, which we suggest may arise from subclinical
bronchoconstriction during sleep, may imply that such
changes could be more pronounced in patients with severe
asthma, or in those recovering from an asthmatic attack. If
further studies confirm this suggestion, such hypoxaemia
may contribute to the rare but tragic deaths from nocturnal
asthmatic attacks. Furthermore, these observations suggest
that future studies ofdrug regimens in asthma should include
sleep monitoring, since spontaneous nocturnal broncho¬
constriction is common and physiologically important.
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